Document:

<PAGE>

                                                                   EXHIBIT 10.23

                        LICENSE AND RESEARCH AGREEMENT

LICENSE AND RESEARCH AGREEMENT (the "Agreement") dated as of May 17, 2000 (the
"Effective Date") by and between 3-DIMENSIONAL PHARMACEUTICALS, INC., a Delaware
corporation having its principal place of business at 665 Stockton Drive, Suite
104, Exton, PA 19341-1151, USA (hereinafter referred to as "3DP") and SCHERING
AG, a corporation organized and existing under the laws of Germany having its
principal place of business at 13342, Berlin, Germany (hereinafter referred to
as "Schering"). 3DP and Schering are sometimes referred to herein individually
as a "Party" and collectively as the "Parties".

WHEREAS:

(A)  3DP has identified a class of non-peptidic, potent urokinase plasminogen
     activator (uPA) inhibitors with potential application in various
     therapeutic fields, and has the right to grant rights and licenses under
     patent applications, patents and know-how relating to such class of
     inhibitors.

(B)  3DP is interested in continuing to carry out research to evaluate further
     uPA inhibitors and Schering is willing to fund such research on the terms
     and subject to the conditions hereinafter set out.

(C)  Schering is interested in obtaining from 3DP certain rights and licenses to
     the patent applications, patents and know-how relating to the above-
     mentioned class of uPA inhibitors already identified by 3DP and to any
     compounds identified during the course of the above-mentioned research, and
     3DP is willing to grant such rights and licenses to Schering under the
     terms and subject to the conditions hereinafter set out.

                                                                               1
<PAGE>

(D)  Schering Berlin Venture Corporation and 3DP have entered into a Stock
     Purchase Agreement of even date herewith (the "Stock Purchase Agreement").

NOW THEREFORE, in consideration of the mutual covenants set forth in this
Agreement and other good and valuable consideration the sufficiency of which is
hereby acknowledged, the Parties agree as follows:

                                   ARTICLE 1

                                  DEFINITIONS

The following terms, when capitalized, shall have the following meanings (such
meanings to be equally applicable to both the singular and the plural forms of
the terms defined) as used in this Agreement:

1.1  "3DP Know-How" means all Know-How, whether currently existing or developed
     during the course of the Research Term or within six (6) months thereafter
     that relates to the research, development, utilization, manufacture, use or
     sale of a Licensed Compound or Licensed Product. Notwithstanding anything
     herein to the contrary, 3DP Know-How shall exclude 3DP Patents and 3DP Non-
     uPA Inhibitor Patents.

1.2  "3DP Non-uPA Inhibitor Compounds" mean compounds and data relating to such
     compounds discovered during the Research Program by 3DP or an Affiliate
     which do not constitute uPA Inhibitors but which the Joint Research
     Committee considers have some biological activity of interest to the
     Research Program or are of potential commercial interest to Schering.

1.3  "3DP Non-uPA Inhibitor Patents means Patents Controlled by 3DP which
     claim Non-uPA Inhibitor Compounds.

                                                                               2
<PAGE>

1.4  "3DP Patents" means: (i) Patents in Schedule A; (ii) Patents to be filed by
     3DP that claim 3DP's orally available uPA Inhibitor lead series, [**] and
     derivatives thereof, as described in the Outline Research Plan; and (iii)
     Patents that claim New Compounds. Notwithstanding anything herein to the
     contrary, 3DP Patents shall exclude any 3DP Know-How, Improvements and 3DP
     Non-uPA Inhibitor Patents.

1.5  "3DP Technology" means 3DP Know-How and 3DP Patents.

1.6  "Accept", "Accepted" or "Acceptance" as used with respect to a Lead
     Candidate, Back-Up or Follow-Up means a Lead Candidate, Back-Up or Follow-
     Up, respectively, that has fulfilled the Biological Criteria agreed upon by
     the Parties pursuant to Section 2.3 and which Schering has decided to
     develop either as an Accepted Lead Candidate or as an Accepted Back-Up or
     Accepted Follow-Up thereof.

1.7  "Accepted Back-Up" means a Back-Up which has fulfilled the Biological
     Criteria agreed upon by the Parties pursuant to Section 2.3 and which
     Schering has decided to develop as a Back-Up to an Accepted Lead Candidate.

1.8  "Accepted Follow-Up" means a Follow-Up which has fulfilled the Biological
     Criteria agreed upon by the Parties pursuant to Section 2.3 and which
     Schering has decided to develop as a Follow-Up to an Accepted Lead
     Candidate.

1.9  "Accepted Lead Candidate" means a Lead Candidate which has fulfilled the
     Biological Criteria agreed upon by the Parties pursuant to Section 2.3 and
     which Schering has decided to develop as a Licensed Product in a specified
     Separate Therapeutic Area.

___________________

**Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission.  The omitted
portions have been filed separately with the Commission.

                                                                               3
<PAGE>

1.10 "Affiliate" means any person, corporation, partnership, firm, joint venture
     or other entity which, directly or indirectly, through one or more
     intermediaries, controls, is controlled by or is under common control with
     3DP or Schering, as the case may be. As used in this definition, "control"
     means the possession of the power to direct or cause the direction of the
     management and policies of an entity, whether through the ownership of the
     outstanding voting securities or by contract or otherwise.

1.11 "Annual Worldwide Net Sales" means the total worldwide Net Sales of a
     Licensed Product in a Separate Therapeutic Area in a Sales Year or in the
     First Sales Year as applicable.

1.12 "Audit Disagreement" shall have the meaning set forth in Section 9.2.

1.13 "Back-Up" shall mean a Licensed Compound that is intended to be reserved as
     a back-up for an Accepted Lead Candidate and is not intended to be
     developed or commercialized unless development and/or commercialization of
     such Accepted Lead Candidate is terminated by Schering.

1.14 "Base Compound" means a uPA Inhibitor existing at the Effective Date which:
     (i) falls within the claims of the Patents referenced in Schedule A or
     falls within the same Chemical Class as such compounds; or (ii) falls
     within 3DP's orally available uPA Inhibitor lead series, [**] and
     derivatives thereof, as described in the Outline Research Plan.

1.15 "Biological Criteria" means the criteria for acceptance of a Lead
     Candidate, Back-Up or Follow-up to be agreed upon by the Parties pursuant
     to Section 2.3.

____________________

**Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission.  The omitted
portions have been filed separately with the Commission.

                                                                               4
<PAGE>

1.16 "Chemical Class": Compounds shall be deemed to fall within the same
     Chemical Class if one compound is a homolog, isomer, analog or first order
     derivative of another compound. A compound is a "homolog" of another
     compound if it differs from that compound by a methylene group or an
     ethylene group or a similar or equivalent group that does not affect the
     relationship of the functional groups in the compound that give rise to its
     activity as a uPA Inhibitor. An "isomer" is a compound differing from
     another compound by positional isomery, geometric isomery or stereochemical
     isomery. An "analog" is a compound which differs from another compound by
     the replacement of a single group within the latter compound. A compound is
     a "first order derivative" of another compound if it is derived from that
     compound by a single chemical reaction.

1.17 "Control" or "Controlled" means possession of the ability to grant a
     license or sublicense of patent rights, know-how or other intangible rights
     as provided for herein without violating the terms of any agreement or
     other arrangement with any Third Party.

1.18 "Drug Approval Application" means an application for Regulatory Approval
     required to be approved before commercial sale or use of a Licensed Product
     as a drug in a regulatory jurisdiction, including, but not limited to, for
     the purposes of Regulatory Approval in the United States, a New Drug
     Application and all supplements filed pursuant to the requirements of the
     FDA (including all documents, data and other information concerning a
     Licensed Product which are necessary for, or included in, FDA approval to
     market the Licensed Product), and, for the purposes of Regulatory Approval
     in the EU, applications for Regulatory Approval to the EMEA.

1.19 "EMEA" means the European Medicines Evaluation Agency or any
     successor agency.

                                                                               5
<PAGE>

1.20 "EU" means the countries which are members of the European Union as such
     membership may change from time to time.

1.21 "FDA" means the United States Food and Drug Administration or any successor
     agency.

1.22 "Field" means all uses of Licensed Products for the prevention, treatment,
     cure or mitigation of all disease states, conditions, disorders and
     indications in humans.

1.23 "First Commercial Sale" means the date on which Schering or an Affiliate or
     sublicensee of Schering first sells commercially, pursuant to a Regulatory
     Approval, a Licensed Product in any country, provided that if such first
     commercial sale has occurred in a country for which pricing or
     reimbursement approval is necessary for widespread sale and no more than a
     reasonable minimal amount of Licensed Product has been sold in such country
     prior to grant of such pricing or reimbursement approval, then such sale
     shall not be deemed a First Commercial Sale until such pricing or
     reimbursement approval has been obtained.

1.24 "First Sales Year" means the period between the date of First Commercial
     Sale of a Licensed Product in a Separate Therapeutic Area in the first
     country in the Territory in which such Licensed Product is sold in such
     Separate Therapeutic Area and the end of the calendar year in which such
     First Commercial Sale is made.

1.25 "Follow-Up" shall mean a Licensed Compound which is proposed by either
     Party for Acceptance as a follow-up to an Accepted Lead Candidate to be
     developed or commercialized for the same Separate Therapeutic Area for
     which the Accepted Lead Candidate is then being developed or
     commercialized; provided, however, that a Licensed Compound which
     constitutes the Follow-Up cannot be the same

                                                                               6
<PAGE>

     Licensed Compound as is already being developed or commercialized as a Lead
     Candidate.

1.25 "Improvements" shall mean Patents and Know-How that are based on research
     conducted by 3DP outside of the Research Program and that are specifically
     and directly related to Licensed Products, to the extent that such Patents
     and Know-How are Controlled by 3DP. For the avoidance of doubt, Patents and
     Know-How claiming New Compounds shall be considered 3DP Patents and 3DP
     Know-How rather than Improvements.

1.26 "IND" means the investigational new drug application relating to one or
     more Licensed Products required to be filed with the FDA pursuant to 21 CFR
     Part 312, including any amendments thereto. References herein to an IND
     shall include, to the extent applicable, any comparable applications
     outside the US such as, for example, the CTX in the EU.

1.27 "Joint Patents" shall have the meaning set forth in Section 7.3.

1.28 "Joint Research Committee" means the committee established pursuant
     to Section 2.3.

1.29 "Know-How" means all data, technical information, know-how, experience,
     inventions, discoveries, trade secrets, compositions of matter and methods,
     and whether or not patentable or confidential, to the extent that such
     Know-How is Controlled by a Party or its Affiliates.

1.30 "Lead Candidate" means a Licensed Compound which is proposed by either
     Party for Acceptance as an Accepted Lead Candidate pursuant to Section 2.6.

1.31 "Licensed Compound" means a Base Compound or a New Compound.

                                                                               7
<PAGE>

1.32 "Licensed Product" means a product in finished dosage form containing a
     Licensed Compound as active ingredient for use in the Field.

1.33 "Major Market Country" means the US, Japan and any country of the European
     Union.

1.34 "Net Sales" means the amount invoiced by Schering, its Affiliates or
     sublicensees for sales of a Licensed Product to Third Parties less the
     following deductions applicable to the Licensed Product for:

     (i)    transportation charges and insurance charges paid by Schering;

     (ii)   sales and excise taxes or customs duties paid by Schering or any
            other governmental charges imposed upon the sale of the Licensed
            Product and paid by Schering;

     (iii)  fees paid to distributors, consignees or agents in connection with
            the sale of the Licensed Product;

     (iv)   reasonable rebates and premiums granted or allowed in connection
            with the sale of a Licensed Product;

     (v)    allowances or credits to customers on account of governmental
            requirements, price differences, rejection, outdating, returns or
            recalls of the Licensed Product;

     (vi)   quantity discounts, cash discounts or chargebacks granted in
            connection with the sale of the Licensed Product;

     (vii)  provisions for price reductions; and

     (viii) costs of customer programs such as cost effectiveness or patient
            assistance studies or programs designed to aid in patient compliance
            with medication schedules in connection with the sale of a Licensed
            Product.

                                                                               8
<PAGE>

     For the purpose of calculating Net Sales, the Parties recognize that (a)
     Schering's customers may include persons in the chain of commerce who enter
     into agreements with Schering as to price even though title to the Licensed
     Product does not pass directly from Schering to such customers and even
     though payment for such Licensed Product is not made by such customers
     directly to Schering and (b) in such cases, chargebacks paid by Schering to
     or through a Third Party (such as a wholesaler) can be deducted by Schering
     from gross revenue in order to calculate Net Sales.  Any deductions above
     which involve a payment by Schering shall be taken as a deduction against
     aggregate sales for the period in which the payment or deduction is made.

     In the event a Licensed Product is sold in the form of a combination
     product containing one or more active ingredients in addition to a Licensed
     Product, Net Sales for such combination product will be adjusted by
     multiplying actual Net Sales of such combination product by the fraction
     A / (A+B) where A is the invoice price of the Licensed Product, if sold
     separately, and B is the invoice price of any other active ingredient or
     ingredients in the combination, if sold separately. If, on a country-by-
     country basis, the other active ingredient or ingredients in the
     combination are not sold separately in that country, Net Sales shall be
     calculated by multiplying actual Net Sales of such combination product by
     the fraction A / C where A is the invoice price of the Licensed Product if
     sold separately, and C is the invoice price of the combination product. If,
     on a country by country basis, neither the Licensed Product nor the other
     active component or components of the combination product is sold
     separately in said country, Net Sales shall be determined between the
     parties in good faith.

1.35 "New Compound" means: (i) any uPA Inhibitor and members of the same
     Chemical Class which is identified, discovered, created or synthesized by
     3DP or an Affiliate in the course of the Research Program; (ii) any
     chemical entity, and any member of the same Chemical Class as such chemical
     entity, that is identified, discovered, created or synthesized by 3DP or an
     Affiliate and is

                                                                               9
<PAGE>

     discovered during the Research Term, but outside of the Research Program,
     to be a uPA Inhibitor, to the extent that such chemical entity is
     Controlled by 3DP or an Affiliate; and (iii) any chemical entity, and any
     member of the same Chemical Class as such chemical entity that is
     identified, discovered, created or synthesized by 3DP or an Affiliate and
     is discovered to be a uPA Inhibitor after the end of the Research Term but
     within six (6) months thereafter, to the extent that such chemical entity
     is Controlled by 3DP or an Affiliate.

1.36 "Patents" mean all patents and patent applications and all patent
     applications hereafter filed, including any continuation, continuation-in-
     part, division, provisional or any substitute applications, any patent
     issued with respect to any such patent applications, any reissue,
     reexamination, renewal or extension (including any supplemental patent
     certificate) of any such patent, and any confirmation patent or
     registration patent or patent of addition based on any such patent, and all
     foreign counterparts of any of the foregoing, to the extent that such
     Patents are Controlled by a Party and its Affiliates.

1.37 "Patent Expenses" means the fees, expenses and disbursements and outside
     counsel fees, and payments to Third Party agents incurred in connection
     with the preparation, filing, prosecution and maintenance of 3DP Patents or
     Joint Patents covering a Licensed Compound or Licensed Product in the
     Field, including costs of patent interference and opposition proceedings
     and actions at law and equity against Third Parties for patent
     infringement.

1.38 "Pivotal Clinical Trial" means a clinical trial designed by Schering or an
     Affiliate or sublicensee which is essential to demonstrate efficacy and
     without which the relevant New Drug Application to the FDA (or equivalent
     in another Major Market Country) would lack adequate and well-controlled
     proof of efficacy likely to be acceptable to the regulatory authorities for
     the grant of marketing approval of a Licensed Product  set by the
     regulatory authorities in the Major Market Country for which the clinical
     trial is designed.

                                                                              10
<PAGE>

1.39 "Regulatory Approval" means any approvals (including pricing and
     reimbursement approvals), product and/or establishment licenses,
     registrations or authorizations of any federal, state or local regulatory
     agency, department, bureau or other governmental entity, necessary for the
     manufacture, use storage, importation, export, transport or sale of
     Licensed Compound or Licensed Product in a regulatory jurisdiction.

1.40 "Research Plan" means the Outline Research Plan (as described in Section
     2.4) for identifying, conceiving, synthesizing, structurally characterizing
     and/or otherwise discovering or optimizing one or more Licensed Compounds
     agreed upon by the Parties and attached to this Agreement as Part I of
     Schedule B; together with the First Year Research Plan and Second Year
     Research Plan to be agreed to between the Parties pursuant to Section 2.4
     and to be attached to this Agreement as Part II and Part III of Schedule B,
     respectively.

1.41 "Research Program" means research activities undertaken pursuant to this
     Agreement as described in the Research Plan, associated with the discovery
     or creation of Base Compounds and New Compounds, including in vitro studies
     of Licensed Compounds, in vivo animal studies for research purposes only
     and related activities.

1.42 "Research Term" means a twenty-four month period commencing on the
     Effective Date.

1.43 "Research Year" means a twelve-month period during the Research Term
     commencing on the Effective Date and ending on an anniversary thereof.

1.44 "Sales Year" means a full calendar year during which any Licensed Product
     is sold in any country of the world in a Separate Therapeutic Area.

                                                                              11
<PAGE>

1.45 "Separate Therapeutic Area" means a broad category of disease(s),
     condition(s) or disorder(s) generally regarded, by virtue of their common
     pathology, area of impact or otherwise, as therapeutically/medically
     distinct from other such categories.  For avoidance of doubt and without
     limitation, examples of Separate Therapeutic Areas are: oncology;
     cardiovascular system; central and peripheral nervous systems;
     endocrinology; dermatology and inflammation.

1.46 "Territory" means all countries of the world.

1.47 "Third Party" means any entity other than 3DP or Schering and their
     respective Affiliates and sublicensees.

1.48 "Urokinase Plasminogen Activator (uPA) Inhibitor" means a compound that
     has (i) [**] as determinated by 3DP using a standardized assay reasonably
     acceptable to the Joint Research Committee [**], and (ii) selectivity
     with respect to the [**], as determined by 3DP using a standardized assay
     reasonably acceptable to the Joint Research Committee, for [**]; and
     (iii) selectivity with respect to the [**], as determined by 3DP using a
     standardized assay reasonable acceptable to the Joint Research Committee,
     for [**].

1.49 "US" or "United States" means the United States of America, its territories
     and possessions, including the District of Columbia, the Commonwealth of
     Puerto Rico, the US Virgin Islands, Guam, and all other places under the
     jurisdiction of the United States of America.

________________
**Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              12
<PAGE>

1.50 "Valid Claim" means any claim of an issued, unexpired patent which shall
     not have been abandoned, withdrawn, canceled or disclaimed, nor held
     invalid or unenforceable by a court of competent jurisdiction in an
     unappealed or unappealable decision.

                                   ARTICLE 2

                               RESEARCH PROGRAM

2.1  Commencement: The Research Program will commence on the Effective Date and
     will continue (unless earlier terminated pursuant to Article 10 below) for
     the Research Term. 3DP shall perform its responsibilities under the
     Research Program in accordance with the terms of the Research Plan. The
     objective of the Research Program is to identify Licensed Compounds which
     may become Lead Candidates for development and commercialization by
     Schering.

2.2  Research Funding: Schering shall fund the Research Program in the amount of
     [**] for each Research Year. Payments for each Research Year will be made
     quarterly in advance. In addition, Schering shall reimburse 3DP the
     documented costs payable to any Third Party in connection with activities
     under the Research Program where such activities and the costs therefor
     have been approved in advance in writing by Schering. The Parties consider
     that the performance of the Research Program as currently envisaged will
     not require the payment of any such costs to Third Parties. No activities
     may be delegated by 3DP under the Research Program without the prior
     written consent of Schering except as agreed to by the Joint Research
     Committee. All payments shall be made in US dollars to the credit of such
     bank account as may be designated by 3DP in writing to Schering. Any
     payments which fall due on a date which is a legal holiday in the

________________
**Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission.  The omitted
portions have been filed separately with the Commission.

                                                                              13
<PAGE>

     State of Pennsylvania or in Berlin, Federal Republic of Germany, may be
     made on the next following day which is not a legal holiday.

2.3  Joint Research Committee:

     (a)   Composition and Purposes:  Upon the execution of this Agreement, 3DP
           ------------------------
     and Schering will establish a Joint Research Committee which shall consist
     of six members, three designated by 3DP and three designated by Schering.
     The  Joint Research Committee shall meet formally at least quarterly or
     with such other frequency, and at such time and location, as may be
     established by the Joint Research Committee, for the following purposes:

     (i)   To review and approve, if appropriate, revisions to the Research
           Plan;

     (ii)  To monitor and review the progress of the Research Program and to
           consider whether any amendment of the Research Program should be
           recommended to the Parties;

     (iii) To review Licensed Compounds proposed by either Party for further
           preclinical testing;

     (iv)  To review and approve Biological Criteria for the Acceptance of Lead
           Candidates, Back-Ups and Follow-Ups;

     (v)   To decide whether and how a Licensed Compound proposed by either
           Party as a potential Lead Candidate, Back-Up or Follow-up should be
           assessed in accordance with the Biological Criteria.

     (vi)  To discuss matters relating to publications and Patents.

     (b)   Decision Making:  The objective of the Joint Research Committee shall
           ---------------
     be to reach agreement by consensus on all matters within the scope of the
     Research Plan.  However, all decisions to be made under this Agreement will
     be made by majority vote in the Joint Research Committee, and if the Joint
     Research Committee cannot agree on any matter (a "Disputed Matter"), the
     Disputed Matter shall be referred to the Chief Executive Officer of 3DP and
     the President

                                                                              14
<PAGE>

     of Schering's Affiliate, Berlex Biosciences, for resolution. If the
     Disputed Matter is not then resolved, Schering's decision shall be final
     and binding.

     (c)  Powers:  Each Party shall retain the rights, powers and discretion
          ------
     granted to it under this Agreement and the Joint Research Committee shall
     not be delegated or vested with any such rights, powers or discretion
     except as expressly provided in the Agreement.  The Joint Research
     Committee shall not have the power to amend or modify this Agreement, which
     may only be amended or modified as provided in Section 12.11.

2.4  Research Plan: 3DP and Schering have agreed upon an outline for a two (2)
     year Research Plan (the "Outline Research Plan") for identifying,
     conceiving, synthesizing, structurally characterizing and/or otherwise
     discovering one or more Licensed Compounds that are commercially viable
     candidates for development as drugs in the Field. The Outline Research Plan
     is attached hereto as Part I of Schedule B. Within forty five (45) days of
     the Effective Date, the Joint Research Committee shall adopt a more
     detailed research plan which describes the research activities to be
     carried out in the first Research Year (the "First Year Research Plan",
     such plan to be consistent with the Outline Research Plan and to be
     attached hereto as Part II of Schedule B. Three months before the end of
     the first Research Year, 3DP and Schering will agree upon a detailed
     research plan which describes the research activities for the second
     Research Year (the "Second Year Research Plan"), such plan to be consistent
     with the Outline Research Plan and to be attached hereto as Part III of
     Schedule B. The Joint Research Committee will be responsible for overseeing
     implementation of the Research Plan. Amendments to the Research Plan shall
     be effective only if agreed in writing by both Parties in accordance with
     the provisions of this Agreement. The Research Plan also shall establish a
     Research Project Team that shall be responsible for implementing the
     Research Plan. The Parties will allocate for the performance of the
     Research Plan the resources, in terms of personnel, equipment, materials
     etc., necessary to perform the Research

                                                                              15
<PAGE>

     Program, such resources to be at least equal to the amounts stipulated in
     the Research Plan.

2.5  Biological Criteria: The Parties have agreed upon provisional biological
     criteria attached hereto as part of the Outline Research Plan as the basis
     for the determination of Biological Criteria under this Agreement. The
     Parties shall, within forty-five (45) days of signature of this Agreement,
     finalize the Biological Criteria, for the Lead Candidate.

2.6  Selection of Lead Candidates, Back-Ups and Follow-Ups:

     (a)  Either Party may propose a Licensed Compound for selection and
          evaluation as a Lead Candidate, Back-Up or Follow-up . If the Joint
          Research Committee decides that such Licensed Compound should be
          evaluated, the Parties will assess whether the Biological Criteria
          have been met. If a Licensed Compound is Accepted, Schering shall be
          free to proceed with the development of such Licensed Compound.

     (b)  In the event that the Parties agree that the Biological Criteria have
          not been met, 3DP shall, at Schering's request and as part of the
          Research Program, carry out such optimization of the Lead Candidate,
          Back-Up or Follow-Up as Schering may reasonably request with a view to
          qualifying such Lead Candidate, Back-Up or Follow-Up to meet the
          Biological Criteria. If the Parties disagree as to whether the
          Biological Criteria have been met in any case, this dispute will be
          dealt with in the same way as Disputed Matters pursuant to Section
          2.3(b) above. Both Parties will use all reasonable efforts in good
          faith to come to agreement on whether the Biological Criteria have
          been met.

2.7  Reversion of Rights to Compounds that are Not Accepted by Schering: When a
     Lead Candidate, Back-Up or Follow-Up is recommended by the Joint Research
     Committee for evaluation and both Parties agree that such Lead Candidate or
     Back-Up or Follow-Up meets all Biological Criteria, Schering may, at its
     absolute discretion, either: (i) Accept the Lead Candidate, Back-Up or

                                                                              16
<PAGE>

     Follow-Up and pay the milestone payment due pursuant to Section 4.1.1; or
     (ii) decline to Accept such compound, in which case Schering agrees to
     negotiate in good faith with 3DP at that time to provide a release of
     rights to 3DP to pursue clinical development of such compound(s) in
     Separate Therapeutic Areas designated by 3DP and which Schering confirms
     are not of interest to Schering. The parties contemplate that the royalty
     and milestone terms of this Agreement would be applicable to such release
     of rights by Schering.

2.8  Reversion of Rights to Compounds Whose Development is Terminated by
     Schering. If Schering, having Accepted a Lead Candidate, Back-Up or Follow-
     Up decides, at any stage, to terminate pharmaceutical development of such
     Lead Candidate, Back-Up or Follow-Up, Schering agrees to negotiate in good
     faith with 3DP at such time to provide a release of rights to 3DP to pursue
     development of such Licensed Compound(s) in Separate Therapeutic Areas
     designated by 3DP and which Schering confirms are not of interest to
     Schering. The parties contemplate that the royalty and milestone terms of
     this Agreement would be applicable to such release of rights by Schering.
     Any product developed by 3DP pursuant to Sections 2.7 or 2.8 of this
     Agreement will be developed in such a way that it cannot be directly
     substituted for off label uses for any Licensed Product being developed or
     commercialized by Schering.

2.9  Designation of Separate Therapeutic Areas.  If:

     (i)   3DP has requested a release of rights pursuant to Sections 2.7 or 2.8
           above to pursue development of a designated Licensed Compound in a
           designated Separate Therapeutic Area; and

     (ii)  Schering has refused to release such rights on the basis that the
           designated Separate Therapeutic Area is of interest to Schering; and

     (iii) Schering is not, within two years of the request for release of
           rights by 3DP, either developing or commercializing a Licensed
           Compound or Licensed Product in such designated Separate Therapeutic
           Area or

                                                                              17
<PAGE>

           developing or commercializing such designated Licensed Compound in
           another Separate Therapeutic Area;

     then 3DP may renew its request for a release of rights to such designated
     Licensed Compound in such designated Separate Therapeutic Area and Schering
     shall negotiate in good faith with 3DP at such time to provide a release of
     rights to 3DP to pursue development of such designated Licensed Compound in
     such designated Separate Therapeutic Area.

2.10 Rights to Non-uPA Inhibitors. To the extent that 3DP or an Affiliate
     Controls any Non-uPA Inhibitor Compounds, 3DP agrees to negotiate in good
     faith with Schering to grant an exclusive, worldwide, sublicensable license
     to Schering to pursue development and commercialization of such Non-uPA
     Inhibitor Compounds in one or more Separate Therapeutic Areas in the Field.
     The parties contemplate that the research funding, royalty and milestone
     terms of this Agreement would be applicable to any such license to
     Schering. In the event that Schering wishes to develop such Non-uPA
     Inhibitors together with a Third Party partner, Schering agrees to first
     negotiate in good faith with 3DP as a potential partner for the development
     of Non-uPA Inhibitor Compounds. In the event that 3DP is not able to grant
     to Schering a license to any Non-uPA Inhibitor Compound as provided above,
     then 3DP undertakes, during the term of this Agreement, not to develop or
     commercialize or permit the development or commercialization of such Non-
     uPA Inhibitor Compound for any Separate Therapeutic Area for which Schering
     develops or commercializes a Licensed Compound or Licensed Product.

2.11 Research Funding: 3DP will utilize the research funding provided by
     Schering pursuant to Section 2.2 above exclusively for the performance of
     the Research Program.

2.12 Research Exclusivity: During the Research Term, the Parties agree to
     cooperate exclusively with each other in carrying out research and
     development relating to uPA Inhibitors. Neither Party shall, during the
     Research Term, carry

                                                                              18
<PAGE>

     out any research in the Field relating to the discovery of uPA Inhibitors
     except pursuant to this Agreement unless the Parties mutually agree
     otherwise in writing. Neither Party shall enter into any agreement with a
     Third Party which would prevent it from performing its obligations under
     this Agreement.

                                   ARTICLE 3

                                LICENSE RIGHTS

3.1  Grant to Schering:

     (a)  3DP hereby grants to Schering an exclusive, worldwide, sublicensable
          license under the 3DP Technology to research, develop, make, have
          made, use, sell and import for sale Licensed Compounds and Licensed
          Products in the Field. A list of the 3DP Patents identified as of the
          Effective Date is attached hereto as Schedule A. Such list shall be
          modified from time to time to reflect any changes to the 3DP Patents
          acquired by or coming under the Control of 3DP or its Affiliates
          during the term of this Agreement or within a period of six (6) months
          thereafter.

     (b)  3DP also hereby grants to Schering a nonexclusive, worldwide,
          sublicensable license under Non-uPA Inhibitor Patents to carry out
          research and development in respect of uPA Inhibitor Compounds during
          the Research Program and to use any results of such research and
          development for the development, manufacture or commercialization of
          Licensed Compounds and Licensed Products.

     (c)  3DP also hereby grants to Schering a nonexclusive, worldwide,
          sublicensable license under Improvements that are Controlled by 3DP
          during the term of this Agreement to research, develop, make, have
          made, use, sell and import for sale Licensed Products in the Field.

                                                                              19
<PAGE>

     (d)  3DP agrees not to develop or commercialize outside of the Field any
          Licensed Compound or Licensed Product that is being developed or
          marketed by Schering without the prior written approval of Schering,
          such approval not to be unreasonably withheld by Schering.

3.2  License Following Expiration: Following the Royalty Expiration Date
     specified in Section 5.1(b) below, and provided that this Agreement has not
     been terminated by Schering under Section 10.2(a) or by 3DP under Section
     10.2(b) or 10.2(c), Schering shall, in each country of the world, have an
     exclusive (even as to 3DP), paid-up, sub-licensable license under 3DP Know-
     How to research, develop, make, have made, use, sell and import for sale
     Licensed Compounds and Licensed Products.

3.3  Transfer of Information: 3DP shall promptly identify and make available to
     the Joint Research Committee, and to Schering upon request, all information
     in 3DP's possession or coming into its possession during the course of this
     Agreement relating to Licensed Compounds, Licensed Products and methods of
     manufacturing the same, which appears to be reasonably necessary or useful
     for exercise by Schering of the rights granted hereunder. Such information
     shall include copies of all Patents, copyrights, copyright registrations
     and applications therefor and all other manifestations of the intellectual
     property embodied in the Licensed Compounds and Licensed Products, whether
     in human or machine readable form.

                                   ARTICLE 4

                         MILESTONE PAYMENTS; DILIGENCE

4.1  Schering will make the following milestone payments to 3DP within 30
     (thirty) days of achievement of any of the following milestones with
     respect to a Licensed Compound or Licensed Product.

                                                                              20
<PAGE>

1. Upon Acceptance of a Lead Candidate as an            [**]
   Accepted Lead Candidate

2. Upon acceptance by the FDA of an IND in the          [**]
   US or equivalent regulatory approval in another
   Major Market Country, whichever occurs first,
   with respect to an Accepted Lead Candidate

3. Upon the [**] dosing of a Licensed Product in        [**]
   humans under the first Pivotal Clinical Trial
   conducted in the US or another a Major Market
   Country, whichever occurs first.

4. Upon Regulatory Approval of an Accepted Lead         [**]
   Candidate in the US or another Major Market
   Country, whichever occurs first.

5. On [**] Commercial Sale of a Licensed Product        [**]
   in the US or in another Major Market Country,        Note: In the event that
   whichever occurs first.                              ----
                                                        the actual [**]
                                                        Commercial Sale is made
                                                        in some country other
                                                        than those identified,
                                                        the milestone

______________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              21
<PAGE>

                                                        for such [**] Commercial
                                                        Sale shall be [**], and
                                                        then [**] shall be paid
                                                        upon the [**] Commercial
                                                        Sale in any of the
                                                        identified countries.

6.   On first achieving, in a Sales Year, Net Sales
     of a Licensed Product of at least [**]

     (i)   Subject to sub-sections (ii), (iii) and (v) below, each of the above
           milestone payments will be payable [**] in respect of each [**] of
           the number of Licensed Products developed or commercialized within
           such [**] of the number of indications for which such Licensed
           Products are developed or commercialized within such [**] of the
           number of countries in which each milestone is achieved.

     (ii)  in the case of an Accepted Follow-Up, the [**] milestone payments
           described above will be payable if the applicable milestones are
           reached, notwithstanding the fact that these milestone payments have
           already been paid in respect of a Lead Candidate in the same
           Separate Therapeutic Area. For the avoidance of doubt, if an
           Accepted Follow-Up is subsequently developed for a second Separate
           Therapeutic Area for which a Lead Candidate has not yet been
           Accepted, such Accepted Follow-Up will be treated as an Accepted
           Lead Candidate in such second Separate Therapeutic Area and will be
           eligible, in such second Separate Therapeutic Area, for payment of
           all applicable milestone payments except for those milestone
           payments which have already been paid in

______________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              22
<PAGE>

           respect of its development as an Accepted Follow-Up to an Accepted
           Lead Candidate in the first Separate Therapeutic Area.

     (iii) In the case of an Accepted Back-Up, the milestone payment described
           at Section 4.1.1 above will be payable, notwithstanding the fact
           that this has already been paid in respect of a Lead Candidate in
           the same Separate Therapeutic Area.

     (iv)  If an Accepted Lead Candidate in a Separate Therapeutic Area fails,
           for any reason, to reach any of the milestones described above, then
           the first Accepted Back-Up or Follow-Up to this Accepted Lead
           Candidate to be developed and/or commercialized in the same Separate
           Therapeutic Area will be eligible for the milestone payments which
           have not yet been made for an Accepted Lead Candidate in such
           Separate Therapeutic Area. So, for example, if Schering pays the
           first three milestone payments only in respect of the first Accepted
           Lead Candidate to be developed in a Separate Therapeutic Area and
           then stops development of the Accepted Lead Candidate and proceeds
           to develop an Accepted Back-Up or Accepted Follow-Up instead, only
           the first, fourth, fifth and sixth milestone payments (if
           applicable) would be payable in respect of that Accepted Back-Up or
           Accepted Follow-Up.

     (v)   In addition, if Schering Accepts a Lead Candidate within three
           months of the Effective Date, a milestone payment of [**] will be
           payable by Schering to 3DP instead of the [**] indicated above as
           the first milestone payment, to reward the additional research
           progress achieved by 3DP during the negotiations between the Parties
           that resulted in the signing of this Agreement.

4.2  Diligence: If a Lead Candidate or Follow-Up is Accepted by Schering,
     Schering shall use reasonable commercial efforts to develop and
     commercialize a

______________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              23
<PAGE>

     Licensed Product containing such Lead Candidate or Follow-Up, such efforts
     to be comparable to the efforts expended by Schering on its proprietary
     compounds of equivalent potential. Schering may discharge its obligations
     pursuant to this Section 4.2 through a sub-licensee or Affiliate.

                                   ARTICLE 5

                                   ROYALTIES

5.1  Royalties

     (a)  General: In further consideration of the rights and licenses granted
          -------
          to Schering under Article III of this Agreement, Schering agrees,
          subject to Sections 5.1(b) and 5.4, to pay to 3DP the following
          royalties on Net Sales of Licensed Products:

          (i)   On Net Sales of a Licensed Product in a Separate Therapeutic
                Area in a Sales Year where Annual Worldwide Net Sales are less
                than [**]

          (ii)  On Net Sales of a Licensed Product in a Separate Therapeutic
                Area in a Sales Year (or First Sales Year if applicable) where
                Annual Worldwide Net Sales are equal to or exceed [**].

     (b)  Royalty Term: Except where expressly provided otherwise in this
          Agreement, all royalties to 3DP shall be paid, on a country-by-country
          basis, from the date of the First Commercial Sale of a Licensed
          Product in

_____________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              24
<PAGE>

          a particular country until the later (the "Royalty Expiration Date")
          of (i) ten (10) years from the First Commercial Sale in such country
          and (ii) the last to expire of any 3DP Patent which includes a Valid
          Claim in such country; provided, however, that if a Licensed Product
          is sold in any country in which 3DP does not have a Valid Claim which
          would prevent the sale of a generic form of such Licensed Product, the
          royalty obligations set forth in Section 5.1(a) with respect to Net
          Sales attributable to the sale of the Licensed Product in such country
          shall be reduced by [**] of the royalty that would otherwise be
          payable with respect to Net Sales attributable to the sale of the
          Licensed Product in such country.

5.2  Royalty Reports And Payments: Schering shall make royalty payments to 3DP
     quarterly within sixty (60) days after the end of each calendar quarter in
     which Net Sales occurred. A report summarizing the Net Sales of Licensed
     Products in each Separate Therapeutic Area on a country-by-country basis
     ("Quarterly Report") shall be delivered to 3DP within sixty (60) days
     following the end of each calendar quarter for which royalties are due. A
     separate report summarizing the Annual Worldwide Net Sales of each Licensed
     Product in each Separate Therapeutic Area (the "Annual Report") shall be
     delivered to 3DP within sixty (60) days of the end of the First Sales Year
     and each subsequent Sales Year.

5.3  Adjustment Of Royalty Rates: The royalty rate applicable to Net Sales of a
     Licensed Product in a Separate Therapeutic Area in the First Sales Year
     shall be deemed to be [**.] If Annual Worldwide Net Sales for such First
     Sales Year are equal to or exceed [**] Schering shall, within sixty (60)
     days of the end of the First Sales Year, pay to 3DP in respect of such Net
     Sales an amount equal to the difference between the royalty amount paid by
     Schering for such Net Sales and the amount which would have been payable if
     the applicable royalty rate had been [**.] The royalty rate applicable to
     Net Sales of a Licensed Product in a

_____________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              25
<PAGE>

     Separate Therapeutic Area in the second and all subsequent Sales Years
     shall be deemed to be the rate actually applicable after adjustment for the
     preceding Sales Year. Within sixty (60) days of the end of each Sales Year,
     Schering shall pay to 3DP or 3DP shall pay to Schering, as the case may be,
     the difference (if any) between the royalty amount paid in respect of such
     Annual Worldwide Net Sales in the preceding Sales Year and the amount which
     would have been payable if the royalty rate actually applicable after
     adjustment had been paid in respect of such Annual Worldwide Net Sales for
     such preceding Sales Year.

     For example, if Annual Worldwide Net Sales of a specific Licensed Product
     in a Separate Therapeutic Area in Sales Year 2 were [**,] the deemed
     royalty rate for Annual Worldwide Net Sales for that Licensed Product in
     Sales Year 3 will be [**.] If, in fact, Annual Worldwide Net Sales in Year
     3 were [**,] Schering shall, within sixty days of the end of Sales Year 3,
     pay to 3DP an extra [**] royalty on Annual Worldwide Net Sales of such
     Licensed Product in Sales Year 3, and the deemed royalty rate for Annual
     Worldwide Net Sales of such Licensed Product in Sales Year 4 will be [**.]

5.4  Third Party Royalty Obligations: If, as a result of a judgment in favor of
     or settlement with a Third Party pursuant to Section 7.6, Schering is
     required to pay monies to a Third Party in order to develop, manufacture or
     sell a Licensed Product in any country, [**] of any such monies may be set
     off against the royalties otherwise due to 3DP hereunder. Notwithstanding
     the foregoing, the permitted set-off may not decrease the royalty otherwise
     owed by Schering to 3DP by more than [**].

5.5  Payments; Interest: Any payments due under this Agreement shall be due on
     such date as specified in this Agreement and, in the event such date is a
     day on which commercial banks are not authorized to conduct business in
     either Pennsylvania, US or Berlin, Federal Republic of Germany, then the
     next

_____________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              26
<PAGE>

     succeeding business day, and shall be made by wire transfer to a designated
     bank account of 3DP.

     Any failure by Schering to make a payment within five days after the date
     when due shall obligate Schering to pay interest to 3DP at a rate per annum
     equal to the Prime Rate as publicly announced by Bank America on Reuters
     Screen "USPRIME1" on the due date or the next business day computed on the
     basis of a 356/360 year, the interest period commencing on the due date and
     ending on the payment day, such interest to be due and payable upon tender
     of the payment.

5.6  Taxes: 3DP shall pay any and all taxes levied on account of research
     payments, milestone payments or royalties it receives under this Agreement.
     If laws or regulations require that taxes be withheld, Schering will (i)
     deduct those taxes from the remittable royalty, (ii) timely pay the taxes
     to the proper taxing authority, and (iii) send proof of payment to 3DP
     within thirty (30) days of receipt of confirmation of payment from the
     relevant taxing authority.

5.7  Payments To Or Reports By Affiliates: Any payment required under any
     provision of this Agreement to be made to either Party or any report
     required to be made by either Party shall be made to or by an Affiliate of
     that Party if designated by that Party as the appropriate recipient or
     reporting entity without relieving such Party from responsibility for such
     payment or report.

5.8  Payment Currency: Payments by Schering under this Agreement shall be made
     in US dollars. The calculation of royalty payments is based on Euro and
     converted into US dollars. Except for Net Sales in the United States, where
     payments are based on Net Sales in countries other than the member states
     of the European Currency Union, the amount of such Net Sales expressed in
     the currency of each country shall be converted into Euros at the exchange
     rate of the last date of the applicable calendar quarter. The applicable
     exchange rate

                                                                              27
<PAGE>

     will be the Euro foreign exchange reference spot rate published on the last
     business day of the applicable calendar quarter by the European Central
     Bank, Frankfurt/Main. If no Euro foreign exchange reference spot rate is
     determined for the relevant currency, the Parties shall agree upon another
     reference rate. Finally, the payable Euro amount shall be converted into US
     dollars by the Euro foreign exchange reference spot rate published by the
     European Central Bank, Frankfurt/Main, at the last business day of the
     applicable calendar quarter. These Euro foreign exchange reference spot
     rates are currently published by Reuters on screen "ECB37".

                                   ARTICLE 6

                                CONFIDENTIALITY

6.1  Confidentiality; Exceptions: Except to the extent expressly authorized by
     this Agreement or otherwise agreed in writing, the Parties agree that the
     receiving Party and its employees (who shall be bound in writing to observe
     the confidentiality provisions of this Agreement) shall keep confidential
     and shall not publish or otherwise disclose or use for any purpose other
     than as provided for in this Agreement any Know-How and other information
     and materials furnished to it by the other Party pursuant to this Agreement
     or any information or Know-How developed during the course of the
     collaboration hereunder, or any provisions of this Agreement that are the
     subject of an effective order of the U.S Securities and Exchange Commission
     granting confidential treatment pursuant to the Securities Act of 1934, as
     amended (collectively, "Confidential Information"), except to the extent
     that it can be established by the receiving Party that such Confidential
     Information:

     (i)  was already known to the receiving Party, other than under an
          obligation of confidentiality, at the time of disclosure by the other
          Party;

                                                                              28
<PAGE>

     (ii)  was generally available to the public or otherwise part of the public
           domain at the time of its disclosure to the receiving Party;

     (iii) became generally available to the public or otherwise part of the
           public domain after its disclosure and other than through any act or
           omission of the receiving Party in breach of this Agreement;

     (iv)  was disclosed to the receiving Party, other than under an obligation
           of confidentiality, by a Third Party who had no obligation to the
           disclosing Party not to disclose such information to others.

6.2        Authorized Disclosure: Each Party may disclose Confidential
     Information hereunder to the extent such disclosure is reasonably necessary
     in filing or prosecuting patent applications, prosecuting or defending
     litigation, complying with applicable governmental regulations, or
     conducting research under this Agreement provided that, if a Party is
     required by law or regulation to make any such disclosures of the other
     Party's Confidential Information it will, except where impracticable for
     necessary disclosures, for example in the event of medical emergency, give
     reasonable advance notice to the other Party of such disclosure requirement
     and, except to the extent inappropriate in the case of patent applications,
     will use its reasonable efforts to secure confidential treatment of such
     Confidential Information required to be disclosed. In addition, and with
     prior written notice to the other Party of each Third Party with whom a
     confidential disclosure agreement is being entered into, each Party shall
     be entitled to disclose, under a binder of confidentiality, Confidential
     Information to any Third Party for the purpose of carrying out the purposes
     of this Agreement and, in the case of 3DP, in connection with the seeking
     of equity financing. Where materiality of disclosure requires a press
     release or other disclosure pertaining to this Agreement by one Party, the
     disclosing Party shall give the other Party a copy of the proposed
     disclosure and afford that Party at least two (2) business days. In
     addition, Schering may use and disclose Confidential Information for all
     purposes related to the exercise of Schering's rights under this Agreement
     provided that Schering takes the same care in respect of such

                                                                              29
<PAGE>

     Confidential Information as it does in respect of its own confidential
     information. Not withstanding the foregoing, each Party acknowledges that
     the other may be obligated to disclose terms of this Agreement and make
     public a copy of this Agreement in the event it becomes a public company as
     required by applicable U.S. law; provided however, that the terms and copy
     of this Agreement shall be redacted such that the extent of any such
     disclosure shall be limited to that which in the reasonable opinion of the
     disclosing Party's legal counsel is legally required. Each Party will
     provide a copy of such disclosure to the other.

6.3  Survival: This Article 6 shall survive the termination or expiration of
     this Agreement for a period of five (5) years.

6.4  Termination Of Prior Agreement: This Agreement supersedes the
     Confidentiality Agreement between 3DP and Schering dated as of June 25,
     1999. All information exchanged between the Parties under the said
     Confidentiality Agreement shall be deemed to be Confidential Information
     and shall be subject to the terms of this Article 6, and shall be included
     within the definition of Confidential Information.

6.5  Publications: In consultation with 3DP, Schering shall determine the
     overall strategy for publication in support of the Product in the
     Territory.

6.6  Publicity Review: Subject to the other provisions of this Article 6, no
     Party shall originate any written publicity, news release, or other
     announcement or statement relating to this Agreement or to performance
     hereunder or the existence of an arrangement between the Parties
     (collectively "Written Disclosure") without the prior prompt review and
     written approval of the other Party, which approval shall not be
     unreasonably withheld or delayed. Notwithstanding the foregoing provisions
     of this Section 6.6, any Party may make any public Written Disclosure it
     believes in good faith based upon the advice of counsel is required by
     applicable law or any listing or trading agreement concerning its publicly
     traded

                                                                              30
<PAGE>

     securities, provided that prior to making such Written Disclosure, the
     disclosing Party shall provide the other Party with a copy of the materials
     proposed to be disclosed and provide the receiving Party with at least two
     (2) business days to review the proposed Written Disclosure. Each Party
     agrees to issue press releases as soon as it reasonably can, on or after
     the Effective Date, subject to expedited review and approval by the other
     Party, such approval not to be unreasonably withheld.

                                   ARTICLE 7

             OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

7.1  Ownership: Each Party shall solely own, and it alone shall have the right
     to apply for, Patents for any inventions made solely by that Party's
     employees or consultants in the course of performing work under this
     Agreement. Inventions made jointly by employees or consultants of 3DP and
     Schering shall be jointly owned by Schering and 3DP. All such inventions
     and Joint Patents are subject to the license granted by 3DP to Schering
     pursuant to Article 3 of this Agreement.

7.2  Disclosure Of Joint Inventions: Any patent application disclosing
     inventions made jointly by the Parties shall be provided by one Party to
     the other reasonably in advance of the intended date for submission of such
     application to a governmental patent authority.

7.3  Patent Filings

     (a)  Each Party, at its sole discretion, cost and responsibility, shall
     prepare, file, prosecute and maintain Patents to cover discoveries and
     inventions made solely by its own employees or consultants relating to
     Licensed Compounds or Licensed Products and use commercially reasonable
     efforts to file initially all such applications in the appropriate forum
     under the circumstances wherein such a Party determines it is commercially
     reasonable to do so. If 3DP decides not to

                                                                              31
<PAGE>

     file or, having filed, to abandon a Patent in a particular country it shall
     notify Schering and, at Schering's request, assign all rights in respect to
     such Patent to Schering. Schering shall file, prosecute and maintain
     Patents to cover inventions relating to the discovery, evaluation,
     manufacture, use or sale of the Licensed Compounds or Licensed Products
     that are made jointly by personnel of 3DP and Schering in the course of the
     Agreement (herein referred to as "Joint Patents"). The determination of the
     countries in which to file Joint Patents shall be made by Schering. In
     consultation with 3DP, and taking reasonably into account any rights
     retained by 3DP under such Joint Patents, Schering shall have the right to
     direct and control all material actions relating to the prosecution or
     maintenance of Joint Patents in the Territory, including interference
     proceedings, reexaminations, reissue opposition and revocation proceedings.

     (b)  The Parties agree to use commercially reasonable efforts to ensure
     that any Patent filed outside the United States prior to a filing in the
     United States will be in a form sufficient to establish the date of
     original filing as a priority date for the purposes of a subsequent filing
     in the United States. Schering shall bear all costs related to the filing
     of Joint Patents. The Parties agree to use commercially reasonable efforts
     to ensure that any Patent filed in the United States prior to filings
     outside of the United States will be in a form sufficient to establish the
     date of original filing as a priority date for the purpose of a subsequent
     filing in any contracting state of the Paris Convention.

7.4  Third Party Patents: Each Party agrees to bring to the attention of the
     other Party any Third Party Patent it discovers or has discovered and which
     relates to the subject matter of this Agreement.

7.5  Enforcement Rights:

     (a)  Notification of Infringement:  If either Party learns of any
          ----------------------------
     infringement or threatened infringement by a Third Party of 3DP Patents,
     Schering Patents or

                                                                              32
<PAGE>

     Joint Patents in the Field, such Party shall promptly notify the other
     Party and shall provide such other Party with all available evidence of
     such infringement.

     (b)  Enforcement in the Territory:  Schering shall have the right but not
          ----------------------------
     the obligation to institute, prosecute and control at its own expense any
     action or proceeding with respect to infringement of any 3DP Patents or
     Joint Patents covering the research, manufacture, use, importation, sale or
     offer for sale of Licensed Compounds or Licensed Products in the Field, by
     counsel of its own choice. 3DP shall have the right, at its own expense, to
     be represented in any action by counsel of its own choice. If Schering
     fails to bring such an action or proceeding or otherwise take appropriate
     action to abate such infringement within a period of one hundred eighty
     (180) days of notice by 3DP to Schering requesting action, 3DP will have
     the right but not the obligation to bring and control any such action or
     proceeding relating to 3DP Patents by counsel of its own choice and
     Schering will have the right to be represented in any such action by
     counsel of its own choice and at its own expense. If one Party brings any
     such action or proceeding, the other Party agrees to be joined as a party
     plaintiff if necessary to prosecute the action or proceeding and to give
     the first Party commercially reasonable assistance and authority to file
     and prosecute the suit. Any damages or other monetary awards recovered
     pursuant to this Section 7.5(b) shall be allocated first to the reasonable
     costs and expenses of the Party bringing suit, then to the reasonable costs
     and expenses, if any, of the other Party. In the event that Schering brings
     such action, any amounts remaining shall be distributed as follows:
     compensatory damages shall be treated as Net Sales in the country and
     calendar quarter received and punitive and exemplary damages shall be paid
     equally to Schering and 3DP. In the event that 3DP brings such action, any
     damages or other monetary awards recovered shall be divided equally between
     the Parties.

     (c)  Settlement with a Third Party: The Party that controls the prosecution
          -----------------------------
     of a given action shall also have the right to control settlement of such
     action,

                                                                              33
<PAGE>

     provided however, that if one Party controls, no settlement shall be
     entered into without the written consent of the other Party (which consent
     shall not be unreasonably withheld) if such settlement would materially and
     adversely affect the interests of the other Party.

7.6  Defense And Settlement Of Third Party Claims: If a Third Party asserts that
     a patent owned by it is infringed by any Licensed Compound or any Licensed
     Product or by the exercise by Schering of any of the rights licensed under
     Article 3 above, Schering will have the right but not the obligation to
     defend against any such assertions at its cost and expense but no
     settlement may be entered into without the written consent of 3DP, which
     shall not be unreasonably withheld. The costs of any such settlement
     (including, without limitation, damages, expense reimbursements,
     compliance, future royalties or other amounts) and of any amount awarded
     against Schering shall be paid by Schering who may offset [**] of such
     payments against the royalty payments that it owes to 3DP under this
     Agreement according to the provisions of Section 5.4.

7.7  Patent Expenses: All worldwide Patent Expenses with respect to 3DP Patents
     shall be borne by 3DP and all worldwide Patent Expenses with respect to
     Joint Patents shall be borne by Schering, subject in both cases to the
     terms of this Agreement.

7.8  Trademarks: Schering shall be responsible for the selection, registration
     and maintenance of all trademarks which it employs in connection with the
     Licensed Products and shall own and control such trademarks and pay any
     costs in connection therewith. 3DP recognizes the exclusive ownership by
     Schering of the proprietary Schering name, logotype or trademark furnished
     by Schering (including Schering's Affiliates) for use in connection with
     the Licensed Product. 3DP shall not, either while this Agreement is in
     effect or at any time thereafter, register, use or attempt to obtain any
     right in or to any such name, logotype or

_____________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              34
<PAGE>

       trademark or in and to any name, logotype or trademark confusingly
       similar thereto. Only Schering will be authorized to initiate, at its own
       discretion and at its own cost, legal proceedings against any
       infringement or threatened infringement of the trademarks applicable to
       the Licensed Product.

7.9    Use Of Names: Neither Party shall use the name of the other Party in
       relation to this transaction in any public announcement, press release or
       other public document without the written consent of such other Party,
       which consent shall not be unreasonably withheld or delayed, provided
       however, that either Party may use the name of the other Party in any
       document filed with any regulatory agency or authority, including the FDA
       and the Securities and Exchange Commission, in which case Schering shall
       be referred to as "Schering AG, Germany". The Parties agree not to use
       the name of the other Party in relation to this transaction in any press
       release, public announcement or other public document without the
       approval of such other Party, which approval shall not be unreasonably
       withheld or delayed.

7.10   No Trademark Rights: Except as otherwise provided herein, no right,
       express or implied, is granted by the Agreement to use in any manner the
       name "Schering" or "3DP" or any other trade name or trademark of the
       other Party or its Affiliates in connection with the performance of the
       Agreement.

                                   ARTICLE 8

                        REPRESENTATIONS AND WARRANTIES

8.1    Representations And Warranties

       (a) Each of the Parties hereby represents and warrants to the other Party
       as follows:

                                                                              35
<PAGE>

           (i)   This Agreement is a legal and valid obligation binding upon
                 such Party and enforceable in accordance with its terms. The
                 execution, delivery and performance of this Agreement by such
                 Party does not conflict with any agreement, instrument or
                 understanding, oral or written, to which it is a party or by
                 which it is bound, nor to such Party's knowledge, violate any
                 law or regulation of any court, governmental body or
                 administrative or other agency having jurisdiction over it; and

           (ii)  3DP has not granted and during the term of the Agreement will
                 not grant any right to any Third Party relating to the 3DP
                 Patents, 3DP Know-How and Joint Patents which would conflict
                 with the rights granted to Schering hereunder.

     (b)   3DP hereby represents and warrants to Schering that 3DP:

           (i)   Has provided, shown or offered to Schering all material
                 information in its possession or control or of which it is
                 aware as of the Effective Date, concerning efficacy, side
                 effects, injury, toxicity or sensitivity, reaction and
                 incidents of severity thereof, associated with any clinical
                 use, studies, investigations or tests with the Licensed
                 Compounds.

           (ii)  Has conducted or has caused its contractors or consultants to
                 conduct research, and will in the future conduct, the Research
                 Program in accordance with applicable United States law, and
                 the scientific standards applicable to the conduct of research
                 in the US.

          (iii)  Has employed and will in the future employ individuals of
                 appropriate education, knowledge, and experience to conduct or
                 oversee the conduct of the Research Program.

                                                                              36
<PAGE>

          (iv)   As of the Effective Date, except as it may have previously
                 disclosed to Schering in writing: (i) 3DP has not received any
                 notices of infringement or any written communications from
                 Third Parties relating in any way to a possible infringement
                 with respect to any potential or actual Licensed Compounds; and
                 (ii) 3DP is not aware that the manufacture, use or sale of Base
                 Compounds or the conduct of the Research Program in accordance
                 with the attached outline of the Research Plan would infringe
                 any valid claims of any Third Party patent rights.

          (v)    As of the Effective Date, it is not aware of any prior act or
                 any fact which causes it to conclude that any 3DP Patent is
                 invalid or unenforceable.

          (vi)   As of the Effective Date, 3DP is not party to any Third Party
                 agreement under which a Third Party acquires rights of any kind
                 to the Base Compounds, or to any identified uPA Inhibitors
                 owned by 3DP at the Effective Date. The 3DP Technology which is
                 subject to the license granted pursuant to Section 3.1 is the
                 sole property of 3DP and is not subject to any license obtained
                 by 3DP from a Third Party. There are no royalties, milestones
                 or other financial obligations payable to any Third Party by
                 3DP in connection with the ownership, use or licensing of the
                 3DP Technology.

          (vii)  3DP owns all rights to the 3DP Technology free and clear of any
                 liens, encumbrances or rights to repurchase.

          (viii) During the term hereof, 3DP will not grant a lien on this
                 Agreement or on any of 3DP's rights or obligations hereunder or
                 on the 3DP Technology.

          (ix)   The rights licensed to Schering under this Agreement are not
                 subject to any existing licenses from Third Parties in which
                 3DP is the licensee.

                                                                              37
<PAGE>

          (x)    During the Research Term, neither 3DP nor its Affiliates shall
                 enter into any agreements which have the effect of knowingly
                 removing from the Control of 3DP or its Affiliates any uPA
                 Inhibitor which, before the date of such third party agreement,
                 was Controlled by 3DP or an Affiliate.

8.2  Indemnification for Breaches of Representations and Warranties: Without
     prejudice to any other right or remedy available to either Party arising
     out of the breach by the other of any of the representations and warranties
     set out at Section 8.1 above, each Party hereby agrees to indemnify, defend
     and hold the other Party and its shareholders, directors, officers, agents
     and employees harmless from and against any and all losses resulting
     directly or indirectly from the breach of any representation or warranty
     made by such Party hereunder. In the event that a Party is seeking
     indemnification under this Section 8.2, it shall inform the other Party of
     a claim as soon as reasonably practicable after it receives notice of the
     claim, shall permit the indemnifying Party to assume direction and control
     of the defense of the claim (including the right to settle the claim solely
     for monetary consideration), and shall cooperate as requested (at the
     expense of the indemnifying Party) in defense of the claim.

8.3       Performance by Affiliates: The Parties recognize that each Party may
perform some or all of its obligations under this Agreement through Affiliates,
provided however, that each Party shall remain responsible for and be a
guarantor of the performance by its Affiliates and shall cause its Affiliates to
comply with the provisions of this Agreement in connection with such
performance.

                                   ARTICLE 9

                           ROYALTY REPORTS AND AUDITS

                                                                              38
<PAGE>

9.1  Royalty Records: Schering will maintain complete and accurate records which
     are relevant to the calculation of Net Sales and royalties on a country-by-
     country basis and Annual Worldwide Net Sales under this Agreement and such
     records shall be open during reasonable business hours for a period of
     three (3) years from creation of individual records for examination at
     3DP's expense and not more often than once each year by a firm of certified
     public accountants selected by 3DP and reasonably acceptable to Schering,
     for the sole purpose of verifying for 3DP the correctness of calculations
     and classifications of such Net Sales or royalty calculations or Annual
     Worldwide Net Sales made under this Agreement. 3DP shall bear its own costs
     related to such audit; provided that, for any underpayments greater than
     five (5) percent by Schering, Schering shall pay 3DP the amount of
     underpayment, interest as provided for in Section 5.4 from the time the
     amount was due and 3DP's out-of-pocket expenses. For any underpayments less
     than five (5) percent by Schering found under this Section, Schering shall
     pay 3DP the amount of underpayment. Any overpayments by Schering will be
     credited to future royalties. Any records or accounting information
     received from the Schering shall be Confidential Information for purposes
     of Article 6. Results of any such audit shall be provided to both Parties,
     subject to Article 6.

9.2  If there is a dispute between the Parties following any audit performed
     pursuant to Section 9.1, either Party may refer the issue (an "Audit
     Disagreement") to an independent certified public accountant for
     resolution. In the event an Audit Disagreement is submitted for resolution
     by either Party, the Parties shall comply with the following procedures:

     (i)   The Party submitting the Audit Disagreement for resolution shall
           provide written notice to the other that it is invoking the
           procedures of this Section 9.2.

                                                                              39
<PAGE>

     (ii)   Within thirty (30) business days of the giving of such notice, the
            Parties shall jointly select a recognized international accounting
            firm to act as an independent expert to resolve such Audit
            Disagreement;
     (iii)  The Audit Disagreement submitted for resolution shall be described
            by the Parties to the independent expert, which description may be
            in written or oral form, within ten (10) days of the selection of
            such independent expert.
     (iv)   The independent expert shall render a decision on the matter as soon
            as practicable.
     (v)    The decision of the independent expert shall be final and binding
            unless such Audit Disagreement involves alleged fraud, breach of
            this Agreement or construction or interpretation of any of the terms
            and conditions hereof;
     (vi)   All fees and expenses of the independent expert, including any Third
            Party support staff or other costs incurred with respect to carrying
            out the procedures specified at the direction of the independent
            expert in connection with such Audit Disagreement, shall be borne by
            each Party in inverse proportion to the disputed amounts awarded to
            the Party by the independent expert through such decision (e.g.
            Party A disputes $100, the independent expert awards Party A $60,
            then Party A pays forty percent (40%) and Party B pays sixty percent
            (60%) of the independent expert's costs.)

                                  ARTICLE 10

                             TERM AND TERMINATION

10.1 Term: This Agreement shall commence as of the Effective Date and, unless
     sooner terminated as provided herein shall continue in effect until such
     time as no royalties are payable under Article 5 hereunder to 3DP, provided
     that the license to 3DP Know-How granted pursuant to Section 3.2 shall
     survive such termination.

                                                                              40
<PAGE>

10.2 Termination

     (a)  Termination at Will:  Schering will have the right to terminate this
          --------------------
          Agreement for the world or on a country-by-country basis at any time
          after the expiry of the Research Term and be fully released of all
          obligations hereunder (except as expressly provided for herein) by
          ninety (90) days' notice given at any time, and 3DP shall thereafter
          retain full rights to use any data and information generated, up to
          the date of termination, by 3DP, Schering, or jointly pertaining to
          the Licensed Compound and the Licensed Product.

     (b)  Termination for Material Breach: Failure by Schering or 3DP to comply
          --------------------------------
          with any of the respective material obligations and conditions
          contained in this Agreement shall entitle the other Party to give the
          Party in default notice requiring it to cure such default. If such
          default is not cured within ninety (90) days after receipt of such
          notice, the notifying Party shall be entitled (without prejudice to
          any of its other rights conferred by this Agreement) to terminate this
          Agreement or, in the event of an uncured material breach by 3DP
          exercise the rights of Schering set forth in Section 10.2(e) by giving
          a notice to take effect immediately. The right of either Party to
          terminate this Agreement as hereinabove provided shall not be affected
          in any way by its waiver of, or failure to take action with respect
          to, any previous default.

     (c)  Termination for Insolvency: In the event that one of the Parties
          ---------------------------
          hereto shall go into liquidation, a receiver or a trustee be appointed
          for the property or estate of that Party and said receiver or trustee
          is not removed within sixty (60) days, or the Party makes an
          assignment for the benefit of creditors (collectively, a "Bankruptcy
          Event"), and whether any of the aforesaid Bankruptcy Events be the
          outcome of the voluntary act of that Party or otherwise, the other
          Party shall be entitled to terminate this

                                                                              41
<PAGE>

          Agreement (or in the event 3DP suffers such a Bankruptcy Event,
          Schering may exercise its rights described in Section 10.2(e))
          forthwith by giving a written notice to 3DP).

     (d)  Effect of Termination:  In the event that this Agreement is terminated
          ---------------------
          by Schering in one or more countries or in its entirety in accordance
          with Section 10.2(a), or this Agreement is terminated by 3DP pursuant
          to Sections 10.2(b) or (c) either in one country or in its entirety,
          Schering will, with respect to each country to which the termination
          applies:

          (i)     deliver to 3DP the 3DP Know-How and assign to 3DP any rights
                  in the 3DP Technology, if any, in either case relating solely
                  to the country that is the subject of the termination;

          (vii)   not use the 3DP Know-How as long as it has to be kept
                  confidential pursuant to Article 6 hereof in such country;

          (viii)  not infringe any of the 3DP Patents in such country; and

          (ix)    provide 3DP with the right to utilize and commercialize the
                  3DP Technology notwithstanding the existence of any Patents
                  that are Controlled by Schering or its Affiliates that cover
                  such 3DP Technology.

     (e)  Effect of Termination by Schering Pursuant to Sections 10.2(b) and
          ------------------------------------------------------------------
          (c): In the event of a Bankruptcy Event or a material default
          ---
          described in Sections 10.2(b) and (c) by 3DP, which default is not
          cured as provided therein, Schering may elect, in lieu of terminating
          this Agreement (and without prejudice to any claim for damages arising
          out of such material default) to declare the license granted pursuant
          to this Agreement to be irrevocable. From the date of receipt of
          notice of such election, 3DP shall have no further rights or
          obligations (except for those arising under Article 6) under this
          Agreement except that 3DP's right to receive financial

                                                                              42
<PAGE>

          payments by Schering pursuant to the terms of this Agreement will
          remain in full force and effect.

     (f)  General: Except where expressly provided for otherwise in this
          -------
          Agreement, termination of this Agreement shall not relieve the Parties
          hereto of any liability, including any obligation to make payments
          hereunder, which accrued hereunder prior to the effective date of such
          termination nor preclude any Party from pursuing all rights and
          remedies it may have hereunder or at law or in equity with respect to
          any breach of this Agreement nor prejudice any Party's right to obtain
          performance of any obligation.

     (g)  Surviving Rights: The rights and obligations set forth in this
          ----------------
          Agreement shall extend beyond the term or termination of the Agreement
          only to the extent expressly provided for herein, or the extent that
          the survival of such rights or obligations are necessary to permit
          their complete fulfillment or discharge.

                                  ARTICLE 11

                                INDEMNIFICATION

11.1      Indemnification: With respect to Licensed Products (determined on a
     country by country basis):

     (a)  Except as specified below, Schering hereby agrees to save, defend and
          hold 3DP and its directors, officers, agents and employees harmless
          from and against any and all suits, claims, actions, demands,
          liabilities, expenses and/or losses, including reasonable legal
          expenses and attorneys' fees (collectively "Losses") resulting from
          the development or commercial sale of the Licensed Products except to
          the extent such Losses result from the

                                                                              43
<PAGE>

          negligence or willful misconduct of 3DP or a breach by 3DP of any of
          its material obligations under this Agreement or of any representation
          or warranty under Article 8, in which case 3DP hereby agrees to save,
          defend and hold Schering and its directors, officers, agents and
          employees harmless from any and all such Losses.

                                                                              44
<PAGE>

     (b) Each indemnified Party agrees to give the indemnifying Party prompt
         written notice of any Loss or discovery of fact upon which such
         indemnified Party intends to base a request for indemnification under
         Section 11.1(a). Each Party shall furnish promptly to the other copies
         of all papers and official documents received in respect of any Loss.
         With respect to any Loss relating solely to the payment of money
         damages and which will not result in the indemnified Party becoming
         subject to injunctive or other relief or otherwise adversely affecting
         the business of the indemnified Party in any manner, and as to which
         the indemnifying Party shall have acknowledged in writing the
         obligation to indemnify the indemnified Party hereunder, the
         indemnifying Party shall have the sole right to defend, settle or
         otherwise dispose of such Loss, on such terms as the indemnifying
         Party, in its sole discretion, shall deem appropriate. The indemnifying
         Party shall obtain the written consent of the indemnified Party which
         shall not be unreasonably withheld or delayed, prior to ceasing to
         defend, settling or otherwise disposing of any Loss if as a result
         thereof the indemnified Party would become subject to injunctive or
         other equitable relief, or any remedy other than the payment of money
         which is the responsibility of the indemnifying Party. The indemnifying
         Party shall not be liable for any settlement or other disposition of a
         Loss by the indemnified Party which is reached without the written
         consent of the indemnifying Party. The reasonable costs and expenses,
         including reasonable fees and disbursements of counsel incurred by any
         indemnified Party in connection with any Loss, shall be reimbursed on a
         quarterly basis by the indemnifying Party, without prejudice to the
         indemnifying Party's right to contest the indemnified Party's right to
         indemnification and subject to refund in the event the indemnifying
         Party is ultimately held not to be obligated to indemnify the
         indemnified Party.

                                                                             45
<PAGE>

                                  ARTICLE 12

                                 MISCELLANEOUS

12.1 ASSIGNMENT:

     (b)  Either Party may assign any of its rights or obligations under this
          Agreement in any country to any of its Affiliates, provided that such
          assignment shall not relieve the assigning Party of its
          responsibilities for performance of its obligations under this
          Agreement .

     (c)  This Agreement shall be binding upon and inure to the benefit of the
          successors and permitted assigns of the Parties. Any assignment not in
          accordance with this Agreement shall be void.

12.2 RETAINED RIGHTS: Nothing in this Agreement shall limit in any respect the
     right of either Party to conduct research and development and to market
     products using such Party's technology other than as herein expressly
     provided.

12.3 FURTHER ACTIONS: Each Party agrees to execute, acknowledge and deliver such
     further instruments, and to do all such other acts as may be necessary or
     appropriate in order to carry out the purposes and intent of this
     Agreement.

12.4      NOTICES: All notices hereunder shall be in writing and shall be deemed
     given if delivered personally or two days after mailed by registered or
     certified mail (return receipt requested), postage prepaid, or sent by
     express courier service to the Parties at the following addresses (or at
     such other address for a Party as shall be specified by like notice;
     provided that notices of a change of address shall be effective only upon
     receipt thereof).

                                                                              46
<PAGE>

     (a)  If to 3DP

          3-Dimensional Pharmaceuticals, Inc.
          Eagleview Corporate Center
          665 Stockton Drive, Suite 104
          Exton, PA 10341

          ATTN: Chief Executive Officer

          with a copy to:

          Morgan, Lewis & Bockius LLP
          1701 Market Street
          Philadelphia, PA 19103

          ATTN: David R. King, Esq.

     (a)  If to Schering:

          Schering Aktiengesellschaft
          13342 Berlin
          Germany,
          Attention: Legal Department

          with a copy to:

          Berlex Biosciences
          15049 San Pablo Avenue
          P.O. Box 4099
          Richmond, CA 94804-0099
          Attention: President

12.5 Waiver:  Except as specifically provided for herein, the waiver from time
     to time by either of the Parties of any of their rights or their failure to
     exercise any

                                                                              47
<PAGE>

      remedy shall not operate or be construed as a continuing waiver of same or
      any other of such Party's rights or remedies provided in this Agreement.

12.6  Severability: If any term, covenant or condition of this Agreement or the
      application thereof to any Party or circumstances shall, to any extent or
      in any country, be held to be invalid or unenforceable, then (i) the
      remainder of this Agreement, or the application of such term, covenant or
      condition of this Agreement shall be valid and be enforced to the fullest
      extent permitted by law; and (ii) the Parties hereto covenant and agree to
      renegotiate any such term, covenant or application thereof in good faith
      in order to provide a reasonably acceptable alternative to the term,
      covenant or condition of this Agreement or the application thereof that is
      invalid or unenforceable, it being the intent of the Parties that the
      basic purposes of this Agreement are to be effected.

12.7  Ambiguities: Ambiguities, if any, in this Agreement shall not be construed
      against any Party, irrespective of which Party may be deemed to have
      authored the ambiguous provision.

12.8      Governing Law and Jurisdiction:  This Agreement shall be governed by
      and interpreted under the laws of the State of New York as applied to
      contracts entered into and performed entirely in New York by New York
      residents. Any lawsuit concerning this Agreement shall be brought in the
      state or federal courts of New York.

12.9  Headings: The sections and paragraph headings contained herein are for the
      purposes of convenience only and are not intended to define or limit the
      contents of said sections or paragraphs.

12.10 Counterparts: This Agreement may be executed in one or more counterparts
      (and by facsimile), each of which shall be deemed an original but all of
      which together shall constitute one and the same instrument.

                                                                             48
<PAGE>

12.11 Entire Agreement; Amendments: This Agreement, including all Exhibits
      attached hereto and thereto, and all documents delivered concurrently
      herewith and therewith, set forth all the covenants, promises, agreements,
      warranties, representations, conditions and understandings between the
      Parties hereto and supersede and terminate all prior agreements and
      understandings between the Parties. There are no covenants, promises,
      agreements, warranties, representations, conditions or understandings,
      either oral or written, between the Parties other than as set forth herein
      and therein. No subsequent alteration, amendment, change or addition to
      this Agreement shall be binding upon the Parties hereto unless reduced to
      writing and signed by the respective authorized officers of the Parties.
      This Agreement, including without limitation the exhibits, schedules and
      attachments thereto, are intended to define the full extent of the legally
      enforceable undertakings of the Parties hereto, and no promise or
      representation, written or oral, which is not set forth explicitly herein
      or therein is intended by either Party to be legally binding. Both Parties
      acknowledge that in deciding to enter into the Agreement and to consummate
      the transaction contemplated hereby neither has relied upon any statement
      or representations, written or oral, other than those explicitly set forth
      herein.

12.12 Expenses: Except as otherwise specified in this Agreement, all costs and
      expenses including, without limitation, fees and disbursements of counsel,
      financial advisors and accountants, travel, lodging, meals and
      entertainment incurred in connection with this Agreement and the
      transactions contemplated hereby shall be paid by the Party incurring such
      costs and expenses.

12.13 Independent Contractors: The status of the parties under this Agreement
      shall be that of independent contractors. Neither Party shall have the
      right to enter into any agreements on behalf of the other Party, nor shall
      it represent to any person that it has any such right or authority.
      Nothing in this Agreement shall be construed as establishing a partnership
      or joint venture relationship between the

                                                                             49
<PAGE>

      Parties. This Agreement is not intended to be a partnership between 3DP
      and Schering for federal, state or local income tax purposes.

IN WITNESS WHEREOF 3DP and Schering have caused this agreement to be executed as
of the date first written above by their respective officers thereunto duly
authorized.

SIGNED for and on behalf of
SCHERING AKTIENGESELLSCHAFT

/S/ G. Stock                            /S/ J.F. Kapp
------------                            -------------

Name:  Prof. Dr. G. Stock               Name:  Dr. J.F. Kapp

Title:  Member of Executive             Title:  Head of Strategic Business
        Board of Directors                      Unit Therapeutics

Date:                                   Date:

SIGNED for and on behalf of
3-DIMENSIONAL PHARMACEUTICALS, INC.

/S/ David U'Prichard
--------------------

Name:  Dr. David U'Prichard

Title:  Chief Executive Officer

Date:

                                                                            50
<PAGE>

                                  Schedule A

Patents
       Appl. No./     Filing Date/ Country      Title         SKGF Docket Status
             Patent No. or   Issue Date                            Number

                                  Publication

[**]

_____________________________
** This page and the next five pages of this Exhibit have been omitted based
upon a request for confidential treatment that has been filed with the
Commission. The omitted pages have been filed separately with the Commission.

                                                                              51
<PAGE>

                                   Schedule B

                                     Part I

                             Outline Research Plan
[**]

_____________________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              52
<PAGE>

[**]

_____________________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              53
<PAGE>

[**]

_____________________________
**Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              54
<PAGE>

[**]

_____________________________
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment that has been filed with the Commission. The omitted
portions have been filed separately with the Commission.

                                                                              55<PAGE>

                             AMENDED AND RESTATED

                             LEASE FOR COMBINATION

                  OFFICE/LABORATORY/LIGHT MANUFACTURING SPACE

                                      AT

                          EAGLEVIEW CORPORATE CENTER

                                    LOT 28

                    LANDLORD: EAGLEVIEW TECHNOLOGY PARTNERS

                  TENANT: 3-DIMENSIONAL PHARMACEUTICALS, INC.
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
                                                                     Page
<S>                                                                  <C>

1.   LEASED SPACE AND PURPOSE.......................................   1
2.   TERM...........................................................   2
3.   RENT...........................................................   3
4.   ADDITIONAL.RENT................................................   6
5.   NEGATIVE COVENANTS OF TENANT; HAZARDOUS SUBSTANCES.............   7
6.   LATE PAYMENT...................................................  10
7.   CONSTRUCTION OF NEW SPACE......................................  10
8.   TENANT'S ALTERATIONS...........................................  16
9.   MECHANIC'S LIENS...............................................  17
10.  CONDITION OF LEASED SPACE......................................  17
11.  BUILDING SERVICES..............................................  17
12.  ASSIGNMENT AND SUBLETTING......................................  18
13.  ACCESS TO LEASED SPACE.........................................  19
14.  REPAIRS........................................................  19
15.  TERMINATION AND EXTENSION......................................  20
16.  INTENTIONALLY OMITTED..........................................  20
17.  INDEMNIMFICATION AND INSURANCE.................................  20
18.  FIRE OR OTHER CASUALTY.........................................  21
19.  CONDEMNATION...................................................  22
20.  ESTOPPEL CERTIFICATES..........................................  22
21.  DEFAULT........................................................  23
22.  REMEDIES.......................................................  24
23.  CONFESSION OF JUDGMENT.........................................  25
24.  WAIVER.........................................................  26
25.  QUIET ENJOYMENT................................................  26
26.  FORCE MAJEURE..................................................  26
27.  SUCCESSORS.....................................................  26
28.  LANDLORD'S LIABILITY...........................................  26
</TABLE>

                                      -i-
<PAGE>

                               TABLE OF CONTENTS

                                  (continued)

<TABLE>
                                                                     Page
<S>                                                                  <C>

29.  SUBORDINATION..................................................  27
30.  SUBSTITUTE SPACE...............................................  28
31.  RULES AND REGULATIONS..........................................  28
32.  GOVERNING LAW..................................................  28
33.  SEVERABILITY...................................................  28
34.  HOLDING OVER...................................................  28
35.  NOTICES........................................................  29
36.  BROKERS........................................................  29
37.  SIGNS..........................................................  30
38.  SECURITY DEPOSIT; SECURITY INTEREST............................  30
39.  USE OF INFORMATION IN ADVERTISING..............................  31
40.  CAPTIONS.......................................................  31
41.  ENTIRE AGREEMENT...............................................  31
42.  RIGHT OF FIRST REFUSAL.........................................  31
43.  OPTION TO CANCEL...............................................  32
44.  RIGHT OF FIRST REFUSAL TO PURCHASE THE BUILDING................  33
45.  COOPERATION OF TENANT..........................................  33
</TABLE>

                                     -ii-
<PAGE>

                          AMENDED AND RESTATED LEASE
                          --------------------------

     LEASE made this ____ day of __________________, 1997 between Eagleview
TECHNOLOGY PARTNERS, a limited partnership, successor in interest to the Hankin
Group ("Landlord"), with its office at 717 Constitution Drive, P.O. Box "562,
Exton, PA 19341

                                      AND

     3-DIMENSIONAL PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"),
with its office at 665 Stockton Drive, Suite 104, Exton, PA 19341

                                  BACKGROUND

     The Hankin Group, predecessor in interest to the Landlord, and Tenant
entered into a Lease on April 28, 1994 for 15,861 square feet of space
("Original Space") in a building located on lot 28, 665 Stockton Drive in the
center known as Eagleview Corporate Center, Route 100, Exton, Uwchlan Township,
Chester County, Pennsylvania ("Original Lease").

     The Original Lease contemplated the possibility of the expansion of the
Original Space. Tenant now desires to expand the Original Space and extend the
term of the Original Lease among other desired amendments to the Original Lease.

     Landlord and Tenant now wish to amend and restate their respective rights,
duties and obligations under the Original Lease in this Amended and Restated
Lease. Accordingly, effective as of the date hereof, the Original Lease is
hereby amended and restated in its entirety as follows:

1.   LEASED SPACE AND PURPOSE.

     (a)  Landlord hereby rents to Tenant all that certain space within a
building t (the "Original Building"), in the center known as Eagleview Corporate
Center, ("Center") Route 100, Exton, Uwchlan Township, Chester County,
Pennsylvania (the term "Center" as used herein shall not include residential
areas), which Original Building is located on Lot 28, 665 Stockton Drive as more
fully shown on the land development plan attached hereto as Exhibit "1A1", the
space leased by Tenant consists of approximately fifteen thousand eight hundred
sixty one (15,861) square feet, more or less, as depicted on the building plan
attached hereto as Exhibit "IA2". plus a storage shed and enclosed area outside
the Original Building as shown on Exhibits "lA3" and "lA4", and is referred to
herein as the "Original Space". The Original Space includes all fixtures,
improvements, additions and other property installed therein at any time during
the term of this Lease, and by virtue of this Lease.

     (b)  Landlord hereby further rents to Tenant all that certain space to be
constructed in accordance with Section 7 below (the "New Building") as an
addition to the Original Building and the Original Space, such additional space
to be leased by Tenant to consist of all of the being co the New Building, being
approximately Fourteen Thousand Five Hundred Fifty (14,550) square feet, more or
less, as depicted on the prebuilding plan attached hereto as Exhibit "IA3",
<PAGE>

and is referred to herein as the "New Space". The New Space includes all
fixtures, improvements, additions and other property installed therein at any
time during the term of this Lease and by virtue of this Lease.

     (c)  The New Space and the Original Space shall be individually and
collectively as the "Leased Space." The Original Building and the New Building
shall be individually and collectively known as the "Building". Tenant shall
have the right to use, in common with others, the parking lot and other public
portions of the Building and of the Center. The Leased Space shall be used and
occupied as an office, laboratory and light manufacturing facility qualifying as
high technology under the regulations adopted by the Pennsylvania Industrial
Development Authority and for no other purpose.

2.   TERM.

     (a)  The term of this Lease and Tenant's obligation to pay rent hereunder
for the Original Space commences on the date of execution of this Lease, and for
the New Space on the "Commencement Date" hereinafter defined, or on such earlier
date determined in accordance with Section 2(c) below.:

     (b)  The occupancy by Tenant of the New Space shall commence upon a date
("Commencement Date") which is the earlier of:

          (i)  the date when the New Space is ready for occupancy; or

          (ii) the date when Tenant shall commence conducting its business in
the New Space.

     (c)  The New Space shall be deemed ready for occupancy when (i) Landlord
has substantially completed Landlord's Work (defined below); and (ii) a use and
occupancy certificate is issued by Uwchlan Township authorizing lawful occupancy
of the New Building and the New Space and a copy of such certificate is
delivered to Tenant. In the event of any disagreement between Landlord and
Tenant as to whether "substantial completion" has occurred, the same shall be
resolved by the Architect. "Substantial completion" shall mean such completion
as shall enable Tenant to reasonably and conveniently use and occupy the New
Space for the conduct of its business. Substantial completion shall be deemed to
have been achieved even though minor or insubstantial details of construction,
mechanical adjustment or decoration remain to be performed the non-completion of
which does not materially interfere with Tenant's use of the Lease Space for the
conduct of its business therein. Tenant and Landlord shall execute a declaration
of the Commencement Date upon the Commencement Date. Notwithstanding the fact
that the Commencement Date may not yet have occurred as to the entire New Space,
when, the "non-laboratory area" of the New Space as designated on Exhibit IA3 is
ready for occupancy, Tenant shall be permitted to occupy the same on such date.
or not Tenant takes occupancy, beginning on such date, Tenant shall pay, in
addition to Original Minimum Annual Rent, a prorated portion for the
"nonlaboratory area" of (1) the Minimum Annual Rent calculated in accordance
with Section 3(c)(i); and (2) Additional Rent in accordance with Section 3(e),
and shall be otherwise subject to all of the terms, conditions and other
obligations of Tenant under this Lease as of such date, with the exception of
obligations relating to the Minimum Annual

                                      -2-
<PAGE>

Rent and payments on account of Real Estate Taxes and Operating Expenses
allocable to laboratory areas in the New Space to be deferred until the
Commencement Date. Tenant and Landlord shall execute an interim declaration of
possession upon substantial completion of the nonlaboratory areas.

     (d)  Landlord shall substantially complete Landlord's Work within eight (8)
months following Tenant's approval of the "Tenant Plans" (as hereinafter
defined), provided that, if such approval occurs later than October 31, 1997,
Landlord shall have a period of (1) one additional day for every day after
October 31, 1997 that the approval has not been given to substantially complete
Landlord's Work (such required date of substantial completion being hereinafter
called the "Landlord's Work Completion Date"). The term ("Term") of this Lease
shall end ten (10) years after the Commencement Date, provided, however, that if
the Commencement Date is not the first day of a calendar month, the Term shall
extend to the last day of the calendar month ten (10) years after the last day
of the calendar month in which the Commencement Date occurs.

3.   RENT.

     (a)  Definitions.

          (i)   "Tenant's Proportionate Share" means for the Original Building,
60.82% and for the New Building, 100%. If Landlord desires, it may combine
Tenant's Proportionate Share for the entire Building, which shall be 74.85%.

          (ii)  "Real Estate Taxes" shall mean all taxes and assessments levied,
assessed or imposed at any time by any governmental authority upon or against
the Building and the land upon which the Building is situate, and also any tax
or assessment levied, assessed or imposed at any time by any governmental
authority in connection with the receipt of income or rents from said Building
or land to the extent that the same shall be in lieu of (and/or in lieu of an
increase in) all or a portion of any of the aforesaid taxes or assessments upon
or against the said Building and/or land, but shall not include any federal or
state income tax (unless the same are imposed in lieu of any of the taxes
against the Building and land described above, or in lieu of an increase in such
taxes), or any franchise capital stock, estate or inheritance taxes.

          (iii) "Operating Expenses" shall mean that part of any and all
expenses, without mark-up or premium, reasonably incurred by Landlord in
connection with its ownership, and operation of the Building, and the land upon
which the Building is situate (i.e., Lot 28), including, without limitation,
insurance maintained on the Building which, in Landlord's judgment, shall be
necessary, all direct labor costs, management fees, service contracts and
supplies used in connection with the cleaning, operating, labor and maintenance
of the Building, all repairs and decorating required to be performed by Landlord
as provided for in this Lease (other than "Landlord's Work" as defined herein),
common area maintenance and snow removal, building supplies, equipment,
purchases and maintenance, all charges for the common areas of the Building for
electricity and water, removal of trash, rubbish, garbage and refuse, the cost
of operating or leasing an identification sign or signs for the Building,
replacing of paving, curbs, walkways, directions or other signs, drainage,
maintenance of fire sprinkling systems (if any), and the Building's pro rata
share of such other expenses as Landlord may deem necessary and proper in
connection with the operation and maintenance of the common areas of the
Building

                                      -3-
<PAGE>

and Center, excluding any costs which under generally accepted accounting
principles are capital expenditures; provided, however, that Operating Expenses
shall also include the annual amortization (over the anticipated useful life) of
a capital improvement failing within any of the following categories: (i) a
labor saving device or improvement which is intended to reduce or eliminate any
other component of Operating Expenses; (ii) an installation or improvement
required by reason of any law, ordinance or regulation, which requirement did
not exist on the date of this Lease and is generally applicable to similar
buildings; (iii) an installation or improvement which directly enhances safety
of tenants in the Building or Center generally. Landlord shall have the right to
bill Tenant directly for any items of Operating Expenses which can be attributed
directly to Tenant's use only. The following shall be excluded from the term
'Operating Expenses": (i) expenses for repairs or other work occasioned by fire,
windstorm or other insured casualty (excluding any deductible amounts) or caused
by and chargeable to a particular tenant; (ii) expenses incurred in leasing or
procuring new tenants (e.g., for lease commissions, advertising expenses and
expenses of renovating space for new or existing tenants); (iii) legal expenses
in enforcing the terms of any lease; (iv) interest and amortization payments on
any mortgage or mortgages; (v) the cost of any item, whether purchased or
leased, that would be considered a capital item or improvement under generally
accepted accounting principles (except to the extent permitted above); and (vi)
any charge or fee paid by, or for which Landlord is reimbursed by, any other
tenant occupying the Building; (vii) Real Estate Taxes and (viii) any cost to
remediate an environmental problem provided said problem was not caused by any
act or omission of Tenant or any contractor, employee, agent, invitee or guest
of Tenant.

     (b)  From the date hereof until the Commencement Date, Tenant shall pay
Landlord minimum annual rent ("Original Minimum Annual Rent") equal to the sum
of $198,524.21 in monthly installments of $16,543.68 each.

     (c)  Tenant shall pay Landlord minimum annual rent from and after the
Commencement Date Annual Rent") equal to the applicable "Shell Rent" and
"Amortized Fit Out-Rent Portion" as described below.

          (i)    For the period from the Commencement Date until February 28,
2005 (the "Rent Adjustment Date"), the "Shell Rent" per annum shall be: (A)
$114,654.00 being, the square footage of the New Space which for the purposes of
this Lease, the parties agree shall be deemed to be 14,550 square feet,
multiplied by $7.88, plus (B) $105,797.63, being the square footage of the
Original Space which for the purposes of this Lease, the parties agree shall be
deemed to be 15,861 square feet, multiplied by $6.6703, plus

          (ii)   For the period from the Rent Adjustment Date through the end of
the Term, the "Shell Rent" per annum shall be $239,638.68, being the square
footage of the entire Leased Space, which for the purposes of this Lease, the
parties agree shall be deemed to be 30,411 square feet, multiplied by $7.88.

          (iii)  For the period from the Commencement Date until the Rent
Adjustment Date, the "Amortized Fit-Out Rent Portion: shall mean $92,726.59
(representing the "Amortized Fit-Out Rent Portion" for the Original Space
calculated pursuant to the Original Lease), plus the "New Space Amortized Fit-
Out Rent Portion' as defined below.

                                      -4-
<PAGE>

     (iv)  For the period from the Rent Adjustment Date through the end of the
Term, the Amortized Fit-Out Rent Portion shall be the New Space Amortized Fit-
Out Rent Portion as defined below

     (v)   For the purposes of this Lease, and the calculation of Minimum Annual
Rent, the following terms shall have the meanings as set forth below:

          (A)  "Fit-Out Cost" shall mean the "Cost to Landlord" of performing
the Fit-Out Work for the New Space.

          (B)  "Cost to Landlord" shall mean the actual cost billed to Landlord
by Eagleview Commercial Construction Company, Inc. (the "General Contractor") of
supplying all labor and materials to perform the Fit-Out Work for the New Space,
including all items as are included within the definition of "Cost of the Work"
pursuant to Article 8 of the "American Institute for Architects AIA Document
Al11 Standard Form of Agreement Between Owner and Contractor where the basis of
payment is the Cost of the Work Plus a Fee," plus a fee of ten (10%) which shall
be charged to Landlord by the General Contractor.

          (C)  "Fit-out Work" shall mean "Landlord's Work" (as defined in
Section 7 below) exclusive of site work, building shell construction, building
shell architectural, site engineering and related work, within the portion of
the New Space intended to be completely fit-out by Landlord prior to the
Commencement Date, presently estimated at 14,550 square feet.

          (D)  "New Space Amortized Fit-Out Rent Portion" shall mean a sum equal
to the monthly payment necessary to repay one half of the Fit-Out Cost, with
interest at ten (10%) percent per annum over a 120 month term in equal monthly
installments, multiplied by twelve (12). The principal base upon which the
Amortized Fit-Out Rent Portion shall be calculated is hereinafter called the
"Amortization Base." Landlord and Tenant have established a preliminary budget
for the Fit-Out Cost of $1,675,450.00, for 14,550 square feet of finished New
Space. By way of illustration, if the actual Fit-Out Cost is $1,675,450.00, one-
half the Fit-Out Cost would be $837,725.00, and the Amortized Fit-Out Rent
Portion for the New Space would be $132,847.32 per year.

     (d)  Minimum Annual Rent and Original Minimum Annual Rent shall be paid in
equal monthly installments on the first day of each calendar month in advance.
If the Commencement Date is not the first day of a calendar month, rent from the
Commencement Date to the first day of the following month shall be apportioned
at the Minimum Annual Rent rate (based on a 365-day year) and shall be paid, on
or before the Commencement Date. All rent shall be payable, in advance, and
without prior notice or demand, at the address of Landlord set forth in the
heading of this Lease or at such other place, or to such other person as
Landlord may from time to time direct by written notice to Tenant.

     (e)  In addition, Tenant shall pay to Landlord as Additional Rent in equal
monthly installments one twelfth (1/12) of Tenant's Proportionate Share of
annual Real Estate Taxes and Operating Expenses, at the time of payment of each
monthly installment of Minimum Annual Rent or Original Minimum Annual Rent,
based upon the most recent costs of Operating Expenses and Real Estate Taxes
available. For the period from the date hereof until the

                                      -5-
<PAGE>

Commencement Date such monthly installment shall be equal to: (i) $2.30,
multiplied by the sum of 15,861 plus, ii) the square footage of the "non
laboratory areas", only if the "non laboratory areas" of the New Space is ready
for occupancy, (iii) divided by 12. For the period from the Commencement Date
until the issuance of a statement pursuant to subsection 3(f) below, such
monthly installment shall be equal to $2.30 multiplied by 30,41 1, divided by
12.

     (f)  Within ninety (90) days of the expiration of each calendar year
Landlord shall furnish Tenant with a written statement, certified by Landlord,
of the actual Operating Expenses and Real Estate Taxes incurred for such year.
Within thirty (30) days of the rendition of such statement, Tenant shall pay any
amounts in excess of those collected pursuant to the payments on account of Real
Estate Taxes and Operating Expenses pursuant to Section 3 (c) hereof, and
Landlord shall refund to Tenant or credit against the next installments of rent
due, any excess of the payments by Tenant under Section 3 (c) over the actual
Tenant's Proportionate Share of Operating Expenses and Real Estate Taxes. In the
event the last year of the term of this Lease shall not be a full calendar year,
then Tenant's obligation for Expenses and Real Estate Taxes attributable to such
year shall be pro rated.

     (g)  For each calendar year, Landlord shall make a reasonable estimate of
the Operating Expenses and Real Estate Taxes and notify Tenant as to such
estimate on or about December 15th of the preceding calendar year.

     (h)  Within ninety (90) days after receipt of each statement, Tenant shall
have the right to audit and contest Landlord's determination of Operating
Expenses and Real Estate Taxes and to inspect Landlord's records with respect
thereto during normal business hours upon at least ten (10) days advance written
notice. If any such audit shall reveal a discrepancy in Landlord's determination
of the Operating Expenses and/or Real Estate Taxes, Landlord and Tenant shall
cooperate in good faith to resolve the discrepancy and mutually agree upon the
amount of the actual Operating Expenses and Real Estate Taxes. In the event it
is determined that Tenant has been charged more than its actual Tenant's
Proportionate Share of Operating Expenses and Real Estate Taxes, Landlord shall
refund the excess payment to Tenant.

     (i)  All sums due under this Article shall be appropriately apportioned and
prorated for any portion of a Lease year, so that Tenant shall not be obligated
to pay any Operating Expenses or Real Estate Taxes that accrue following the
expiration or earlier termination of the Term of this Lease. In the event that
this Lease shall expire or terminate at any time other than at the end of a
calendar year, then within thirty (30) days after statements reflecting the
actual Operating Expenses for the year in which such expiration or termination
occurs are submitted by Landlord to Tenant (pro-rated on the basis of the number
of calendar year days included within such partial Lease year divided by 365
days), either Landlord or Tenant shall pay to the other party the adjustment sum
due. The provisions of this paragraph shall survive the expiration of this
Lease.

4.   ADDITIONAL.RENT.

     Tenant shall pay to Landlord as "Additional Rent" (in addition to sums
payable pursuant to sections 3 (c) and 3 (d) the following:

                                      -6-
<PAGE>

     (a)  Expenses Incurred by Landlord as a Result of Tenant's Default. Any and
          -------------------------------------------------------------
all damages, costs and expenses (including without limitation thereto reasonable
attorney's fees) which Landlord may suffer or incur by reason of the occurrence
of an Event of Default under this Lease, and any damage to the Building or the
real estate of which the Building is a part caused by any act or omission of
Tenant, together with interest to the date of payment (whether before or after
entry of judgment and issuance of execution thereon) at a rate equal to five
(5%) percent above the prime interest rate (or similar rate if the prime
interest rate is no longer published) of First Union Bank, N.A. or its
successor, in effect during the period said payment is due ("Default Rate").

     (b)  Use and Occupancy Taxes. All use and Occupancy taxes imposed by any
          -----------------------
governmental body allocable to Tenant's use and occupancy of the Leased Space.

     (c)  Utilities. All charges for beat, gas, water, electric, trash and
          ---------
sewage disposal for the Leased Space, whether billed directly by the providers
of the same to Tenant, or by Landlord as the owner of the Building. Landlord
shall cause electric, gas (if any), water and sewer to be separately sub-
metered. Landlord shall bill Tenant for Landlord's sub-metered amount of
Tenant's consumption of water and sewer.

5.   NEGATIVE COVENANTS OF TENANT; HAZARDOUS SUBSTANCES.

     (a)  Tenant will not:

          (i)    damage the Leased Space or any other part of the Building;

          (ii)   except in the ordinary course of laboratory business and as
permitted in accordance with all applicable laws, regulations and ordinances,
bring into or permit to be kept in the Leased Space any dangerous, explosive or
obnoxious substances;

          (iii)  violate any of the terms and conditions of the Amended and
Restated Declaration of Easements and Protective Covenants and Restrictions
dated July 12, 1990, as supplemented and clarified by a certain Supplement and
Clarification dated April 2, 1991, and as amended by: First Amendment to Amended
and Restated Declaration of Easements and Protective Covenants and Restrictions
dated August 26, 1991, Second Amendment to Amended and Restated Declaration of
Easements and Protective Covenants and Restrictions For Eagleview Corporate
Center dated July 15, 1993., Third Amendment to Amended and Restated Declaration
of Easements and Protective Covenants and Restrictions For Eagleview Corporate
Center dated December 2, 1993 Fourth Amendment to Amended and Restated
Declaration of Easements and Protective Covenants and Restrictions dated May 15,
1997 and Fifth Amendment to Amended and Restated Declaration of Easements and
Protective Covenants and Restrictions for Eagleview Corporate Center dated July
22, 1997. copies of which have been delivered to Tenant, and such further
amendments thereto as may be adopted from time to time;

          (iv)   conduct itself or permit its agents, servants, employees or
invitees to conduct themselves in a manner that in Landlord's judgment
reasonably exercised is unsafe;

                                      -7-
<PAGE>

          (v)    manufacture any commodity or prepare or dispense any food or
beverages in the Leased Space, except for consumption in Leased Space by Tenant,
its employees or invitees;

          (vi)   remove, attempt to remove or manifest any intention to remove
Tenant's goods or property from the Space other than in the ordinary course of
business;

          (vii)  vacate or abandon the Lease Space, or permit the Leased Space
to be empty or unoccupied for a period in excess of 15 consecutive days; or

          (viii) do or suffer to be done, any act, matter or thing objectionable
to the fire insurance companies or Board of Underwriters whereby the fire
insurance or any other now in force or hereafter to be placed on the Leased
Space or the Building or Center shall become void or suspended, or whereby the
same shall be rated as a more hazardous risk than at the Commencement Date.
Tenant agrees to pay to Landlord as Additional Rent, any and all increases in
premiums for insurance carried by Landlord on the Leased Space, or on the
Building, caused in any way by the occupancy of Tenant; or

          (ix)   use water in quantities beyond 3000 gallons per day, or dispose
of effluent which requires pretreatment as a condition to being treated in
accordance with regulations established by the Downingtown Area Regional
Authority for its wastewater treatment plants, or violate any of the terms or
conditions of the Industrial Waste Discharge Rider attached hereto and made part
hereof . If Tenant's required water usage exceeds 3000 gallons- per day,
Landlord shall not unreasonably withhold its consent to Tenant's request for
greater usage; provided, however, that in such event, Tenant shall pay to
Landlord (in addition to the metered charge for water and sewer service) a per
gallon connection fee equal to the Tenant's required water usage in excess of
3000 gallons per day (the "Excess Capacity"), multiplied by the Landlord's
calculation of the per gallon cost of designing, permitting, acquiring and
constructing the waste treatment facilities which will treat Tenant's Excess
Capacity. The per gallon cost shall be calculated by adding all costs incurred
by Landlord in designing, permitting, acquiring and constructing the waste
treatment facilities (including the value of land contributed by Landlord for
the treatment plant at the per acre price as agreed among Landlord, Uwchlan
Township and the Uwchlan Township Municipal Authority). In calculating any such
fee, the calculation shall, to the extent possible, be based on the same factors
and criteria as are applicable in calculation of reservation and tapping fees
chargeable to developers or potential users (other than Landlord) of the waste
treatment facilities pursuant to any agreements governing the same among
Landlord, Uwchlan Township and the Uwchlan Township Municipal Authority.

     (b)  Tenant's Responsibility Regarding Hazardous Substances.
          ------------------------------------------------------

          (i)  Hazardous Substances. The term "Hazardous Substances," as used in
this Lease, shall include, without limitation, flammables, explosives,
radioactive materials, asbestos, polychorinated biphenyls (PCB's), chemicals
known to cause cancer or reproductive toxicity, pollutants, contaminants,
hazardous wastes, toxic substances or related materials, petroleum and petroleum
products, and substances declared to be hazardous or toxic under any law or
regulation now or hereafter enacted or promulgated by any governmental
authority.

                                      -8-
<PAGE>

          (ii) Tenant's Restrictions. Tenant shall not cause or permit to occur:

               (A)  Any violation of any federal, state, or local law,
ordinance, or regulation now or hereafter enacted, related to environmental
conditions on, under, or about the Space or Center, or arising from Tenant's use
or occupancy of the Leased Space, including, but not limited to, soil and ground
water conditions; or

               (B)  The use, generation, release, manufacture, refining,
production, processing, storage, or disposal of any Hazardous Substance on,
under, or about the Space or Center, except as may be permitted by applicable
laws, rules, ordinances and regulations, and then only in strict accordance with
such laws, rules, ordinances and regulations.

        (iii)  Environmental Clean-Up.

               (A)  Tenant shall, at Tenant's own expense, comply with all laws
regulating the use, generation, storage, transportation, or disposal of
Hazardous Substances ("Laws").

               (B)  Tenant shall, at Tenant's own expense, make all submissions
to, provide all information required by, and comply with all requirements of all
governmental authorities (the "Authorities") under the Laws.

               (C)  Should any Authority demand that a clean-up plan be prepared
and that a clean-up be undertaken because of any deposit, spill, discharge, or
other release of Hazardous Substances that occurs during the Term of this Lease,
at or from the Leased Space, or which arises at any time from Tenant's use or
occupancy of the Leased Space, then Tenant shall, at Tenant's own expense,
prepare and submit the required plans and all related bonds and other financial
assurances; and Tenant shall carry out all such clean-up plans.

               (D)  Tenant shall make available for Landlord's review all
information regarding. the use, generation, storage, transportation, or disposal
of Hazardous Substances that is reasonably requested by Landlord. If Tenant
fails to fulfill any duty imposed under this subsection (iii) within a
reasonable time, Landlord, upon written notice to Tenant, may do so; and in such
case, Tenant shall cooperate with Landlord in order to prepare all documents
Landlord deems necessary or appropriate to determine the applicability of the
Laws to the Leased Space and Tenant's use thereof, and for compliance therewith,
and Tenant shall execute all necessary documents promptly upon Landlord's
request. No such action by Landlord and no attempt made by Landlord to mitigate
damages under any Law shall constitute a waiver of any of Tenant's obligations
under this Subsection (iii).

               (E)  Tenant's obligations and liabilities under this Subsection
(iii) shall survive the expiration of this Lease.

          (iv) Tenant's Indemnity.

               (A)  Tenant shall indemnify, defend, and hold harmless Landlord,
the manager of the Center, and their respective officers, directors,
beneficiaries, shareholders, partners, agents and employees from all fines,
suits, procedures, claims, and actions of every

                                      -9-
<PAGE>

kind, and all costs associated therewith (including attorneys' and consultants'
fees) arising out of or in any way connected with any deposit, spill, discharge,
or other release of Hazardous Substances that occurs during the Term of this
Lease, at or from the Leased Space, or which arises at any time from Tenant's
use or occupancy of the Leased Space, or from Tenant's failure to provide all
information, make all submissions, and take all steps required by all
Authorities under the Laws and all other environmental laws.

               (B)  Tenant's obligations and liabilities under this Subsection
(iv) shall survive the expiration f this Lease.

               (C)  Tenant's indemnity obligation under clause (A) above shall
not apply to Hazardous Substances present prior to the Commencement Date of the
Original Lease and not brought into the Building by Tenant, its contractors and
agents.

     (c)  Attached to this Lease and made part hereof is a Rider regarding
Industrial Waste Discharge within Eagleview Corporate Center.

6.   LATE PAYMENT.

     If any payment required by Tenant under any of the terms hereof shall not
be paid by the date it is due, Tenant shall, upon demand, pay a late charge to
Landlord equal to $.06 for each dollar so due and such late charge shall be
deemed Additional Rent for purposes of this Lease.

7.   CONSTRUCTION OF NEW SPACE.

     (a)  Core and Shell Work. Landlord shall provide, at Landlord's cost and
          -------------------
expenses all labor, materials and expertise necessary for the construction of
the New Building core and shell ("Core and Shell") as described in the core and
shell plans and specifications to be developed by Landlord ("Core and Shell
Plans"). All Core and Shell work shall be done (or caused to be done) in a good
and workmanlike manner in conformity with the Core and Shell Plans and in
compliance with all applicable laws, ordinances, regulations and codes. Landlord
will make available the Core and Shell Plans for comment by Tenant as they are
developed, but Tenant shall not have the right to approve the Core Shell and
Plans, and it shall remain Landlord's responsibility to develop the Core and
Shell Plans, and construct all Core and shall work in accordance with the
preceding sentence.

     (b)  Landlord's Work. (i) Landlord shall provide all labor, materials and
          ---------------
expertise necessary for the improvement of the New Space ("the Landlord's Work),
the pre layout and specification for which are set forth m Exhibits "lA3" and
"lA4" attached hereto. Tenant agrees to furnish to Architect such information as
is necessary to enable the Architect to complete the required architectural
drawings and specifications for the Landlord's Work which shall, to the extent
practicable, be consistent with the preliminary layout and specifications in
Exhibits "1A3" and "1A4". Based upon the information delivered by Tenant,
Landlord shall submit to Tenant schematic plans and outline specifications,
together with a preliminary estimate of the cost of the Landlord's Work (the
"Phase 1 PI"). Following approval of the Phase 1 Plans pursuant to subsection
(ii) below, Landlord shall submit to Tenant preliminary mechanical, electrical
and plumbing plans, and a revised estimate of the cost of the Landlord's Work
(the "Phase 2 Plans"). Following approval of the Phase 2 Plans pursuant to
subsection (ii) below, Landlord shall submit

                                     -10-
<PAGE>

to Tenant final, working construction drawings and a revised estimate of the
cost of the Landlord's Work (the "Phase 3 Plans"). The Phase 1 Plans, Phase 2
Plans and Phase 3 Plans are hereinafter collectively called the "Phase Plans."

     (ii) Upon receipt of each of the Phase 1 Plans and Phase 2 Plans
(collectively the "Preliminary Plans"), Tenant shall have 14 days to review the
same, during which it shall either approve, in writing, the submitted
Preliminary Plans or submit to Landlord changes and modifications thereto. If
Tenant approves the submitted Preliminary Plans or fails to respond to Landlord
within such 14-day period, such documents shall be deemed approved. If, however,
Tenant proposes changes or modifications, the Architect shall revise the
Preliminary Plans to reflect such changes and modifications and such revised
Preliminary Plans shall be delivered to Tenant, together with a revised estimate
of the cost of the Landlord's Work. Upon receipt of the Phase 3 Plans, Tenant
shall have 7 days to review the same, during which period it shall either
approve, in writing, the submitted Phase 3 Plans or submit to Landlord changes
and modifications thereto. If Tenant approves the submitted Preliminary Plans or
fails to respond to Landlord within such 7-day period, such documents shall be
deemed approved. If, however, Tenant proposes changes or modifications, Landlord
shall have the Phase 3 Plans revised to reflect such changes and modifications
and such revised Phase 3 Plans shall be delivered to Tenant, together with a
revised estimate of the cost of the Landlord's Work. Upon Tenant's approval, in
writing, of the revised Phase 3 Plans (which approval shall be deemed given if
Tenant fails to disapprove within five days after Tenant's receipt thereof), the
revised Phase 3 Plans will be deemed approved. At all stages of the design and
planning process, Landlord shall assist Tenant in coordinating any desired
revisions and will provide Tenant with suggestions to facilitate potential cost
savings. The Phase 3 Plans are referred to herein collectively as the "Tenant
Plans."

    (iii) Tenant agrees that it will not withhold or delay approval of any of
the Plans (or any revisions them") which am consistent with the prior phase of
plans, or revisions requested by Tenant. Any and all fees and expenses charged
by the Architect as a result of changes by Tenant in the scope of the Landlord's
Work or the basis of design of the Landlord's Work are in addition to the Fit
Out Cost and shall be paid by Tenant in addition to all other sums payable by
Tenant pursuant to this Lease.

     (iv) Within 5 days after determination of the Tenant Plans, Landlord shall
provide Tenant with a final determination of the cost of the T Landlord's Work,
which amount, when approved in writing by Tenant, shall be deemed to be the Fit-
Out Cost. Landlord and Tenant stipulate and agree that Tenant shall have no
obligation to approve a Fit-Out Cost that is in excess of $1,675,450.00. AU
cost estimates furnished by Landlord shall list the cost for each item or
component of Landlord's Work in reasonable detail. Landlord shall bear the sole
responsibility for insuring that the Tenant Plans conform to the Building Core
and Shell. Landlord shall, in its own name, prepare and award all contracts
('Construction Contracts") with general contractors (unless Landlord shall serve
as the general contractor) and subcontracts and other contracts as may be
necessary to effectuate the Landlord's Work; provided that Landlord shall not
execute (without Tenant's written approval) any Construction Contract that would
cause the cost of the Landlord's Work to exceed the Fit-Out Cost. Landlord
agrees that the cost of the Landlord's Work shall be equal to the actual cost
paid under the Construction Contracts, without any further mark-up or price
increase by Landlord. Tenant acknowledges that the General

                                     -11-
<PAGE>

Contractor is an affiliate of Landlord, and accordingly the cost to Landlord
under the Construction Contract with such General Contractor shall include a
mark-up of ten (10%) percent for profit.

     (c)  Landlord Requirements:
          ---------------------

          (i)  Landlord shall cause the Landlord's Work to be done in a good and
workmanlike manner in conformity with the Tenant Plans and the Construction
Contracts and in compliance with all applicable laws, ordinances, regulations
and codes. Landlord shall cause the Landlord's Work to be carried forward
expeditiously and with adequate work forces so as to achieve Substantial
Completion of the Landlord's Work on or before the Landlord's Work Completion
Date. Landlord shall secure the building permit and all other permits and fees,
licenses and inspections necessary for the proper execution and completion of
the Landlord's Work, the cost of which shall be included in the Fit-Out Cost.
Landlord shall comply with and give all notices required by laws, ordinances,
rules, regulations and lawful orders of public authorities bearing on the
performance of the Landlord's Work. Landlord shall be responsible for
initiating, maintaining and supervising reasonable safety precautions and
programs in connection with the performance of the Landlord's Work. Landlord
shall deliver possession of the Leased Space to Tenant in a broom-swept and
fully serviceable fashion.

         (ii)  Immediately prior to Occupancy Of the New Space by Tenant, Tenant
and Landlord jointly shall inspect the New Space in order to determine and
record its condition and to prepare a comprehensive list of items that have not
been completed (or which have not been correctly or property completed) in
conformity-with the Tenant Plans ("Punch List Items"). Thereafter, Landlord
shall proceed promptly to complete and correct all Punch List Items. Failure to
include an item on the punch list does not alter the responsibility of Landlord
to complete construction of the New Space in accordance with the Tenant Plans.

        (iii)  Landlord shall promptly correct the Landlord's Work rejected by
Tenant because the same has not been executed in accordance with the Tenant
Plans or because of defects in workmanship or materials. Landlord shall bear the
costs of correcting such rejected Landlord's Work. If, within one year after the
Commencement Date, any of the Landlord's Work is found to be not in accordance
with the requirements of the Tenant Plans, Landlord shall correct it promptly
after receipt of written notice from Tenant to do so. Landlord's obligation
under this subsection shall survive Tenant's occupancy of the New Space upon
Substantial Completion. Tenant shall give Landlord notice promptly after
discovery of any condition requiring correction hereunder. If Landlord fails to
correct the Landlord's Work within a reasonable time, Tenant shall provide
Landlord with written notice and reasonable opportunity to cure the same, and if
it is not so cured, Tenant may correct it, in which case Tenant may deduct the
cost and expense of completing such work from the next due installments of
Minimum Annual Rent. Notwithstanding anything contained herein to the contrary,
neither Landlord nor the General Contractor shall be responsible to correct any
alleged defects in Landlord's Work more than one (1) year following the
Commencement Date (the "Warranty Period"), except for latent defects in
existence prior to the Commencement Date, which could not, in the exercise of
reasonable diligence, have been discovered by Tenant prior to the expiration of
the Warranty Period. In the event Landlord or General Contractor receives an
express warranty from any subcontractor or material supplier which extends
beyond the Warranty Period, Landlord shall

                                     -12-
<PAGE>

cooperate with Tenant in Tenant's efforts to enforce such warranties against the
issuers thereof. With respect to Landlord's Work, Tenant acknowledges that the
express warranties provided by this lease are in lieu of any other warranties,
express 'or implied, applicable to the Landlord's Work, and Landlord and General
Contractor DISCLAIM ANY IMPLIED WARRANTIES, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, HABITABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Tenant agrees
that its remedy for breach of any warranty relating to the Landlord's Work is
limited to the cost of replacement or repair of the defect, AND TENANT HEREBY
WAIVES ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES.

     (d)  Tenant Requirements and Rights.
          ------------------------------

          (i)  Tenant shall designate a representative authorized to act on
Tenant's behalf with respect to the Landlord's Work. Tenant shall examine
documents submitted by Landlord and shall render decisions pertaining thereto
promptly to avoid unreasonable delay in the progress of the Landlord's Work.
Additionally, Tenant shall furnish information required of it as promptly and
expeditiously as necessary for the orderly progress of the Landlord's Work. In
this regard, Tenant shall endeavor to render such decisions and furnish such
information within five (5) working days after Landlord's written request for
the same is received by the Tenant representative.

          (ii) During the performance of the Landlord's Work, Tenant, its
employees, agents and contractors, may enter upon the New Space- from time to
time for the purpose of (A) observing and inspecting the execution and progress
of the Landlord's Work, and (B) constructing and completing all work which
Tenant requires for its use and occupancy of the New Space which is not part of
the Landlord's Work, provided that all such work undertaken by Tenant shall be
performed in a manner so as to avoid interference with the performance of the
Landlord's Work.

     (e)  Changes in the Landlord's Work.
          ------------------------------

          (i)  Changes in the Landlord's Work may be accomplished only by (A) a
"Change Order" (defined below) or (B) an "Order for Minor Change" (defined
below). A Change Order shall be based upon agreement between Landlord and
Tenant; an Order for Minor Change may be issued by Landlord alone, subject to
the right of Tenant to dispute the Order. Changes in the Landlord's Work shall
be performed in conformity with the provisions of this Section 7(e), and the
provisions in the Change Order or the Order for Minor Change. Landlord shall
maintain at the Landlord's office, and make available for review by Tenant, a
register of (I) all requests for changes to the Tenant Plans, (II) all such
requests resulting in a Change Order, (III) all Orders for Minor Change.

          (ii) Tenant shall have the right to request changes in the Landlord's
Work by making a written request to Landlord describing the requested change,
provided that Landlord shall not be obliged to execute the requested change
(unless the scope of same is such that, if requested by Landlord, the same would
be a Minor Change in the Tenant Work as described in subparagraph 7(e)(iii)),
unless a Change Order is issued with respect thereto. A "Change Order" is a
written instrument. prepared by Landlord and signed by Landlord and Tenant
stating their agreement upon all of the following: (A) a change in the
Landlord's Work; (B) the extent of the

                                     -13-
<PAGE>

adjustment in the Fit-out Cost; and (C) the extension of the Landlord's Work
Completion Date, if necessary. The Landlord's Work Completion Date shall be
extended by any delays in Landlord's Work occasioned by a request for a change
initiated by Tenant or a Change Order. To the extent any net increase in the Fit
Out Cost as a result of a Change Order would cause the Amortization Base to
exceed $837,725.00., such amount shall be paid by Tenant to Landlord upon
execution of the Change Order, and shall be part of the "Direct Payment Portion"
(as defined below).

         (iii) Landlord shall have the authority to order Minor Changes in the
Landlord's Work not involving any change in the Fit-Out Cost or extension of the
Landlord's Work Completion Date and not inconsistent with the Tenant Plans (a
"Minor Change"). Such Minor Changes in the Landlord's Work shall be effected by
written Order for Minor Change issued by Landlord, which shall be binding on
Tenant unless, within five (5) working days after the same is received by
Tenant, Tenant notifies Landlord that it disputes the Order for Minor Change. In
such event, the Order for Minor Change shall be treated as a request for a
Change Order and shall become effective and binding on Landlord and Tenant only
after mutual agreement of the parties as provided in this subsection 7(e).

     (f)  Payment of Fit-Out Cost
          -----------------------

          (i)  The lesser of one half of the Fit-Out Cost or $837,725.00 is
included within Minimum Annual Rent pursuant to Section 3 (b) above as the New
Space Amortized Fit-Out Rent Portion. The remaining portion of the Fit-Out Cost
(the "Direct Payment Portion") shall be paid by Tenant to Landlord as the
Landlord's Work progresses as follows: Two Hundred Nine Thousand Four Hundred
Thirty One and 25/100 ($209,431.25 ) Dollars ("Initial Payment") has been paid
by Tenant to Landlord on account of the Direct Payment Portion at the time of
the execution of this Lease. The balance of the Direct Payment Portion
(presently estimated at $628,293.75) shall be paid by Tenant to Landlord as
follows: As the Landlord's Work progresses, Landlord shall submit to Tenant,
once every 30 days, an invoice for payment for such portion of the Landlord's
Work which has been substantially completed or for materials delivered to the
site. Such invoice shall be submitted on an AIA form 702/703 or other form
reasonably acceptable to Tenant, and shall include such requisitions for
payment, bills, charges and other supporting documentation as Tenant shall
reasonably request. Tenant shall approve or reject such invoices within five (5)
business days of receipt, or the same shall be deemed approved. Any rejection of
an invoice shall state the reasons therefor with particularity, and Tenant shall
state which sums reflected in the invoice Tenant objects to, and the portion
which is not objected to by Tenant shall be disbursed in accordance with the
provisions below. If Landlord and Tenant cannot agree on whether the Landlord's
Work reflected in an invoice has been substantially completed in accordance with
the Tenant Plans and the other requirements of this Lease, such dispute shall be
decided by the Architect. Upon approval of an invoice, Tenant shall immediately,
pay Landlord one-half of the Fit-Out Cost reflected in such invoice (or at such
time as the total of all invoices equals or exceeds $1,675,450.00, the entire
Fit Out Costs reflected in such invoice). Landlord covenants to pay the
remaining portions of all invoices with its own funds (subject to its right of
reimbursement through the Amortized Fit-Out Rent Portion described above).
Landlord and Tenant agree that Tenant shall have no obligation to approve, and
shall not be liable for the payment of, any invoice that would cause the Fit-Out
Cost to exceed 1,675,450.00, unless such excess results from approved Tenant
Plans or changes to the Tenant Plans requested by Tenant. Upon Substantial
Completion of the Landlord's Work, the

                                     -14-
<PAGE>

actual Fit-Out Cost will be calculated, and the lesser of $837,725.00 or one
half of such Fit-Out Cost will be applied to calculate the Amortized Fit-Out
Rent Portion under Section 3(c), and the balance shall be the Direct Payment
Portion. If, for any reason (i.e., a Change Order), the cost of the Landlord's
Work results in an increase in the initial determination of Fit-Out Cost under
Section 7(b), such excess amount, shall be allocated to the Direct Payment
Portion, and shall be paid immediately to Landlord when such final cost is
determined.

          (ii)  To the extent reasonable, Landlord and Tenant will allocate to
the Direct Payment Portion items of removable personal property and trade
fixtures unique to Tenant's operation included within the Landlord's Work and
Fit-Out Cost. Such item shall be identified in a list to be agreed upon by T
Landlord and Tenant, and the items in such list which hall have an invoice cost
to Landlord not in excess of $100,000.00 in the aggregate, are hereinafter
called 'Trade Fixtures," and shall become the property of Tenant upon payment of
the Direct Payment Portion, subject to the provisions in the following sentence
and the rights of Landlord thereto elsewhere provided in this Lease.
Notwithstanding the foregoing, Tenant shall not remove from the Leased Space,
nor assign, sell, encumber, transfer or grant a security interest in the Trade
Fixtures prior to the expiration of the originally scheduled Term of the Lease,
without Landlord's prior written consent, and in the event of the termination of
this Lease for any reason whatsoever after the Commencement Date, but prior to
the originally scheduled expiration of the Term, title to and the right of
possession of the Trade Fixtures shall vest in Landlord, free and clear of any
right of Tenant or any other party thereto, and Tenant shall, if required by
Landlord, execute a bill of sale or such other document of transfer as Landlord
may require.

          (iii) Notwithstanding anything to the contrary contained herein, all
labor, material and other costs and expenses arising from or relating to
inconsistencies between the Tenant Plans and the Core and Shell Plans shall be
the sole responsibility of Landlord, without recourse to or reimbursement from
Tenant.

          (iv)  Landlord shall keep accurate records of all costs, fees,
disbursements and amounts incurred by it in the performance of the Landlord's
Work and shall furnish Tenant on a monthly basis with true and correct
statements of such costs. Tenant shall have the right to review and contest
Landlord's determination of the cost of the Landlord's Work and to inspect
Landlord's records with respect thereto during normal business hours upon three
(3) days prior written notice. If any such audit shall reveal a discrepancy in
Landlord's determination of the cost of the Landlord's Work, an appropriate
adjustment shall be made to the Fit-Out Cost.

     (g)  Delay Payment.
          -------------

          (i)  If Landlord fails to substantially complete the Landlord's Work
by the Landlord's Work Completion Date, for any reason other than a cause
described in Section 26 below, then Landlord shall pay to Tenant (A) an amount,
if any, equal to the occupancy costs incurred by Tenant for the period from the
Landlord's Work Completion Date until the Commencement Date, in excess of the
rent which would be payable by Tenant under this Lease but for the delay.

          (ii) A `Tenant Delay' is any delay resulting from (i) revisions to any
of the Phase 1, Phase 2 or Phase 3 Plans by Tenant, (ii) the performance or
nonperformance of any

                                     -15-
<PAGE>

work or activity by Tenant or any of its employees, agents or separate
contractors or consultants provided Landlord gives Tenant written notice of such
delay as promptly as possible, but in any event within ten (10) days following
any such delay), and (iii) changes in the Landlord's Work requested by Tenant as
established by written Change Order signed by Landlord and Tenant. The
Landlord's Work Completion Date shall be extended for a "reasonable" period of
time in the event of a Tenant Delay. For the purpose of the preceding sentence,
the term "reasonable' shall be mutually determined by Landlord and Tenant at the
time of the event resulting in a Tenant Delay. Any delay arising from or
relating to inconsistencies between the Tenant Plans and the Core and Shell
Plans shall not constitute a Tenant Delay, unless Landlord notifies Tenant of
such inconsistency at the time of delivery of the Tenant Plans to Tenant, and
the same arises from a request by Tenant with respect to the Tenant Plans.

8.   TENANT'S ALTERATIONS.

     (a)  During the term of this Lease, Tenant shall not make any alterations
or additions to the Leased Space or the Building without the prior written
consent of Landlord, which consent shall not be unreasonably withheld or
delayed. All such work to be done or performed in or about the Building by
Tenant shall be performed (i) at Tenant's sole cost and expense, (ii) in
accordance with the plans and specifications prepared by and at the expense of
Tenant and given to and, approved by Landlord, and (iii) in conformity with all
applicable laws, codes and regulations. During the course of performance of said
work, Tenant will carry or cause to be carried Comprehensive General Liability
insurance, in the minimum limit of $1,000,000.00, naming Landlord as an
additional insured. For the purpose of this Lease, "Minor Tenant Alterations"
shall mean alterations or additions to the Leased Space and the Building which
are not structural in nature, do not affect Building systems, do not involve
partitioning, and the cost for labor, tools, materials (other dm specialized
laboratory equipment), and supplies does not exceed $10,000.00. Tenant shall
have the right to perform Minor Tenant Alterations, the plans and specifications
for which are approved by Landlord pursuant to clause (iii) above, by
contractors or Tenant's employees approved by Landlord. Tenant shall provide
Landlord with as-built drawings of such Minor Tenant Alterations, and shall
reimburse Landlord for the cost of review of the plans and specifications and
inspection of the Minor Tenant Alterations at a rate not to exceed $60 per hour
for personnel employed by Landlord or its affiliates. With respect to any
alterations or additions to the Leased Space other than Minor Tenant
Alterations, such work shall be performed at Tenant's cost by Landlord. Landlord
shall provide Tenant with a fixed price bid to perform such work, and if Tenant
is dissatisfied with such bid, Landlord shall provide an alternative bid on the
basis of the cost of the work plus ten (10%) percent.

     (b)  All alterations, interior decorations, improvements or additions made
to the Leased Space by Tenant, except for movable furniture, equipment and trade
fixtures, shall immediately become Landlord's property. At the expiration of the
Term of this Lease, Tenant shall have the right to remove all movable furniture,
equipment, and trade fixtures installed by Tenant in the Space ("Tenant's
Property"), provided that Tenant repairs any damaged caused to the Leased Space
by said removal, and provided that Tenant shall have no right to sell or dispose
of any decorations, improvements or installed in the Space by Landlord without
the express written consent of Landlord. All of Tenant's Property remaining on
the Leased Space after the expiration of the Lease, or after any sooner
remaining on termination, shall be deemed to be abandoned property and shall
automatically, at Landlord's election, become the property of

                                     -16-
<PAGE>

Landlord. If Landlord shall notify Tenant to remove such property, Tenant shall
do so at its cost and expense prior to the expiration of the Term of the Lease.
If Tenant fails to do so, Tenant shall pay to Landlord the cost of disposal.

9.   MECHANIC'S LIENS.

     Prior to Tenant performing any construction or other work on or about the
Leased Space for which a lien could be filed against the Leased Space or the
Building, Tenant shall enter into a written waiver of liens agreement with the
contractor who is to perform such work, and such written agreement shall be
filed, in accordance with the Mechanics' Lien Law of the state where the
Building is located prior to the commencement of such work. Notwithstanding the
foregoing, if any mechanics' or other lien shall be filed against the Leased
Space or the Building purporting to be for labor or material shed or to be
furnished at the request of the Tenant, then Tenant shall at its expense cause
such lien to be discharged of record by payment, bond or otherwise, within
thirty (30) days after the filing thereof. If Tenant shall fail to cause such
lien to be discharged by payment, bond or otherwise within such period, Landlord
may cause such lien to be discharged by payment, bond or otherwise, without
investigation as to the validity thereof or as to any offsets or defenses
thereto, and Tenant shall, upon demand, reimburse Landlord for all amounts paid
and costs incurred, including attorneys' fees, in having such lien discharged of
record.

10.  CONDITION OF LEASED SPACE.

     Tenant acknowledges and agrees that, except as expressly set forth in this
Lease, there have been no representations or warranties made by or on behalf of
Landlord with respect to the Leased Space or the Building or with respect to the
suitability of either for the conduct of Tenant's business. The taking
possession of the New Space by Tenant shall conclusively establish that the New
Space and the New Building were at such time in satisfactory condition, order
and repair as required by Section 2 hereof, subject to the provisions respecting
latent defects and the punch list in Section 7 hereof. Tenant acknowledges that
it presently occupies the Original Space and that it accepts the condition
thereof.

11.  BUILDING SERVICES.

     Landlord shall provide maintenance to the common areas of the Building and
the Center (including snow removal), and provision of a and dumpster removal
service for normal office trash and rubbish, all as are commercially reasonable,
provided Tenant has that this is a "triple net" and operating expenses, (except
any of the foregoing that are the responsibility of Landlord under the terms of
this Lease). Tenant shall have access to the Leased Space at all (i.e., 24 hours
a day, 365 days a year) during the term of this Lease, but Landlord shall not be
required to provide services beyond normal business hours. Landlord shall not be
liable in damages or otherwise for temporary delay or failure in furnishing any
services or facilities to be provided by Landlord under this Lease or any other
agreement between Tenant and Landlord (or its agents) or implied by law. In no
event shall such delay or failure regardless of cause, constitute an eviction,
disturbance of Tenant's use and possession of the Leased Space, render Landlord
liable to Tenant, authorize abatement of rent, relieve Tenant from performance
of its obligations under this Lease, or result in a termination of this Lease.

                                     -17-
<PAGE>

12.  ASSIGNMENT AND SUBLETTING.

     (a)  Tenant shall not, without the prior written consent of Landlord,
assign or mortgage this Lease or any interest therein or sublet the Leased Space
or any part thereof. For the purposes of this section, the sale or assignment of
a controlling interest in the Tenant corporation shall be deemed an assignment,
but the assignment to a parent or wholly-owned subsidiary of the Tenant shall be
permitted, provided that such assignee assumes the obligations of Tenant and
that such assignment shall not relieve Tenant of its obligations hereunder. With
respect to any assignment or subletting, whether approved by Landlord or not,
any money or other economic consideration received by Tenant as a result of such
subletting or assignment (net of Tenant's costs and expenses), whether
denominated as rent under the sublease or otherwise, which exceeds, in the
aggregate, $22.94 per year multiplied by the square footage of the Leased Space
which is the subject of the sublease or assignment, plus Tenant's Proportionate
Share of Operating Expenses and Real Estate Taxes, shall be payable to Landlord
as Additional Rent under this Lease without affecting or reducing any other
obligation of Tenant hereunder.

     (b)  Regardless of Landlord's consent, no subletting or assignment shall
release Tenant of Tenant's obligation or alter the primary liability of Tenant
to pay the rental and to perform all other obligations to be performed by Tenant
hereunder. The acceptance of rental by Landlord from any other person shall not
be deemed to be a waiver by Landlord of any provision hereof. Consent to one
assignment or subletting shall not be deemed consent to any subsequent
assignment or subletting. In the event of default by any assignee of Tenant or
any successor of Tenant in the performance of any of the terms hereof, Landlord
may proceed directly against Tenant without the necessity of exhausting remedies
against such assignee or successor. Landlord may consent to subsequent
assignment or subletting of this Lease or amendments or modifications to this
Lease with assigned of Tenant, without notifying Tenant, or any successor of
Tenant, and without obtaining its or their consent thereto and such action shall
not relieve Tenant of liability under this

     (c)  Notwithstanding the foregoing limitations on assignment and
subletting, Landlord shall consent to an assignment of this Lease to a lending
institution which provides for Tenant of the Direct Payment Portion, if such
institution's financial statement is reasonably judged by Landlord to be equal
or superior to Tenant's as of the date of the assignment or subletting, and such
institution agrees to assume and be bound by the provisions of this Lease.

                                     -18-
<PAGE>

13.  ACCESS TO LEASED SPACE.

     Landlord, its employees and agents shall be permitted to enter the Leased
Space for the purpose of inspecting the same, showing the Leased Space to
prospective purchasers, tenants and mortgagees, or for making necessary Building
repairs, provided that (i) Landlord shall give Tenant at least 24 hours' prior
written notice of such entry (except in case of an emergency), (ii) a
representative of Tenant shall be present and supervise each such entry, and
(iii) Tenant shall be permitted to deny entry to any portions of the Leased
Space containing confidential or proprietary information, specialized equipment
or hazardous materials. Tenant shall designate an employee to receive alarm or
emergency calls, and provide Landlord with a key to the Leased Space which shall
trigger an alarm upon use, if the same can be reasonably accommodated by
Tenant's security system.

14.  REPAIRS.

     (a)  Landlord shall make all repairs necessary to maintain the roof, load
bearing walls (other than paint and wall coverings on the interior surface of
such walls) floors (other than carpeting, tile and similar floor coverings) and
foundations of the Building, and plumbing and electrical fixtures and equipment
serving portions of the Building in addition to the Leased Space; In no event
shall Landlord be obligated to repair any damage caused by any act, omission or
negligence of the Tenant or its employees, agents, invitees, licensees,
subtenants or contractors. If Landlord fails to effectuate such repairs within a
reasonable time, Tenant shall provide Landlord with written notice and
reasonable opportunity to cure the same, and if it is not so cured, Tenant may
effectuate such repairs, in which case Tenant may deduct the cost and expense of
performing such repairs from the next installments of Minimum Annual Rent due.

     (b)  Except as the Landlord is obligated for repairs as provided above,
Tenant shall make, at its sole cost and expense, all repairs necessary to
maintain the Leased Space, including without limitation, all plumbing, heating,
ventilation, air conditioning and electrical lines, pipes, fixtures and
equipment located within the Leased Space not expressly to be by maintained by
Landlord pursuant to subsection (a) and shall keep the Leased Space and the in
neat and orderly condition normal wear and tear excepted. Without limiting the
generality of the foregoing, Tenant at its expense is specifically to make
promptly all (i) to that portion of any pipes, lines, ducts, wires or conduits
contained within the Space; (ii) to the glass windows, plate glass doors, and
any fixtures or appurtenances composed of glass; (iii) to Tenant's sip; (iv) to
any heating or air conditioning equipment installed in or servicing the Leased
Space; and (v) to the Space or to any part of the Center when such repairs are
necessitated by any act or omission (negligent or otherwise) of Tenant or
Tenant's agents or employees, or by failure of Tenant to perform any of its
obligations under Lease. Tenant at its own expense shall enter into a
maintenance contract with a reputable heating and air conditioning service
company acceptable to Landlord, for the entire Term, and provide Landlord with a
copy of the same. If the Tenant refuses or neglects to make such repairs, or
fails to diligently prosecute the same to completion, or fails to enter into the
aforementioned maintenance contract, after written notice from Landlord of the
need therefor, Landlord, may make such repairs or enter into such maintenance
contract at the expense of Tenant and such expense shall be collectible as
Additional Rent. Any such repairs and any labor performed or materials furnished
in, on or about the Leased Space shall be performed and held by Tenant in strict
compliance with all applicable laws, regulations, ordinances and

                                     -19-
<PAGE>

requirements of all duly constituted authorities or governmental bodies having
jurisdiction over the Building, and the requirements of any board of
underwriters having jurisdiction thereof. Landlord shall have the right to
approve any and all contractors and suppliers to furnish materials and labor for
such repairs. Landlord shall not unreasonably withhold its consent to Tenant's
providing, in lieu of a maintenance contract as required above, a full time,
qualified employee on site who is responsible for maintenance of the heating,
ventilation and air conditioning system.

     (c)  Provided that Landlord shall exercise reasonable efforts to effectuate
its repairs in a manner which will keep at a minimum Landlord's interference
with Tenant's use and occupancy of the Leased Space, Landlord shall not be
liable by reason of any injury to or interference with Tenant's business arising
from the making of any repairs, alterations, additions or improvements in or to
the Leased Space, the Building or Center or to any appurtenances or equipment
therein.

15.  TERMINATION AND EXTENSION.

     Unless renewed or extended by written instrument executed by Landlord and
Tenant, the Term of this Lease shall expire in accordance with Section 2(c)
without notice.

16.  INTENTIONALLY OMITTED.

17.  INDEMNMCATION AND INSURANCE.

     (a)  Tenant covenants and agrees that it shall, without notice or demand
and at its own cost and expense, and save harmless Landlord against and from,
and Landlord shall not be liable to Tenant for, any and all claims by or on
behalf of any person arising in any manner whatsoever from, out of or in
connection with:

          (i)    the use and occupancy of the Space by Tenant, its agents,
employees and invitees,

          (ii)   any failure by Tenant to perform any of the terms or conditions
of this Lease required to be performed by Tenant,

          (iii)  any failure by Tenant to comply with any statutes, regulations,
ordinances or orders of any governmental authority, or

          (iv)   any accident, death, injury, or damage, loss or theft of
property in or about the Space (whether involving property belonging to Tenant
or any other person) resulting from any cause whatsoever, unless such accident,
death, injury, damage, loss or theft is caused by the willful misconduct or sole
negligence of the Landlord, its agents, employees or contractors, or claims
arising from deficiencies in Landlord's performance of Landlord's Work under
this Lease, and from and against all costs, attorney fees, expenses and
liabilities incurred in or as a result of any such claim or action or proceeding
brought against Landlord by reason of any such claim. Tenant, upon notice from
Landlord covenants to resist or defend such action or proceeding by legal
counsel reasonably satisfactory to Landlord.

                                     -20-
<PAGE>

          Tenant shall keep in force public liability insurance with respect to
the Leased Space, including contractual insurance with respect to the covenants
and agreements above (excluding (ii) and (iii) above), with companies and in
form, acceptable to the Landlord to afford protection of not less than One
Million ($1,000,000.00) Dollars with respect to personal injury or death and
property damage, and shall keep in force and effect "all risk" hazard insurance
insuring the personal property of Tenant located in the Leased Space (including
without limitation, the Trade-Fixtures) for the full replacement cost thereof
with companies and in form acceptable to the Landlord. All such insurance
policies obtained by Tenant shall name the Landlord as an additional insured and
loss payee and provide thirty (30) days' notice of cancellation. Copies or
certificates of such policies shall be delivered to Landlord.

          (b)  Landlord shall, without notice or demand and at its own cost and
expense, indemnify and save harmless Tenant against and from, and Tenant shall
not be liable to Landlord for, any and all claims by or on behalf of any person
arising in any manner whatsoever from, out of or in connection with:

               (i)  the location of any Hazardous Substance on, in or about the
Leased Space or the Center prior to the commencement of the Original Lease
(unless attributable solely to Tenant, its agents, employees or contractors),
and

               (ii) the failure of the Building shell work and common areas to
comply with the Americans with Disabilities Act and other applicable statutes,
regulations, ordinances or orders of governmental authority.

          Landlord shall maintain at all times public liability and property
damage and casualty insurance on Building and on the land upon which the
Building is situated in amounts consistent with the amounts of coverage
maintained on similar properties in the suburban Philadelphia region.

          (c)  As to any loss or damage which may occur upon the property of a
party hereto, such party hereby releases the other, to the extent of such
damaged party's insurance indemnities, from any and all liability for such loss
or damage even if such loss or damage shall be brought about by the fault or
negligence of such other party, or the agent or employees of such other party;
provided, however, that this release shall be effective only with respect to
loss or damage occurring during such time as the applicable policies of
insurance shall contain a clause to the effect that this release shall not
affect said policies or the right of the insured to recover thereunder. If any
policy does not contain such a clause, the party shall, at the written request
of the other party to this Um, have such a clause added to said policy if an
endorsement so providing is obtainable, if the same is obtainable at no
additional charge; if there is such a charge, the insured party shall notify the
other, and obtain such clause if such other agrees to pay the additional charge.

18.  FIRE OR OTHER CASUALTY.

     (a)  If the Leased Space or any portion of the Building or common area
necessary to provide Tenant with access to the Leased Space is partially damaged
by fire or other casualty such that (i) such damage can be repaired by Landlord
within 180 days after the date of such

                                     -21-
<PAGE>

casualty, (ii) Tenant is able to conduct its business therein at a reduced level
on a temporary basis, and (iii) insurance proceeds are available to Landlord,
the damages shall be repaired by and at the expense of Landlord and the rent,
until such repairs shall be made, shall be apportioned from the date of such
fire or other casualty according to the part of the Leased Space which is usable
by Tenant.

     (b)  Landlord agrees to repair damage to the Leased Space within a
reasonable period of time but in no event later than 180 days after the date of
the casualty, after receipt from Tenant of written notice of such damage, except
that Tenant agrees to repair and replace its own furniture, furnishings and
equipment, including the Trade Fixtures.

     (c)  If the Leased Space is totally damaged or is rendered wholly
untenantable by fire or other casualty or if, as a result of such casualty,
Tenant shall be deprived of access to the Leased Space for a period reasonably
estimated to exceed 180 days, or if Landlord shall decide not to restore or not
to rebuild the same, then or in any such events Landlord or Tenant may, within
(30) days after such fire or other casualty, give the other written notice of
on, and thereupon the term of this Lease shall expire by lapse of time upon the
third day after such notice is given, and Tenant shall vacate the Leased Space
and surrender the same to Landlord. Upon the termination of this Lease under the
conditions hereinbefore provided, Tenant's liability for rent shall cease as of
the day following the casualty.

19.  CONDEMNATION.

     If the Leased Space or the Building or any material part of either shall be
condemned for public use, then and in that event, upon the vesting of tide to
the same for such public use, this Lease shall terminate, anything herein
contained to the contrary notwithstanding, except that Tenant shall have the
right to prove and collect the value of the trade fixtures installed by it,
including moving expenses. In the event of such termination of this Lease, all
rent paid in advance shall be apportioned as of the date of such termination.
Notwithstanding the foregoing, if only a part of the Leased Space shall be so
taken and the part not so taken shall be sufficient for the operation of
Tenant's business, Tenant, at its election, may retain the part not so taken and
there shall be a proportional reduction in the rent. AU compensation awarded or
paid upon such a total or partial taking of the Leased Space shall belong to and
be the property of the Landlord without any participation by the Tenant,
provided, however, that nothing contained herein shall be construed to preclude
the Tenant from prosecuting any claim directly against the condemning authority
in such condemnation proceedings for loss of business, or depreciation to,
damage to, or cost of removal of, or for the value of stock, trade fixtures,
furniture, and other personal property belonging to the Tenant; provided,
however, that no such claim shall diminish or otherwise adversely affect the
Landlord's award or the award of any mortgagee.

20.  ESTOPPEL CERTIEFICATES.

     At any time, and from time to time, upon the written request of Landlord or
any "Mortgagee" (as defined in section 29 hereof), Tenant, within fifteen (15)
days of the date of such written request, agrees to execute and deliver to
Landlord and/or such Mortgagee, a written statement: (a) ratifying this Lease;
(b) confirming the commencement and expiration dates of the terms of this Lease;
(c) certifying that Tenant is in occupancy of the Leased Space, and that the

                                     -22-
<PAGE>

Um is in full force and effect and has not been modified, assigned, supplemented
or amended except by such writings as shall be stated; (d) certifying that all
conditions and agreements under this Lease to be satisfied or performed by
Landlord have been satisfied and performed except as shall be stated; (e)
certifying that Landlord is not in default under the Lease and there are no
defenses or offsets against the enforcement of this Lease by Landlord, or
stating the defaults and/or defenses claimed by Tenant; (f) reciting the amount
of advance rent, if any, paid by Tenant and the date to which such rent has been
paid; (g) reciting the amount of security deposited with Landlord, if any; and
(h) any other information which Landlord or the Mortgagee shall require. The
failure of Tenant to execute, acknowledge and deliver to Landlord and/or any
Mortgagee a statement in accordance with the provisions herein within the period
set forth herein shall constitute an acknowledgement by Tenant which may be
relied upon by any person holding or in accordance with the an acknowledgment by
to any interest whatsoever the Leased Space or the Building that this Lease has
not been assigned, amended, changed or modified, is in full force and effect and
that the Annual, and Additional Rent have been duly and fully paid not beyond
the respective due dates immediately preceding the date of the request for such
statements and shall constitute as to any persons entitled to rely on such
statements a waiver of any defaults by Landlord or defenses or offsets against
the enforcement of this Lease by Landlord which may exist prior to the date of
the written request.

21.  DEFAULT.

     The occurrence of any of the following shall constitute an "Event of
Default' under this Lease:

     (a) Failure of Tenant to take possession of the New Space within ninety
(90) days after the Commencement Date.

     (b) The vacation or abandonment of the Leased Space by Tenant for a period
in excess of 15 consecutive days.

     (c) A failure by Tenant to pay, when due, any installment of rent hereunder
or any such other sum herein required to be paid by Tenant where such failure
continues for ten (10) days after written notice from Landlord that the same is
due.

     (d) A failure by Tenant to observe and perform any other terms or
conditions of this Lease to be observed or performed by Tenant, where such
failure continues for thirty (30) days after written notice thereof from
Landlord to Tenant; provided, however, that if such failure cannot be cured
within 30 days, such failure shall not be an Event of Default hereunder so long
as within such 30 day period, Tenant commences to cure such failure and
thereafter diligently pursues curing such failure within a period not to exceed
90 days from the date of such notice.

     (e) The making by Tenant of any assignment for the benefit of creditors; an
adjudication that Tenant is bankrupt, insolvent, or unable to pay its debts; the
filing by or against Tenant of a petition in bankruptcy or of a petition for
reorganization or arrangement under any law relating to bankruptcy (unless, in
the case of a petition filed against Tenant, the same is dismissed within sixty
(60) days after the filing thereof); the appointment of a trustee or receiver to
take possession of substantially all of Tenant's assets located in the Leased
Space or of

                                     -23-
<PAGE>

Tenant's interest in this Lease (unless possession is restored to Tenant within
(30) days after such appointment); or the attachment, execution or levy against,
or other judicial seizure of, substantially all of Tenant's assets located in
the Leased Space or of Tenant's interest in this Lease (unless the same is
discharged within thereof).

22.  REMEDIES.

     Upon the occurrence of any Event of Default:

     (a) Landlord may perform for the account of Tenant the cure of any such
Event of Default and immediately recover as Additional Rent any expenditures
made and the amount of any obligations incurred in connection therewith, plus
interest at the Default Rate from the date the obligations are incurred by
Landlord until payment therefor to Landlord, whether before or after entry of
judgment and issuance of execution thereon.

     (b) Landlord may accelerate all Minimum Annual Rent and Additional Rent due
for the balance of the Term of this Lease and declare the same to be immediately
due and payable;

     (c) In determining the amount of any future payments due Landlord relating
to Operating Expenses and/or Real Estate Taxes, Landlord may make such
determination based upon the most recent estimates of Operating Expenses and/or
Real Estate Taxes available;

     (d) Landlord, at its option, may serve notice upon Tenant that this Lease
and the then unexpired term hereof shall cease and expire and become absolutely
void on the date specified in such notice, to be not less than five (5) days
after the date of such notice without any right on the part of the Tenant to
save the forfeiture by payment of any sum due or by the performance of any term
or condition broken; and, thereupon and at the expiration of the time limit in
such notice, this Lease and the Term hereof, as well as the right, title and
interest of the Tenant hereunder, shall wholly cease and expire and become void
in the same manner and with the same force and effect (except as to Tenant's
liability) as if the date fixed in such notice were the date herein granted for
expiration of the Term of this Lease. Thereupon, Tenant shall immediately quit
and surrender to Landlord the Leased Space, and Landlord may enter into and
repossess the Leased Space by summary proceedings, detainer, ejectment or
otherwise and remove all occupants thereof and, at Landlord's option, any
property thereon without being liable to indictment, prosecution or damages
therefor. No such expiration or termination of this Lease shall relieve Tenant
of its liability and obligations under this Lease; whether or not the Leased
Space shall be relet; provided, however, that in the event Landlord relets the
Leased Space prior to the originally scheduled expiration of the Term
("Replacement Rent"), and Tenant has theretofore paid accelerated Minimum Annual
Rent and Additional Rent for the entire Term of the Lease, Landlord shall
reimburse Tenant the amount of the Replacement Rent, reduced by all costs and
expenses incurred by Landlord in connection with such reletting, including
without limitation those items described in subsection (e) below;

     (e) Landlord may, at any time after the occurrence and continuance of any
Event of Default and (i) the abandonment of the Leased Space by Tenant, or (ii)
entry of a judgment or order for possession in favor of Landlord, re-enter and
repossess the Leased Space and any part thereof and attempt in its own name, as
agent for Tenant if this Lease not be terminated, or on its

                                     -24-
<PAGE>

own if this Lease be terminated, to relet all or any pan of the Space for and
upon such terms and to such persons and for such period or periods as Landlord,
in its sole discretion, shall determine, including a term beyond the termination
of this Lease; and Landlord shall not be required to accept any tenant offered
by Tenant or observe any instruction given by Tenant about such reletting. For
the purpose of such reletting, Landlord may decorate or make repairs, changes,
alterations or additions in or to the Leased Space to the extent deemed by
Landlord desirable or convenient; and the cost of such decoration, repairs,
changes, alterations or additions shall be charged to and be payable by Tenant
as Additional Rent hereunder, as well as any reasonable brokerage and attorneys
fees incurred by Landlord; and any sums collected by Landlord from any new
tenant obtained shall be credited against the balance of the rent due hereunder
as aforesaid. Tenant shall pay to Landlord monthly, on the days when the rent
would have been payable under this Lease, the amount due hereunder less the
amount obtained by Landlord from such new tenant;

     (f) Landlord shall have the right of injunction, in the event of a breach
or threatened breach by Tenant of any of the terms and conditions hereof, to
restrain the same and the right to invoke any remedy allowed by law or in
equity, whether or not other remedies, indemnities or reimbursements are herein
provided. The rights and remedies given to Landlord in this Lease are distinct,
separate and cumulative remedies; and no one of them, whether or not exercised
by Landlord, shall be deemed to be in exclusion of any of the others.

23.  CONFESSION OF JUDGMENT.

     WHEN THIS LEASE SHALL BE TERMINATED BY COVENANT OR CONDITION BROKEN, EITHER
DURING THE ORIGINAL TERM OR ANY RENEWALS OR EXTENSIONS THEREOF, AND ALSO WHEN
AND AFTER THE TERM HEREBY CREATED OR, ANY RENEWAL OR EXTENSION THEREOF SHALL
HAVE EXPIRED, IT SHALL BE LAWFUL FOR ANY ATTORNEY OF ANY COURT OF RECORD AS
ATTORNEY FOR TENANT TO FILE AN AGREEMENT FOR ENTERING IN ANY COMPETENT COURT AN
AMICABLE ACTION FOR JUDGMENT IN EJECTMENT AGAINST TENANT AND ALL PERSONS CLABMG
UNDER TENANT, AND A JUDGMENT FOR THE RECOVERY BY LANDLORD OF POSSESSION MAY
ISSUE FOR WITHOUT ANY PRIOR WRITTEN OR PROCEEDINGS WHATSOEVER. IF FOR ANY
REASON AFTER SUCH ACTION SHALL HAVE BEEN COMMENCED, IT SHALL BE CANCELED OR
SUSPENDED AND POSSESSION OF THE LEASED SPACE REMAINS IN OR IS RESTORED TO
TENANT, LANDLORD SHALL HAVE THE RIGHT UPON ANY SUBSEQUENT DEFAULT OR TERMINATION
OF TERM LEASE, OR ANY RENEWAL OR EXTENSION HEREOF, TO BRING ONE OR MORE ANUCABLE
ACTIONS IN EJECTMENT AS HEREINBEFORE SET FORTH TO RECOVER POSSESSION OF THE
LEASED SPACE. IF IN ANY AMICABLE ACTION IN EJECTMENT, LANDLORD SHALL CAUSE TO BE
FILED IN SUCH ACTION AN AFFIDAVIT SETTING FORTH THE FACTS NECESSARY TO
AUTHORIZE THE ENTRY OF JUDGMENT AND IF A TRUE COPY OF THIS LEASE (AND THE TRUTH
OF THE COPY STATED IN SUCH AFFIDAVIT SHALL BE. SUFFICIENT PROOF) BE FILED IT
SHALL NOT BE NECESSARY TO FILE THE ORIGINAL AS A WARRANT OF ATTORNEY, ANY LAW,
RULE OF COURT, CUSTOM OR PRACTICE TO THE

                                     -25-
<PAGE>

CONTRARY NOT WITHSTANDING. TENANT EXPRESSLY RELEASES TO LANDLORD, AND TO ANY AND
ALL ATTORNEYS WHO MAY APPEAR FOR TENANT, ALL ERRORS IN THE SAID PROCEEDINGS, AND
ALL LIABILITY THEREFOR. TENANT EXPRESSLY WAIVES THE BENEFIT OF ALL LAWS, NOW OR
HEREAFTER IN FORCE, EXEMPTING ANY GOODS WITHIN THE LEASED SPACE OR ELSEWHERE
FROM DISTRAINT, LEVY OR SALE.

24.  WAIVER.

     The failure or delay on the part of Landlord to enforce or exercise at any
time any of the terms and conditions of this Lease shall in no way be construed
to be a waiver thereof, nor in any way to affect the validity of this Lease or
any part hereof, or the right of Landlord to thereafter enforce each and every
such term or condition. No waiver by Landlord of any breach of this Lease shall
be held to be a waiver of any other or subsequent breach. The receipt by
Landlord of rent at a time when the rent is in default under this Lease shall
not be construed as a waiver of such default. The receipt by Landlord of a
lesser amount than the rent due shall not be construed to be other than a
payment on account of the rent then due, nor shall any statement on Tenant's
check or any letter accompanying Tenant's check to be deemed an accord and
satisfaction, and Landlord may accept such payment without prejudice to
Landlord's right to recover the balance of the rent due or to pursue any other
remedies provided in this Lease. No act or thing done by this Lease shall be
deemed an acceptance or a surrender of the Leased Space, and no agreement to
accept such a surrender shall be valid unless in writing and_ signed by
Landlord.

25.  QUIET ENJOYMENT.

     If and so long as Tenant pays the rent reserved hereunder and observes and
performs all the terms and conditions on Tenant's part to be observed and
performed hereunder, Tenant shaft and may peaceably and quietly have, hold and
enjoy the Leased Space for the entire Term hereof, subject to all of the
provisions of this Lease.

26.  FORCE MAJEURE.

     Time periods for Landlord's performance of its obligations (including
without limitation Landlord's construction obligations) under any of the terms
of this Lease shall be extended for periods of time during which the Landlord's
performance is prevented due to circumstances beyond the Landlord's control,
including without limitation, strikes, embargoes, governmental regulations, acts
of God, war or other strife or Tenant Delays.

27.  SUCCESSORS.

     The respective rights and obligations provided in this Lease shall bind and
shall inure to the parties hereto, and their successors and permitted assigns.

28.  LANLORD'S LIABILITY.

     Landlord's responsibility under this Lease shall be limited to its interest
in the Leased Space and in the Building, and no members of Landlord's
partnership shall be personally liable hereunder. Tenant agrees to took solely
to Landlord's interest in the Leased Space and in the

                                     -26-
<PAGE>

Building for the collection of any judgment, and, in entering any such judgment,
the person entering the same shall request the prothonotary to mark the judgment
index accordingly. If the Leased Space or the Building is transferred or
conveyed, Landlord shall be relieved of aid covenants and obligations under this
Lease thereafter, provided that notice of said transfer or conveyance is given
to Tenant by Landlord and Landlord's successor expressly agrees to assume
Landlord's obligations hereunder.

29.  SUBORDINATION.

     Tenant agrees: (a) that, except as hereinafter provided, this Lease is, and
all of Tenant's rights hereunder are and shall always be, subject and
subordinate to any mortgage, leases of Landlord's property (in sale-leaseback)
pursuant to which Landlord has or shall retain the right of possession of the
Leased Space (and/or the Building) or security instruments (collectively called
"Mortgage") that now exist, or may hereafter be placed upon the Leased Space or
the Building, or any part thereof and all advances made or to be made thereunder
and extensions thereof; and (b) that if the holder of any such Mortgage
("Mortgagee") or if the purchaser at any foreclosure sale or at any sale under a
power of sale contained in any Mortgage shall at its sole option so request,
Tenant will attorn to, and recognize such Mortgagee or purchaser, as the case
may be, as Landlord under this Lease for the balance then remaining of the term
of this Lease, subject to all terms of this Lease; and (c) that the aforesaid
provisions shall be self-operative and no further ins t or document shall be
necessary unless required by any such Mortgagee or purchaser. Notwithstanding
anything to the contrary set forth above, any Mortgagee may at any time
subordinate its Mortgage to this Lease, without Tenant's consent, by execution
of a written document subordinating such Mortgage to this Lease to the extent
set forth therein, and upon this Lease shall be deemed prior to such Mortgage to
the extent set forth in such written document without regard to their respective
dates of execution, delivery and/or recording and in that event, to the extent
set forth in such written document such Mortgagee shall have the same rights
with respect to this Lease as though this Lease had been executed add a
memorandum thereof recorded prior to the execution, delivery and recording of
the Mortgage as though this Lease had been assigned to such Mortgagee. Should
Landlord or any Mortgagee or purchaser desire confirmation of either such
subordination or such attornment, as the case may be, Tenant upon written
request, and from time to time, will execute and deliver without charge and in
form satisfactory to Landlord, to the Mortgagee or the purchaser all instruments
and/or documents that may be required to acknowledge such subordination and/or
agreement to attorn, in recordable form within fifteen (15) days following a
request therefor from Landlord. In the event Tenant fails to execute and deliver
the instruments and documents as provided for herein within the time period set
forth, Tenant does hereby make, constitute and appoint Landlord or such
Mortgagee or purchaser, as the case may be, as Tenant's attorney-in-fact and in
its name, place and stead to do so, or Landlord may treat such failure as an
event of default. The aforesaid power of attorney is given as security coupled
with an interest and is irrevocable. Tenant shall agree to any reasonable
changes to this Lease as may be required by a Mortgagee, which changes do not
materially alter the non-economic terms, or alter in any way the economic terms,
of this Lease.,

     Landlord shall use its best efforts to obtain and furnish to Tenant,
simultaneously with Tenant's execution of this Lease, an agreement ("Non-
Disturbance Agreement") executed and acknowledged by the holder(s) of any
mortgage now encumbering the Building ("Existing. Holder") whereby each Existing
Holder agrees to not disturb Tenant in its rights, use and

                                     -27-
<PAGE>

possession of the Leased Space, the Building and the Center under this Lease or
to terminate this Lease, except to the extent permitted to Landlord by the terms
of this Lease, notwithstanding the foreclosure or the enforcement of the
mortgage or termination or other enforcement of an underlying lease or
installment purchase agreement. Landlord shall also use its best efforts to
obtain and furnish to Tenant a Non-Disturbance Agreement from the holder(s) of
any mortgage encumbering the Building given by Landlord after the date hereof.

     In connection with any financing obtained by Landlord to construct the Core
and Shell and/or to perform Landlord's Work hereunder, if the institution
providing such financing to Landlord shall require any modifications to this
Lease to accommodate such financing, Tenant shall not unreasonably withhold or
delay its consent to such modifications to be reflected in an amendment to the
Lease, provided that Tenant shall not be obligated to execute any such amendment
which would diminish any of Tenant's rights or Landlord's duties hereunder, or
expand the liability or obligations of Tenant under this Lease. Tenant shall
supply such reasonable information regarding its operations as such institution
may require as a condition to such financing.

30.  SUBSTITUTE SPACE.

     INTENTIONALLY DELETED.

31.  RULES AND REGULATIONS.

     Tenant agrees to comply with the reasonable rules and regulations
established by Landlord from time to time and delivered in writing to Tenant,
which Landlord agrees will be applied uniformly to all tenants. The existing
rules and regulations are attached hereto as bit "C".

32.  GOVERNING LAW.

     This Lease shall be governed by and construed in accordance with the laws
of the state in which the Building is located.

33.  SEVERABILITY.

     If any provisions of this Lease shall prove to be invalid, void or illegal,
it shall in no way affect any other provision hereof and the remaining
provisions shall nevertheless remain in full force and effect.

34.  HOLDING OVER.

     If Tenant shall, with the consent of Landlord, hold over after the
expiration of the term hereof, such tenancy shall be deemed a month-to-month
tenancy, which tenancy may be terminated as provided by applicable state law.
During such tenancy, Tenant agrees to pay to Landlord the fair market value for
the Leased Space, as reasonably determined by Landlord, and to be bound by all
the terms and conditions herein. If Landlord shall not give written consent to
such hold over, such tenancy may be terminated as above provided, and until
Tenant has vacated the Leased Space, it agrees to pay to Landlord rent at a
monthly rental double the rate payable by Tenant at the expiration of the Term
of this Lease.

                                     -28-
<PAGE>

35.  NOTICES.

     All notices and statements required or permitted under this Lease shall be
in writing, delivered in person or sent by United States Registered or Certified
Mail, postage prepaid, by Federal Express or other recognized overnight courier
service, or by hand delivery, addressed as follows:

     As to Tenant:              3-Dimensional Pharmaceuticals, Inc.
                                        665 Stockton Drive
                                        Suite 104
                                        Exton, PA 19341
                                        Attention:   Mr. Thomas Stagnaro
                                                     President

     With a copy to:            Edward J. Matey, Jr. Esquire
                                        Morgan, Lewis & Bockius, LLP
                                        2000 One Logan Square
                                        Philadelphia, PA 19103

     As to Landlord:            Eagleview Technology Partner
                                        c/o The Hankin Group
                                        P.O. Box 562
                                        717 Constitution Drive
                                        Exton, PA 19341
                                        Attention:   Robert S. Hankin, Partner

     With a copy to:            Edward J. Hollin, Esquire
                                        Riley, Riper, Hollin & Colagreco
                                        P.O. Box 568
                                        240 Daylesford Plaza
                                        Paoli, PA 19301

Either party may at any time, in the manner set forth for giving notices to the
other, designate a different address to which notices to it shall be sent.

36.  BROKERS.

     Tenant represents and warrants to Landlord that Tenant has not dealt with
any broker, firm, company or person in connection with the negotiation for or
the obtaining of this Lease, and Tenant shall indemnify, defend and hold
Landlord harmless from and against any claim by any person ( claiming a
commission or other form of compensation by virtue of having dealt with Tenant
with regard to this Lease, and any attorneys' fees or other expenses incurred by
Landlord in connection therewith.

                                     -29-
<PAGE>

37.  SIGNS.

     Tenant shall not, without the prior written consent of Landlord, paint,
place or erect any sign on the exterior doors or walls of the Leased Space or of
the Building or Center.

38.  SECURITY DEPOSIT; SECURITY INTEREST.

     (a) Landlord acknowledges receipt of the t3r Deposit for the Original
Space. On or before the Commencement Date, Tenant agrees to deposit with
Landlord, , an additions sum sufficient to the Security Deposit to a sum equal
to one monthly installment of Minimum Annual Rent and Additional Rent, to be
held by Landlord as security for the faithful performance of all the terms and
conditions of this Lease ("Security Deposit"). Upon the occurrence of an Event
of Default, Landlord shall have the right, at any time and from dm to time
during the continuance of such Event of Default, to apply the Security Deposit
or any part thereof, for the purpose of curing any such default or for the
purpose of reimbursing Landlord for any damage or costs occasioned by such
default, but the right of Landlord to apply the Security Deposit shall not
affect any other remedies available to Landlord under this Lease or under
applicable law. If the Security Deposit, or any part thereof, is so applied by
Landlord, Tenant shall, within three (3) days after demand, deposit additional
funds with Landlord to restore the Security Deposit, and failure to do so shall
constitute a default under this Lease.

     If the Tenant shall have faithfully complied with all the terms and
conditions of this Lease, the Security Deposit (without interest unless required
by law) shall be refunded to Tenant within (30) days after the expiration or
sooner determination of this- Lease provided, however, that Tenant first shall
have vacated the Leased Space and surrendered possession thereof to the Landlord
by delivery of keys, in accordance with the Lease provisions and shall have
returned the Leased Space to Landlord in the condition required hereunder.

     Nothing herein contained shall require Landlord to hold the sums so
deposited as a trust fund, nor establish any relationship other than that of
debtor and creditor with respect to said funds so deposited.

     If Landlord shall assign or otherwise transfer its interest in this Lease
to a successor who agrees m writing to assume all of Landlord's obligations
under this Lease, Landlord shall have the right to transfer the Security Deposit
to the assignee or other transferee of such interest (with like right of
transfer to any subsequent assignee or other transferee) and upon such transfer,
Landlord shall be released and relieved from all liability and/or responsibility
with respect to this Security Deposit and/or the return or application thereof.

     (b) As security for Tenant's performance of its obligations under this
Lease, Tenant hereby grants to Landlord a security interest under the Uniform
Commercial Code in all of Tenant's goods and property, on or about the Leased
Space, now owned or hereafter acquired, including without limitation, the Trade
Fixtures and the 'Trade Fixtures" as de under the Original Lease. Tenant shall
upon request by Landlord, execute such financing statements and other
instruments as Landlord may require in order to perfect the lien of such
security interest, and Tenant hereby appoints Landlord (and any assignee of
Landlord's rights under this Lease) as T's attorney in to execute on behalf of
Tenant, such financing statements and other instruments so

                                     -30-
<PAGE>

requested by Landlord, it being intended that such power of attorney be coupled
with an interest and irrevocable. Landlord agrees that the lien of the security
interest granted pursuant to this section, is, with the exception of Landlord's
security interest and right in the Trade Fixtures, and the "Trade Fixtures"
under the Original Lease hereby made under, subject and subordinate to any
security interest which Tenant has granted or may hereafter grant to a bank,
savings and loan institution, pension fund or institutional or equipment lender
in the business of making commercial loans, which security interest is intended
to secure an obligation of Tenant incurred in connection with the financing of
Tenant's working capital needs, or inventory or equipment to be utilized at the
Leased Space. Although the foregoing subordination provisions are intended to be
self executing, if requested by any bank, savings and loan institution, pension
fund or institutional lender in the business of making commercial loans,
Landlord shall execute a separate subordination agreement to confirm the
foregoing, upon payment of a processing fee of $250.00.

     Landlord acknowledges that Tenant may utilize a third party to provide
financing for certain equipment to be located in the Leased Space other than the
Trade Fixtures (the Financed Equipment"), and the "Trade Fixtures" under the
Original Lease. Tenant shall cause such third party lender . to execute and
deliver a subordination agreement for the benefit of Landlord in the form
attached hereto as Exhibit "D."

39.  USE OF INFORMATION IN ADVERTISING.

     Landlord and any leasing agent employed by Landlord shall be permitted to
utilize the name of Tenant, and other general public information about the
Tenant, in advertising and promotional material utilized by them, provided that
such use is authorized in writing by Tenant.

40.  CAPTIONS.

     The title to sections of this Lease are for convenience of reference only,
and are not to be construed as defining, limiting or modifying the scope or
intent of any of the terms and conditions of this Lease.

41.  ENTERE AGREEMEENT.

     This Lease, and the Exhibits and documents specifically referenced herein,
contains all covenants and agreements between Landlord and Tenant relating in
any manner to the rental, use and occupancy of the Leased Space and Tenant's use
of the Building and the Center and other matters set forth in this Lease. No
prior agreement or understanding pertaining to the same shall be valid or of any
force or effect and the terms, covenants and conditions of this Lease shall not
be altered, modified or added to except in writing signed by Landlord and
Tenant.

42.    RIGHT OF FIRST REFUSAL.

       If at any am during the term of the Lease, Landlord receives a request
for a proposal from a prospective tenant for other space in the Building,
Landlord shall notify Tenant in writing of the same (hereafter a "Landlord's
Notice"). The Landlord's Notice shall contain a description of the space, and
the economic terms under which Landlord would propose to lease the same to the
third party. If within five (5) business days following receipt of a Landlord's
Notice, Tenant

                                     -31-
<PAGE>

desires to expand into the space in the Building which is the subject of the
Landlord's Notice, Tenant shall notify Landlord in writing of Tenant's desire
and requirements (a "Request for Proposal"), which Request for Proposal shall
make specific reference to this section of this Lease. Landlord, upon receipt of
such Request for Proposal, shall provide to Tenant a written outline of terms,
which shall be generally consistent with the terms contained in the Landlord's
Notice, including without limitation Landlord's reasonably estimated value of
concessions, which outline is not intended to be an offer creating a power of
acceptance, but which shall be the framework for negotiations between Landlord
and Tenant for a lease of such available space ("Expansion Proposal"). Landlord
and Tenant shall thereupon endeavor to consummate a lease embodying the terms of
such Expansion Proposal, and such other terms and conditions as may be desired
and agreed upon by the parties, within thirty (30) days following Landlord's
issuance of the Expansion Proposal. In the event that for any reason, Tenant
does not issue a Request for Proposal within five (5) business days after
receipt of a Landlord's Notice, Tenant shall have no rights with respect to the
space which was the subject of Landlord's Notice, unless Landlord fails to
execute a lease for such space with the prospective tenant, in which event
Tenant's right to receive a Landlord's Notice shall apply to the next request
for a proposal received by Landlord from a prospective Tenant for such space. If
following Tenant's issuance of a Request for Proposal, Landlord and Tenant do
not execute a lease pursuant to an Expansion Proposal within such (30) day
period, Landlord shall thereafter be permitted to lease the space described in
the Expansion Proposal, and Tenant shall thereafter have no rights whatsoever
with respect to such space, and Landlord shall not thereafter be obligated to
provide a Landlord's Notice, or an Expansion Proposal in response to any
subsequent request or inquiry by Tenant pertaining to such space thereafter.

43.  OPTION TO CANCEL.

     Provided that there exists no Event of Default by Tenant under this Lease,
nor any event which, following the issuance of notice, the passage of time, or
both, would be an Event of Default, Tenant shall have the right to terminate
this Lease, effective five (5) years prior to the scheduled expiration of the
Term (the "Early Termination Date"), by Tenant's delivering to Landlord written
notice of its election to terminate this Lease not later than six (6) months
prior to such Early Termination Date. Landlord shall thereafter notify Tenant in
writing of the termination fee payable by Tenant (the 'Termination Fee"), which
shall be an amount equal to the present value as calculated by Landlord of the
Minimum Annual Rent and Additional Rent for the five (5) years of the full ten
(10) year Term of this Lease commencing on the Commencement Date, utilizing an
interest factor equal to the then current yield on US Treasury securities having
a maturity date closest to the scheduled date of expiration of the Term of this
Lease. In calculating Additional Rent for future periods as a component of the
Termination Fee, Landlord shall have the right to estimate reasonable future
increases in Tenant's Proportionate Share of Operating Expenses and Real Estate
Taxes, based upon historical data and information known to Tenant. Landlord's
calculation of the Termination Fee shall not be disturbed absent manifest abuse
of discretion. The Termination Fee shall be due and payable to Landlord within
ten (10) days following Landlord's notice to Tenant of the amount thereof.
Notwithstanding any such termination by Tenant, Tenant shall make all payments
of Minimum Annual Rent and Additional Rent through the Early Termination Date,
and all provisions of this Lease with respect to Tenant's obligation to vacate
and restore the Leased Space shall apply. Upon an early termination, all Trade
Fixtures under this Lease and the Original Lease shall become the property

                                     -32-
<PAGE>

of Landlord. Tenant's failure to exercise its option to terminate and pay the
Termination Fee in strict accordance with the provisions of this section, time
being of the essence hereof, shall be deemed a waiver of its right to early
termination.

44.  RIGHT OF FIRST REFUSAL TO PURCHASE THE BUILDING.

     If at any time during the Term of the Lease, Landlord receives a proposal
from a prospective purchaser of the Building to purchase the same which Landlord
would be willing to accept, Landlord shall notify Tenant in writing of the game
(hereafter a "Landlord's Sale Notice"). The Landlord's Sale Notice shall contain
a description of the economic terms under which Landlord would propose to sell
the same to the third party. If within five (5) business days following receipt
of a Landlord's Notice, Tenant desires to purchase the Building which is the
subject of the Landlord's Sale Notice, Tenant shall notify Landlord in writing
of Tenant's desire ("Tenant's Purchase Notice"). Landlord, upon receipt of such
Tenant's Purchase Notice, shall tender to Tenant a written agreement of sale,
which shall be generally consistent with the terms contained in the Landlord's
Sale Notice. Landlord and Tenant shall thereupon endeavor to consummate an
agreement of sale embodying the terms of such Landlord's Sale Notice within
fifteen (15) days following Landlord's delivery of the draft agreement of sale.
In the event that for any reason, Tenant does not issue A Tenant's Purchase
Notice within such five (5) business day period, or Landlord and Tenant do not
execute an agreement of sale within such fifteen (15) day period, Landlord shall
thereafter be permitted to sell the Building, and Tenant shall thereafter have
no rights whatsoever with respect to purchasing the Building, and Landlord shall
not thereafter be obligated to provide a Landlord's Sale Notice to Tenant, and
this right of first refusal shall be of no force and effect. This right of first
refusal shall not apply to a sale or transfer to an affiliate of Landlord, or in
connection with a financing transaction by way of sale and leaseback or the
like, whereby Landlord or its affiliate retains the economic benefits of
ownership.

45.  COOPERATION OF TENANT.

     Tenant acknowledges that the New Space is an extension of the Original
Space. Tenant shall cooperate with Landlord and take all actions needed to
assist Landlord to separate the New Building from the Original Building in
accordance with the Pennsylvania Uniform Planned Community Act or the
Pennsylvania Condominium Act or otherwise, in order to enable the Building and
the Original Building to be treated as separate "units" or "parcels" which may
be independently owned, mortgaged or conveyed. Landlord shall pay all costs to
file any required documents and Landlord's attorney's fees for the preparation
of said required documents.

                                     -33-
<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Amended and Restated Lease
to be duly executed the day and year first above written, intending to be
legally bound hereby.

                                        LANDLORD
                                        EAGLEVIEW TECHNOLOGY PARTNERS
                                        a Pennsylvania limited Partnership

                                        BY: HANKIN TECHNOLOGY PARTNERSHIP,
                                        General Partner

                                        BY: HANKIN PROPERTIES PARTNERSHIP
                                        its partner

                                        BY: /s/ Robert S. Hankin
                                           ----------------------------------
                                        ROBERT S. HANKIN, Partner

                                        BY: THE HANKIN GROUP, its Partner

                                        BY: /s/ Robert S. Hankin
                                           ----------------------------------
                                        ROBERT S. HANKIN, Partner

                                        TENANT:
                                        3-DIMENSIONAL PHARMACEUTICALS,
                                        INC., a corporation organized and
                                        existing under the laws of Delaware

                                        BY: /s/
                                           ----------------------------------

     The undersigned, a limited partner of Landlord, hereby executes this
document to evidence its consent thereto, but such execution shall not subject
the undersigned to any liability hereunder for any reason, including without
limitation any non-performance of any obligation of Landlord hereunder.

                                        CHESTER COUNTY DEVELOPMENT COUNCIL

                                        BY: /s/
                                           ----------------------------------

                                     -34-
<PAGE>

                             SCHEDULE OF EXHIBITS

         1A1      Land Development Plan

         1A-2     Building Plans showing Original Building

         1A3      Preliminary Building Plan showing New Space

         1A4      Preliminary Specifications for New Space

         C        Rules and Regulations

         D        Form Subordination Agreement

                                      -1-
<PAGE>

                                   EXHIBIT C
                                   ---------

                             RULES AND REGULATIONS
                             ---------------------

1.   DEFINITIONS.
     -----------

     Wherever in these Rules and Regulations the word "Tenant" is used, it shall
be taken to apply to and include the Tenant and his agents, employees, invitees,
licensees, subtenants and contractors, and is to be deemed of such number and
gender as the circumstances require. The word "room" is to be taken to include
the space covered by the Lease. The word "Landlord" shall be taken to include
the employees and agents of Landlord. Wherever terms of these Rules and
Regulations conflict with terms of the Lease the terms of the Lease shall
govern.

2.   OBSTRUCTION.
     -----------

     The streets, sidewalks, entrances, halls, passages, elevators, stairways
and other common areas provided by Landlord shall not be obstructed by Tenant,
or used by it for any other purposes than for ingress and egress.

3.   WASHROOMS.
     ---------

     Toilet rooms, water-closets and other water apparatus shall not be used for
any purposes other than those for which they were constructed.

4.   GENERAL PROHIBITIONS.
     --------------------

     In order to insure proper use and care of the Leased Space Tenant shall
not:

     (a)  Keep animals or birds in the Leased Space (except laboratory animals
for testing purposes in accordance with applicable laws, ordinances and
regulations may be kept with Landlord's consent, which shall not be unreasonably
withheld).

     (b)  Use rooms as sleeping apartments.

     (c)  Allow any sign, advertisement or notice to be fixed to the outside of
Building, except as provided in the Lease.

     (d)  Make noises or disturbances of any kind so as to unreasonably disturb
other tenants or tend to injure the reputation of the Building or Center.

     (e)  Mark or, defile elevators, water-closets, toilet rooms, walls,
windows, doors or any other part of the Building or Center.

     (f)  Except as may be approved by Landlord, place anything on the outside
of the Building, including roof setbacks, window ledges and other projections;
or drop anything from the windows, stairways or parapets; or place trash or
other matter in the balls, stairways, elevators or light wells of the Building.

                                      -1-
<PAGE>

     (g)  Cover or obstruct any window, skylight, door or transom that admits
light, except for permitted mini-blinds on windows, permitted signs or notices.

     (h)  Interfere with the heating or cooling apparatus.

     (i)  Install any shades, blinds, or awnings without consent of Landlord.

     (j)  Give its employees or other persons permission to go upon the roof of
the Building without the written consent of Landlord, except in connection with
performance of Tenant's maintenance obligations.

5.   BUSINESS MACHINES.
     -----------------

     Business machines and mechanical equipment which cause vibration, noise,
cold or heat that may be transmitted to Building structure or to any area
outside the Leased Space shall be placed and maintained by Tenant, at its sole
cost and expense, in settings of cork, rubber, or spring type vibration
eliminators sufficient to absorb and prevent such vibration, noise, cold or
heat.

6.   RIGHTS RESERVED TO LANDLORD.
     ---------------------------

     Without abatement or diminution in rent, Landlord reserves and shall have
the following additional rights:

     (a)  To install and maintain a sign or signs on the exterior of the
Building.

                                      -2-
<PAGE>

                                   EXHIBIT D
                                   ---------

                            SUBORDINATION AGREEMENT
                            -----------------------

     THIS SUBORDINATION AGREEMENT, (this "Agreement") is made this __ day of
____, 200_, by and among _________, a ________ corporation (the _____ ), a
Pennsylvania partnership (the _______) and 3-Dimentional Pharmaceuticals, Inc.,
a Delaware corporation (the "Debtor").

                              B A C K G R O U N D

     ___________ has made or intends to enter into a lease agreement ("Lease")
with the Debtor for premises to be constructed by ____________ at Lot 28,
Eagleview Corporate Center, Uwchlan Township, Chester County, Pennsylvania (the
premises which are or will be the subject of the Lease being hereinafter called
the "Leased Space"). Pursuant to the Lease, Debtor has granted to ___________ a
security interest under the Pennsylvania Uniform Commercial Code, in all
personal property owned by Debtor and now or hereafter located at the Leased
Space, to further secure all obligations of Debtor to Hankin under the Lease.
The personal property encumbered by Hankin's security interest includes, without
limitation, those items of personal property defined as "Trade Fixtures" in the
Lease, which are more fully listed in Exhibit "A" attached hereto (if such list
has not been prepared as of the date hereof, Hankin and Debtor shall prepare and
initial such list, which shall then become part of this Agreement as Exhibit A).
The "Trade Fixtures" as defined in the Lease are referred to herein as "Trade
Fixtures."

     ___________ has executed, or intends to execute, an equipment lease or
leases (collectively the "Equipment Lease") with Debtor, for a total rental of
__________ ($_______ ) Dollars. The property which is the subject of the
Equipment Lease is or will be located at the Leased Space, and is collectively
called the "Non-Trade Fixture Personalty." The Non-Trade Fixture Personalty is
more fully listed in Exhibit "B" attached hereto (if such list has not been
prepared as of the date hereof, _____________ and Debtor shall prepare and
initial such list, which shall then become part of this Agreement as Exhibit B).
In the event of any inconsistency between Exhibits A and B such that any
personal property would appear to be both Trade Fixtures and Non-Trade Fixture
Personalty, such personal property shall be deemed part of Trade Fixtures only,
except that the parties agree that the total cost of Trade Fixtures shall not
exceed $100,000.00. In addition, ___________ has made, or intends to make an
unsecured loan to Debtor in the stated principal amount of $_______ (the "______
Loan"). The documents evidencing the Loan are hereinafter called the Loan
Documents.

     Debtor, Hankin and _______ acknowledge and agree that Hankin would not
enter into the Lease with Debtor, and _________ would not enter into the
Equipment Lease to Debtor, but for the covenants of as set forth in this
Agreement; it being agreed that the Lease benefits ____________ and the
Equipment Lease benefits Hankin.

     The parties desire to evidence their agreements as to the subordination of
some of the rights of Comdisco to the rights of Hankin, the subordination of
some of the rights of Hankin to the rights of ________ as more fully set forth
below.

                                      -1-
<PAGE>

     NOW, THEREFORE, the parties hereto, each intending to be legally bound
hereby, agree as follows:

                                  AGREEMENTS

     NOW, THEREFORE, in consideration of the premises, One Dollar ($1.00) and
for other good and valuable consideration, the receipt and sufficiency of which
are acknowledge, the parties agree as follows:

     1.   Priority of Hankin as to Trade Fixtures. Hankin shall have the first
          ---------------------------------------
priority lien on and security interest in the Trade Fixtures. __________ shall
have no property rights in, lien on or security interest in the Trade Fixtures,
and hereby waives the right to levy, execute upon or assert any right in the
Trade Fixtures pursuant to any judgment obtained against Debtor or otherwise, it
being intended that any and all interest of Hankin in the Trade Fixtures shall
be free and clear of any interest of Comdisco therein. Hankin's rights shall
apply regardless of the perfection, nonperfection, cessation of perfection or
order of perfection of the parties' respective interests. _________ agrees that
it shall give actual notice of the limitations on __________ right to levy upon
or execute against Trade Fixtures, upon any default under the Equipment Lease or
Loan Documents, to any assignee or third party acquiring any subsequent assignee
of the lessor's or lender's interest in the Equipment Lease or Loan Documents
respectively. Hankin hereby consents to the performance by ___________ of any of
Debtor's obligations under the Lease, and the assignment by Debtor to
___________ of its interest in the Lease, provided that _________ financial
statement is reasonably judged by Hankin to be equal or superior to Debtor's as
of the date of the assignment, and ________ agrees to assume and be bound by the
provisions of the Lease.

     2.   Priority of Comdisco as to Non-Trade Fixture Personalty. Any and all
          -------------------------------------------------------
right, title and interest of Hankin the Non-Trade Fixture Personalty is under,
subject and subordinate to rights of ________ therein pursuant to the Equipment
Lease. Hankin shall have a lien on and security interest in the rights of Debtor
in the Non-Trade Fixture Personalty pursuant to the Equipment Lease, subject and
subordinate to _______`s rights therein. This priority shall apply regardless of
the perfection, nonperfection, cessation of perfection or order of perfection of
the parties' respective interests. Nothing contained herein shall be deemed to
limit any rights obtained by _________ as a permitted assignee to Debtor's
rights under the Lease (in accordance with Section 12(c) thereof), to retain
sublease rentals to which the "Tenant" under the Lease is entitled.

     3.   Control of Property. Until all of the Debtor's obligations (whether
          -------------------
pre-existing or hereafter incurred) to Hankin have been performed or paid in
full (including, but not limited to, the payment of all Minimum Annual Rent and
Additional Rent which the Debtor is obligated to pay to Hankin), Hankin shall
control the disposition of and the exercise of remedies with respect to the
Trade Fixtures in the event of a default by the Debtor in any of its obligations
to Hankin. Debtor and ___________ do hereby waive any and all claims against
Hankin which it may now or hereafter have on account of the Hankin's action in
using or disposing of all or any of the Trade Fixtures. __________ waives any
right to control to timing, nature or extent of Hankin's collection efforts
against the Debtor, including disposition of the Trade Fixtures. Hankin may
exercise or refrain from exercising its rights against the Debtor or the Trade
Fixtures Personalty within the Leased Space., and shall permit Comdisco to enter
the Leased Space upon reasonable prior

                                      -2-
<PAGE>

notice to Hankin for the purpose of exercising its rights under the Equipment
Lease. The Non-Trade Fixture Personalty shall not be considered part of real
property or a fixture, regardless of whether or by what means it is or may
become affixed to real property. In exercising its rights to remove the Non-
Trade Fixture Personalty pursuant to the Equipment Lease, Comdisco shall, at its
sole cost and expense, repair any damage to the Leased Space or the building of
which it is a part caused by Comdisco's negligence or failure to observe
reasonable precautions as Hankin may require, in the removal of the Non-Trade
Fixture Personalty.

     4.   Miscellaneous. No waiver of any of its rights and remedies hereunder
          -------------
and no modification or amendment of this Agreement shall be deemed to be made
unless the same shall be in writing, duly by the parties hereto, and each such
waiver, if any, shall apply only with respect to the specific instance involved
and shall in no way impair the rights and remedies of the parties hereunder in
other respects at any other time. This Agreement shall be binding upon and
benefit the parties and their respective successors and assigns. __________
irrevocably consents and submits to the jurisdiction and venue of the Court of
Common Pleas of Chester County, Pennsylvania, and of any other state or federal
court sitting in the Commonwealth of Pennsylvania over any suit, action or
proceeding arising out of or relating to this Agreement. ____________
irrevocably waives, to the fullest extent permitted by law, any objection that
it may now or hereafter have to the laying of the venue of any such suit, action
or proceeding brought in any such court and any claim that any such suit, action
or proceeding brought in any such court has been brought in an inconvenient
forum. The section headings of this Agreement are for convenience only and shall
not limit or otherwise affect any of the terms hereof. This Agreement shall be
deemed executed and delivered in and shall be construed, governed and enforced
in accordance with the laws of the Commonwealth of Pennsylvania in effect from
time to time.

                                      -3-
<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed,
under seal, on the date and year first above written.

WITNESS/ATTEST:

_____________________________           BY:_______________________(SEAL)
                                        NAME:
                                        TITLE:

_____________________________           BY:_______________________(SEAL)
                                        NAME:
                                        TITLE:

WITNESS/ATTEST:                         3-DIMENSIONAL PHARMACEUTICALS, INC.

_____________________________           BY:_______________________(SEAL)
                                        NAME:
                                        TITLE:

                                      -4-
<PAGE>

STATE OF                      :

                              :        SS

COUNTY OF                     :

     On this __ day of _______, 200_, before me, the undersigned, a Notary
Public of the State of ___________, personally appeared _____________, who
acknowledged himself/herself to be the ____________ of ________________, a
corporation and that he/she as such partner, being duly authorized to do so,
executed the foregoing agreement for the purposes therein contained by signing
the name of the said entity by himself/herself as _________________.

     As witness my hand and Notary Public.

                                             __________________________

     My commission expires: _____________________

STATE OF                      :

                              :        SS

COUNTY OF                     :

     On this __ day of _______, 200_, before me, the undersigned, a Notary
Public of the State of ___________, personally appeared _____________, who
acknowledged himself/herself to be a partner of ________________, a
Pennsylvania partnership, and that he/she as such partner, being duly authorized
to do so, executed the foregoing agreement for the purposes therein contained by
signing the name of the said entity by himself/herself as partner.

     As witness my hand and Notary Public.

                                             __________________________

     My commission expires: _____________________
<PAGE>

STATE OF                 :

                         :    SS

COUNTY OF                :

     On this day of ______, 200_, before me, the undersigned, a Notary Public of
the State of _______, personally appeared ________, who acknowledged
himself/herself to be the of ___________, a corporation and that he/she as such
________, being duly authorized to do so, executed the foregoing agreement for
the purposes therein contained by signing the name of the said entity by
himself/herself as ____________.

     As witness my hand and Notary Public.

                                   _________________________

     My commission expires:_________________
<PAGE>

                      RIDER TO LEASE OR AGREEMENT OF SALE

                     REGARDING INDUSTRIAL WASTE DISCHARGE

                       WITHIN EAGLEVIEW CORPORATE CENTER

                                  BACKGROUND
                                  ----------

          Eagleview Corporate Center Association("Association") owns a
wastewater treatment facility known as the Eagleview Wastewater Treatment
Facility (the "EWTF"). The Association entered into an agreement ("Treatment
Agreement") with Uwchlan Township (collectively the "Municipality") for the
treatment of wastewater generated within the drainage basin of the EWTF.

          The Treatment Agreement requires the Association to establish uniform
acceptability standards for waste discharges to the EWTF and stipulates that no
connection for waste discharge other than sanitary sewage shall be made without
the written consent of the Association, and the Treatment Agreement requires the
Association to use its best efforts to provide a wastewater influent to the EWTF
meeting certain quality standards.

          The Association has adopted standards for the discharge of wastewater
to the sewer systems tributary to the EWTF and procedures for the approval of
industrial waste discharge.

          By virtue of the lease or agreement of sale to which this Rider is
attached, the tenant or buyer thereunder (hereafter the "Industrial Discharger")
will become an occupant of Eagleview Corporate Center and a potential discharger
of waste into the EWTF. The purpose of this Rider is to incorporate this Rider
into the said lease or agreement of sale, as applicable, and by executing such
lease or agreement of sale, the Industrial Discharger shall be obligated as set
forth below.

          NOW, THEREFORE, for one dollar and other good and valuable
consideration, the receipt of which is hereby acknowledged, the Industrial
Discharger intending to be legally found, hereby covenants and agrees as
follows:

                                       2
<PAGE>

          1.   AUTHORIZATION.  Upon receiving possession of the property which
               -------------
is the  subject of its lease or agreement of sale (the "Effective Date"), the
Industrial Discharger shall be permitted to discharge the volume specified in
Appendix C to the Municipality's sanitary sewer system, from its facilities
located at the site specified in Appendix C, subject to the terms and conditions
of this Rider. The Industrial Discharger agrees to comply with all of the
provisions of this Rider. The Industrial Discharger remains fully responsible
for its discharge and all applicable statutes, resolutions, rules and
regulations and the Association and Municipality assume no responsibility or
liability therefor. Further, the Industrial Discharger agrees to indemnify and
hold harmless the Association and Municipality from all actions, causes of
action, manners of suit or liability resulting from the Industrial Discharger's
discharge into the Municipality's sewer system or the EWTF.

          2.   TERM.  The provisions of this Rider shall become effective on the
               ----
Effective Date, and shall remain in effect for a one-year period. If during the
term or any renewal term the Association or the Municipality elects not to
cancel this Rider on or before its anniversary, this Rider shall automatically
renew itself for another period of one year or until the Industrial Discharger
is no longer an occupant in Eagleview Corporate Center. Notwithstanding any
termination of this Agreement, such termination shall not terminate the
indemnification obligations of the Industrial Discharger for discharge occurring
prior to termination. If this Rider is attached to an agreement of sale, the
Industrial Discharger agrees that its obligations hereunder shall be referenced
in its deed, it being agreed that the same shall survive closing and delivery of
the deed, and shall run with the land.

          3.   TRANSFER.  The Industrial Discharger's rights hereunder are not
               --------
transferable except to a successor of the Industrial Discharger who assumes all
of the obligations of the Industrial Discharger hereunder and only with the
written approval of the Municipality and the Association. No such transfer or
assumption shall discharge the Industrial Discharger of liability for violation
of this Rider.

          4.   INCORPORATED DOCUMENTS. The following documents and requirements
               ----------------------
are incorporated into this Rider as if they were written herein and the
Industrial Discharger agrees to comply, at its expense, with their provisions:

          (a)  Specific requirements set forth in Appendix C hereto, as the same
may be amended from time to time.

                                       3
<PAGE>

          (b)  Laws and regulations pertaining to industrial waste, including
applicable Federal Categorical Pretreatment Standards, as enacted or adopted by
any governmental entity.

          5.   CONFLICTING REQUIREMENTS.  In the event of an conflict between or
               -------------------------
among statutes, resolutions or regulations, prohibitions, limitations, or
conditions applicable to the Industrial Discharger, the Industrial Discharger
shall comply with the more stringent requirements.

          6.   WASTEWATER DISCHARGE LIMITS.
               ---------------------------

          (a)  The wastewater discharged by the Industrial Discharger shall
conform at all times to the requirements and wastewater discharge limitations
established by the Association, as amended from time to time, and to the
requirements and wastewater discharge limitations established by the
Municipality, as amended from time to time.

          (b)  The current wastewater discharge requirements and quality and
quantity limitations of the Association are set forth in Appendix B.

          (c)  The current wastewater discharge requirements and quality and
quantity limitations of the Municipality are set forth in Appendix A.

          (d)  As the Association or the Municipality amend their discharge
requirements or quality and quantity limitations, Appendices A and B shall be
amended, as applicable, and the amended Appendices shall be attached hereto. The
Industrial Discharger shall be informed by the Association or Municipality as
appropriate of any changes to the discharge requirements or quality or quantity
limitations in Appendices A and B at least thirty days prior to the effective
date of change. The Association and Municipality shall use their best efforts to
inform the Industrial Discharger at least sixty days prior to the effective
date, in the event that any such changes require major changes in pretreatment
by the Industrial Discharger. If the public health and safety permit, and the
Industrial Discharger's failure to comply with the amended discharge
requirements does not itself or with other failures to comply place the
Association or Municipality in substantial danger of violating any agreement,
permit, regulation or law, then the Industrial Discharger shall be allowed a
reasonable extension of time to comply with the changes, provided the Industrial
Discharger requests such an extension and submits to the

                                       4
<PAGE>

Association and the Municipality an implementation schedule within the thirty
(30) day period preceding the effective date of the change.

          7.   PRETREATMENT.  The Industrial Discharger shall provide any
               ------------
necessary wastewater treatment to achieve compliance with the discharge
limitations specified in this Rider. The right to discharge wastewater into the
Municipality's collection system is contingent upon the Industrial Discharger
providing such pretreatment. Any facilities required to pretreat wastewater to a
level acceptable to the Association or the Municipality shall be provided,
operated, and maintained at the Industrial Discharger's expense. Detailed plans
showing the pretreatment facilities and operating procedures shall be submitted
to the Association and the Municipality before construction of the facility. In
no event will the review of such plans and operating procedures by the
Association and Municipality relieve the Industrial Discharger from
responsibility for the efficacy of the pretreatment facility and the quality and
quantity of its effluent.

          8.   MONITORING REQUIREMENTS.
               -----------------------

          (a)  Wastewater Sampling Manhole.  A suitable manhole shall be
               ---------------------------
installed at the location specified in Appendix C to facilitate observation,
sampling, and measuring of the wastewater discharge. The Manhole shall be
installed and maintained in a safe condition at the expense of the Industrial
Discharger and shall be accessible at all times to persons authorized by the
Association or the Municipality. The Industrial Discharger hereby consents to
the entry upon its land, and agrees to facilitate such entry, by representatives
of the Association and Municipality, and consents to the use of the manhole for
observation, sampling, and measuring of the wastewater discharge at any time.

          (b)  Sample Collection.  The industrial waste discharged into the
               -----------------
sanitary sewers shall be sampled and analyzed by and at the expense of the
Industrial Discharger. Frequency of sampling and analysis shall be during the
months of March, June, September, and December. The sampling and analysis shall
be representative of conditions occurring during the calendar quarter in which
the sample is taken. The Industrial Discharger shall submit to the Association
and the Municipality, within 15 days of receipt of the results of the laboratory
analysis, a discharge monitoring report. The monitoring report shall include the
date, specific place, method, and time of sampling and the names of the person
or persons who took the samples; a copy of the original laboratory report
listing the results of the analyses, the dates the analyses were performed, the
names of the person or persons who performed the analyses, and the analytical
methods used; an estimate of the average daily volume of industrial wastewater
discharged during the reporting period from the Industrial Discharger's
facilities at the site specified in Appendix C; and a certification signed by an
authorized representative of the

                                       5
<PAGE>

Industrial Discharger, that the information provided, based on the
representative's knowledge and belief, is true and correct.

          If the Industrial Discharger sample and/or analyzes for any pollutant
more frequently than required by this Agreement, the Industrial Discharger shall
include the results of any observation or analysis in its discharge monitoring
report.

          All samples are to be time composited samples collected during the
regular industrial waste discharge hours not to exceed 24 hours. The Industrial
Discharger shall follow the proper sample preservation techniques set forth in
40 C.F.R. Part 136 and amendments thereto. The Industrial Discharger shall
obtain written approval from the Association for the analytical laboratory to be
used, prior to submitting its samples to the laboratory for analysis. A
composite sample shall consist of a collection of equal volume grab samples
combined in a single container. Maximum interval between individual grab samples
shall conform to the following schedule:

     Total Industrial Discharge Between             Maximum Interval Samples
Duration in 24-Hours                                    (Minutes)

     10-24 hours (including 10)                               60
     4 to 10 hours (including 4, not including 10)            30
     Less than 4 hours                                        15

          (c)  Analysis Parameters.
               -------------------

               (1)  The quarterly wastewater samples must be analyzed for the
following substances and characteristics:

               5-Day Biochemical Oxygen Demand

               Chemical Oxygen Demand

                                       6
<PAGE>

               pH

               Suspended Solids

               Total Kjeldahl Nitrogen

               (2)  Once per calendar year during the quarterly sampling,
wastewater samples must also be analyzed for the following substances:

               Benzidine

               Bromoform

               3, 3-Dichlorobenzidine

               Chlordane

               Chloroform

               Chlorodibromomenthane

               Chromium, VI

               Dishlorobromomethane

               Methyl Bromide

               Methyl Chloride

               Heptachlor

               All analyses shall be performed using methods approved by the
United States Environmental Protection Agency and the Pennsylvania Department of
Environmental Resources for NPDES reporting.

          9.   NON-COMPLIANCE REPORTING.  The Industrial Discharger shall notify
               ------------------------
the Association and the Municipality of any non-complying discharge within 24
hours of becoming aware of the non-compliance. The Industrial Discharger shall
also repeat any sampling and analysis by which it became aware of non-complying
discharge and submit the results of the second analysis to the Association and
the Municipality within 15 days after

                                       7
<PAGE>

becoming aware of the non-compliance. The Industrial Discharger shall provide a
written report to the Association and Municipality within 10 days of receipt of
a laboratory analysis indicating a non-compliance discharge. The report shall
state the nature of the non-compliance, the reason for the non-compliance, and
the steps being taken or to be taken to bring the discharge into compliance. The
report shall also set forth a reasonable compliance schedule listing the actions
to be taken and the date by which they will be taken.

          10.  WASTE CHARACTERISTIC CHANGE. Any proposed changes in facilities,
               ---------------------------
process, or flow which increase the volume of wastewater discharged or the
quality of the discharge must be reported to the Association and the
Municipality at least ninety (90) days prior to such a change. If required by
the Association or Municipality, the Industrial Discharger shall apply for a new
Industrial Waste Discharge Agreement which reflects the proposed changes.

          11.  RIGHT OF ENTRY. Any duly authorized representative of the
               --------------
Association or the Municipality, bearing proper credentials and identification,
shall be permitted at any reasonable time without prior notice to enter upon all
properties served by the Association's treatment plant for the purpose of
inspecting, observing, measuring, sampling and testing.

          12.  FILES.  All records and information resulting from the monitoring
               -----
activities required by this Agreement shall be retained permanently by the
Industrial Discharger.

          13.  DISCHARGE DILUTION.  The Industrial Discharger shall not increase
               ------------------
the use of process waster, or in any way, attempt to dilute a discharge as a
partial or complete substitute for adequate pretreatment to achieve compliance
with the limitations established by the Association, or the Municipality, or as
set forth in this Agreement.

          14.  PERMIT SUSPENSION.  This Rider and the authorization to discharge
               ------------------
may be cancelled by the Association or the Municipality for any of the following
causes:

          (a)  Failure of the Industrial Discharger to accurately report
wastewater characteristics;

                                       8
<PAGE>

          (b)  Failure of the Industrial Discharger to report significant
changes in operation which affect wastewater characteristics;

          (c)  Refusal of access to the Industrial Discharger's premises for the
purposes of observing, sampling, or measuring the wastewater discharge; or

          (d)  Any violation of any requirement of this Industrial Waste
Discharge Rider; or

          (e)  Any default by the Industrial Discharger under the lease or
agreement of sale from which the Industrial Discharger's occupancy rights in
Eagleview Corporate Center arises.

          If the Industrial Discharger is notified of a cancellation of its
rights under this Industrial Waste Discharge Rider, it shall immediately stop
the discharge of all industrial wastewater into the Municipality's sewer system.

          15.  FEES AND EXPENSES.  In the event of any change in the
               -----------------
characteristics and quantity of wastewater from those represented by Industrial
Discharger to be discharged by it upon the Effective Date, or as may be
disclosed on Appendix C, the Industrial Discharger shall pay all of the expenses
incurred by the Municipality in its review and approval of such changes, and of
modifications to this Industrial Waste Discharge Rider and of those expenses
incurred on account of the Association's review and the approval of the same
within thirty days of receipt of a bill therefor.

          The Industrial Discharger shall reimburse the Association and the
Municipality, as applicable, within 30 days of invoice, for expenses incurred by
those bodies for monitoring, inspecting, sampling, and testing (including
laboratory analyses) the industrial waste discharge, authorized by this Rider,
as necessary to determine the Industrial Discharger's compliance with the
requirements of the Association, the Municipality, and this Rider.

          The Industrial Discharger shall also reimburse the Association and
Municipality within thirty days of invoice for the expenses (including
attorney's fee) incurred by the Association and/or Municipality in enforcing
this Rider. Enforcing this Rider for the purposes of

                                       9
<PAGE>

the preceding sentence shall include without limitation not only litigation,
administrative action, or the like but actions including demands for compliance,
investigations to determine compliance, and any other action caused by the
Industrial Discharger's failure to comply with any part of this Rider.

          16.  SURCHARGE.  The Industrial Discharger shall be subject to the
               ---------
imposition and payment of a surcharge for extra-strength waste for 5-Day BOD
concentrations in excess of 300 mg/1 or suspended solids concentrations in
excess of 320 mg/1 or Total Kjeldahl Nitrogen concentrations greater than 45
mg/1. The surcharge calculation shall be based on the following:

          (a)  The average of all 5-Day BOD, suspended solids and Total Kjeldahl
Nitrogen sample results for the billing quarter, in the Association's records,
including the sample results submitted by the Industrial Discharger and results
obtained from the Association's and/or the Municipality's sampling.

          (b)  The average wastewater flow for the billing quarter, as
determined from water consumption records for the Industrial Discharger.

          (c)  The Association's surcharge formulas.

          (d)  For industries with multiple wastewater discharge locations,
appropriate adjustments to the surcharge formula will be made by the Association
for wastewater flows not included in the sampling program.

          (e)  The surcharge shall be collected by the Municipality and paid
over to the Association.

          17.  MEASUREMENT OF WASTEWATER VOLUME. The Industrial Discharger may
               --------------------------------
install, at its expense, a wastewater flow meter to measure continuously the
volume of its discharge to the sanitary sewer system. Plans and specifications
for the complete metering facility shall be submitted to the Municipality and
the Association for approval prior to installation.

                                      10
<PAGE>

          In the absence of a suitable wastewater flow meter, wastewater flows
shall be assumed to equal the metered water usage. Where all of the water used
is metered and obtained from a third party, the volume of water usage shall be
determined from the third party's meter readings.

          In cases where the Industrial Discharger has sources of water supply
in addition to or other than the third party's supply, the Industrial
Discharger, at its own expense, shall install a meter or meters, suitable to the
Association and the Municipality, to meter the total volume of water usage.

          18.  SLUG DISCHARGES.
               ---------------

          (a)  The Industrial Discharger shall provide and maintain at its own
expense facilities and management practice adequate to prevent a slug discharge
of any regulated or prohibited substance to the sewer system. For the purpose of
this Rider, a slug discharge is any discharge of a regulated or prohibited
substance of a non-routine, episodic nature, including but not limited to an
accidental spill or a non-customary batch discharge. If the Association
determines that a slug control plan is needed, the Industrial Discharger shall,
within ninety days of receipt of the notice, prepare a plan and submit it to the
Association. The plan shall contain, at a minimum, the following elements:

          (1)  Description of the discharge practices, including non-routine,
batch discharges;

          (2)  Description of stored chemicals;

          (3)  Slug discharge notification procedures;

          (4)  Procedures and facilities to prevent slug discharges.

                                      11
<PAGE>

          (b)  In the case of a slug discharge to the sewer system, the
Industrial Discharger shall immediately telephone and notify the EWTF at (215)
458-1900 and the Municipality at the telephone number set forth in Appendix C of
the incident. The notification shall include information regarding the location
of the discharge, the type of pollutants involved, the concentration and volume
of the discharge and corrective actions taken and planned.

          (c)  Within five calendar days following a slug discharge, the
Industrial Discharger shall submit to the Association and to the Municipality a
detailed written report describing the cause of the discharge and the measures
to be taken by the Industrial Discharger to prevent similar occurrences. Such
notification shall not relieve the Industrial Discharger of any expense, loss,
damages, or other liability which may be incurred as a result of the slug
discharge.

          (d)  A notice shall be permanently posted on the Industrial
Discharger's bulletin board or other prominent place advising employees whom to
call in the event of a slug discharge. The Industrial Discharger shall ensure
that all of its employees who may cause or suffer such a slug discharge to occur
are specifically advised of the emergency notification procedure.

          19.  SPECIAL REQUIREMENTS.
               --------------------

          The Industrial Discharger agrees to adhere to the Special Requirements
in Appendix C, attached hereto.

          20.  ASSOCIATION'S AND  MUNICIPALITY'S  RIGHTS TO ENFORCE.  The
               ----------------------------------------------------
Association and Municipality are intended beneficiaries of the provisions of
this Rider, and shall have the right to enforce the same against the Industrial
Discharger, notwithstanding the fact that they are not parties to the lease or
agreement of sale to which it is attached.

                                      12
<PAGE>

          IN WITNESS WHEREOF, the Industrial Discharger has executed this
Industrial Waste Discharge Agreement as of the day and year first set forth
herein.

                                        INDUSTRIAL DISCHARGER:

     WITNESS:

     ________________________           BY: ____________________________________

                                            F. Raymond Salemme, Ph.D.

                                            President & Chief Executive Officer

                                            3-Dimensional Pharmaceuticals, Inc.

                                      13
<PAGE>

                                  APPENDIX A

                            DISCHARGE REQUIREMENTS

                     AND QUANTITY AND QUALITY LIMITATIONS

                  OF THE DOWNINGTOWN AREA REGIONAL AUTHORITY

I.   The following qualitative limits shall apply to the wastewater discharge to
     the sanitary sewer system.

     ITEM                                     PARTS PER MILLION
     ----                                     -----------------

1.  Arsenic                                         0.0

2.  Barium                                          2.0

3.  Beryllium                                       1.0

4.  Cadmium                                         0.1

5.  Chromium (hexavalent)                           1.0

6.  Chromium (trivalent)                            1.0

7.  Cobalt                                          0.5

8.  Copper                                          1.0

9.  Cyanides (as CN)                                0.5

10. Iron                                            5.0

11. Lead                                            0.1

12. Manganese                                       1.0

13. Mercury                                         0.0

14. Nickel                                          2.0

15. Phenols                                         1.0
<PAGE>

                                  APPENDIX A

                                   (Cont'd)

16. Selenium                                                0.0

17. Zinc                                                    1.0

II. Industrial Discharger shall not discharge nor cause to be discharged, any
    of the following described substances, materials, or wastes into the
    sanitary sewer system:

1. Any cooling water, either polluted or unpolluted from industrial or
   commercial processes.

2. Any ashes, cinders, sand, mud, straw, shavings, metal, glass, rags, feathers,
   fur, plastics, wood, paunch manure, butchers offal, hair or other solid or
   viscous substance capable of causing obstruction to the flow in the sanitary
   sewers or the interference with the proper operation of the sewage treatment
   plant.

3. Any inert, insoluble solids such as: asphalt, clay, slag, and mill scale, or
   sludges and slurries.

4. Any waters or waste containing radioactive isocopes.

5. Any vapor or steam.

6. Any liquid having a temperature higher than one hundred forty (140) degrees
   Fahrenheit.

7. Any fluid waste containing in excess of one hundred 9100) parts per million
   of fat, oil, wax, grease, either vegetable or mineral, or containing
   substance s which may solidify between thirty-two (32) and one hundred (100)
   degrees Fahrenheit.

                                       2
<PAGE>

                                  APPENDIX A

                                   (Cont'd)

8.  Gasoline, naptha, fuel oil or other volatile, explosive or flammable
    substance which by reason of its nature or quality may cause fire or
    explosion or be in any way injurious to persons, to the sanitary sewers or
    to the wastewater treatment facilities.

9.  Any unshredded garbage. The installation and operation of any garbage
    grinder equipped with a motor of three quarter (3/4) horsepower or greater
    shall be subject to review and approval by the Authority.

10. Any fluid having a pH lower than six (6.0) and higher than nine (9.0).

11. Any wastewater containing any substances which are not compatible to
    treatment or reduction by the biochemical wastewater treatment processes
    employed or are amenable to the treatment only to such a degree that the
    effluent of the treatment works cannot meet the requirements of agencies
    having jurisdiction over the discharge to the receiving stream.

12. Any waste collected from septic tanks, cesspools, holding tanks, privies, or
    chemical or portable toilets.

III. The Discharger shall comply with the mass loading limits for 5-Day
     Biochemical Oxygen Demand, Suspended Solids, Total Kjeldahl Nitrogen, and
     Chemical oxygen Demand. The magnitude of the allowable loading shall depend
     on the establishment's average daily industrial waste discharge volume for
     the calendar quarter according to the following:

1.  For Industrial Waste discharges less than 17,000 gpd, the daily loading
    shall not exceed 140 pounds per day of 5-Day Biochemical Oxygen demand, 140
    pounds per day of Suspended Solids, 15 pounds per day of Total Kjeldahl
    Nitrogen, and 280 pounds per day of Chemical Oxygen Demand.

2.  For Industrial Waste discharges greater than 17,000 gpd, the daily loading
    limit, in units of pounds per day, shall be established in accordance with
    the following formulas:

                                       3
<PAGE>

                                  APPENDIX A

                                   (Cont'd)

     (a) BOD5 Limit - 8,340 Q

     (b) Suspended Solids Limit - 8,340 Q

     (c) Total Kjeldahl Limit - 625 Q

     (d) Chemical Oxygen Demand Limit - 16,680 Q

   where Q = Allowable Industrial Waste discharge volume, in units of million
   gallons per day, as established in the Industrial Waste Discharge Agreement

     In order to assure the full utilization of the DRWPCC's permitted hydraulic
capacity and to protect the quality of the DRWPCC's effluent, DARA will
periodically review the adequacy of the mass loading limits and may, from time
to time, adjust the mass loading limit formulas.

                                       4
<PAGE>

                                                                      Appendix B

                          INDUSTRIAL WASTE ORDINANCE

                                    OF THE

                            BOROUGH OF DOWNINGTOWN
<PAGE>

     Enacted August 14, 1974
<PAGE>

     ACCEPTANCE OF INDUSTRIAL WASTES AND _______________________

(ILLEGIBLE PORTION OF PAGE - TOP OF PAGE CUT OFF WHEN COPYING)

     PROHIBITING THE DISCHARGE OF CERTAIN TYPES OF WASTE INTO THE DOWNINGTOWN
REGIONAL WASTEWATER SYSTEM; REQUIRING PRELIMINARY TREATMENT OF CERTAIN
INDUSTRIAL WASTES; IMPOSING CERTAIN CONDITIONS IN CONNECTION WITH PRELIMINARY
TREATMENT: PROVIDING THE BASIS FOR SEWER RENTALS OR CHARGES FOR THE USE OF THE
SYSTEM AND THE HANDLING AND/OR TREATMENT OF INDUSTRIAL WASTES: REQUIRING THE
EXECUTION OF A WRITTEN AGREEMENT PRIOR TO ACCEPTANCE OF INDUSTRIAL WASTE:
PROVIDING FOR PENALTIES AND SURCHARGES.

          WHEREAS: The economy and desirability of the treatment of combined
industrial waste and sanitary sewage is recognized, not all types or unlimited
quantities of industrial waste can be so treated; and

          WHEREAS: It shall be the established policy of the Borough of
Downingtown to admit to the fullest extent practicable those types and
quantities of industrial wastes that (1) are not harmful to the structures,
collection system, processes, personnel or the operation of the Downingtown
Regional Waster Pollution Control Facilities, or (2) are not specifically
prohibited by this ordinance, the Commonwealth of Pennsylvania - Department of
Environmental Resources, the United States Environmental Protection Agency or
any other legal regulatory agencies with jurisdiction concerning these matters;
and

          WHEREAS: It is recognized that to provide this service, above normal
operating effort and facility utilization may be required, the cost of which
must be borne by the organization receiving the benefits;

          NOW, THEREFORE, BE IT ENACTED AND ORDAINED by the Mayor and Borough
Council of the Borough of Downingtown and it is hereby enacted by the authority
of the same:

     SECTION I. DEFINITIONS
                -----------

     As used herein, the following terms shall have the meanings stated:

                                       2
<PAGE>

     1.   "Borough" shall mean the Borough of Downingtown, Chester County,
           -------
Pennsylvania.

     2.   "Consulting Engineer" shall mean the engineer retained by the
           -------------------
Borough, versed in Sanitary Engineering.

     3.   "Person" shall mean any individual, group, company, association,
           ------
society or corporation applying for permission to connect or use the Downingtown
Regional Wastewater system.

     4.   "Downingtown Regional Wastewater System" shall mean the treatment
           --------------------------------------
facilities, pumping station, interceptor lines, meter pits and appurtenance
_________ (blank from top of page cut off on xerox copy) purpose of receiving,
conveying and treating wastewater from Downingtown and outlying communities
connected to the Downingtown Regional System by Agreement.

     5.   "Wastewater" shall mean the normal water borne waste from a household,
           ----------
and toilet wastes from residences, business buildings, institutions, commercial
and industrial establishments.

     6.   "Sanitary Sewers" shall mean the system of pipes and facilities
           ---------------
operated by the Borough for the collection of domestic wastewater and acceptable
industrial wastes in and for the Borough of Downingtown.

     7.   "Industrial Waste" shall mean any solids, liquids, or gaseous
           ----------------
substance or form of energy rejected or escaping from any industrial,
manufacturing trade or business process or from the development, recovery or
processing of natural resources and distinct from wastewater.

     8.   "Commercial Establishment" shall mean any structure intended to be
           ------------------------
used wholly or in part for the purpose of carrying on a trade, business, or
profession or for social, amusement, religious, educational, charitable or
public uses.

                                       3
<PAGE>

     9.   "Industrial Establishment" shall mean any structures intended to be
           ------------------------
used wholly or in part for the manufacturing, fabricating, storing, or
warehousing, processing, cleaning, laundering or assembling of any product,
commodity or article.

     10.  "Private dwelling or living unit" shall mean any structure intended to
           -------------------------------
be occupied as a whole by one family or an apartment intended to be occupied by
one family or any other one-family living unit.

     11.  "Average daily flow" shall mean the past quarters' total wastewater
           ------------------
divided by 91.25.

     12.  "Downingtown Regional Water Pollution Control Center" shall mean all
           ---------------------------------------------------
the facilities for treating and disposing of wastewater, as are required to meet
the requirements set forth by the Pennsylvania Department of Environmental
Resources or agency holding jurisdiction.

     13.  "Compatible Pollutant" shall mean biochemical oxygen demand, suspended
           --------------------
solids, pH, and fecal coliform bacteria, plus additional pollutants the
Downingtown Regional Water Pollution Control Center was designed to treat, and
in fact does remove to a substantial degree. The term substantial degree is not
                                                      -----------
subject to precise definition, but generally contemplates removals in the order
of 80 percent or greater. Minor incidental removals in the order of 10 to 30
percent are not considered substantial. Examples of the additional pollutants
which may be considered compatible, but which must be evaluated on an individual
basis, include:

     14.  (BLANK from top of page cut off in xeroxing)

     Fats, oils, and greases of animal or vegetable origin

     15.  "Incompatible Pollutant" shall mean any pollutant which is not defined
           ----------------------
as a compatible pollutant.

                                       4
<PAGE>

     16.  "Regulatory Agency" shall mean the Pennsylvania Department of
           -----------------
Environmental Resources, its agents or other agency holding jurisdiction with
regard to the enforcement of the terms of any Permit given for permission to
continue operating at the Downingtown Regional Water Pollution Control Center.

     17.  "Major Contributing Industry" shall mean an industry that (1) has a
           ---------------------------
flow of 50,000 gallons or more per average work day; or (2) has a flow greater
than five percent of the flow carried by the municipal system receiving the
waste; or (3) has in its waste a toxic pollutant in toxic amounts as defined in
standards issued by Regulatory Agencies; or (4) has a significant impact, in
standards issued by Regulatory Agencies; or (4)has a significant impact, either
singly or in combination with other contributing industries, on the wastewater
facilities or on the quality of the effluent from that treatment works.

     18.  "Pretreatment" shall mean treatment of wastes from industrial sources
           ------------
before their introduction into the sanitary sewers or wastewater mains.

     19.  "Suspended Solids" shall mean the solids that either float on the
           ----------------
surface or are in suspension in water, wastewater or other liquids which are
removed by laboratory filtration.

     20.  "BOD (Biochemical Oxygen Demand)" shall mean the quantity of oxygen
           ------------------------------
expressed in parts per million (milligrams per liter) by weight, utilized in the
biochemical oxidation of organic matter under laboratory procedure that shall be
found in the latest revised edition of Standard Methods.

     21.  "Chlorine Demand" shall mean the amount of Chlorine in parts per
           ---------------
million (milligrams per liter) by weight, which must be added to the wastewater
to produce a specified residual chlorine content or to meet the requirements of
some other objective, in accordance with procedures set forth in Standard
Methods.

     22.  "pH" shall mean the logarithm of the reciprocal of the hydrogen-ion
           --
concentration expressed in moles per liter and indicate the degree of acidity or
alkalinity of a substance.

     23.  "PPM" (parts per million) shall be synonymous with milligrams per
           ---
liter for purposes of this Ordinance. The unit shall be a weight to weight
ratio: the parts per million of a

                                       5
<PAGE>

substance multiplied by the factor 8.343 shall be equivalent to pounds of
substance per million gallons of wastewater.

     24.  "Standard Methods" shall mean the laboratory and analytical
           ----------------
__________________ (blank from top of page cut off when xeroxed) American Public
Health Association, the American Water Works Association and the Water Pollution
Control Federation.

     25.  "Garbage" shall mean the solid waste from the domestic and commercial
           -------
preparation, cooking and disposal of food, and from the handling, storage and
sale of produce.

     26.  "Slug" shall mean any discharge of wastewater or waste exceeding a
           ----
concentration or flow greater than five times that of an average 24-hour
discharge, which is discharged for a period of 15 minutes or more duration.

     27.  "Surcharge" shall mean the additional charge in excess of the basic
           ---------
charge and never less than the basic charge for the treatment of industrial
waste, based upon the extra strength of waste applied as a factor against
charges for sanitary sewage.

     28.  "Shall" is mandatory, "May" is permissive.
           -----

     SECTION II. ADMISSIONOF INDUSTRIAL WASTE
                 ----------------------------

          1.   (a)  In order to control the admission of industrial waste or any
other waste not defined either as sanitary wastewater or a compatible pollutant
for discharge into the sanitary sewer system, the written approval of the
Borough must be obtained prior to the discharge of such waste, and as evidenced
in writing by an industrial waste discharge agreement.

               (b)  As not all waste can be satisfactorily treated at the
wastewater treatment facilities, pretreatment may be required before acceptance
into the sanitary sewers. Any waste containing substances which are not
compatible to treatment or reduction by the biological treatment processes
employed or are amendable only to such a degree that the

                                       6
<PAGE>

treatment works effluent cannot meet the required degree of purity required by
Regulatory Agencies having jurisdiction over the discharge to the stream, such
waste will require pre-treatment to the degree as negotiated by the agreement.

          2.   (a)  Each industry making application for permission to discharge
an industrial waste into the sanitary sewers shall furnish complete information
as to the quantity of such waste, the nature and quality of materials therein
and the characteristics thereof. Such application shall be the basis for
negotiation of an agreement.

               (b)  Any person, firm or corporation presently discharging
industrial waste into the sanitary sewers, shall within 90 days after
notification by the Borough, file an application for the continued use of the
sanitary sewers and submit the information required in paragraph 2(a) for
consideration for an agreement.

               (c)  Except by special permission, the average daily flow of any
single waste shall be limited to .5% of the average daily flow received by the
treatment facilities, _______________ (blank from top of page cut off when
xeroxed) waste can be discharged into the sanitary sewers shall be a the
discretion of the Borough or the Consulting Engineer.

               (d)  Adequate means shall be provided at each industrial
connection with the wastewater main for periodic sampling. A suitable manhole
shall be installed in the building's sewer line discharging the waste into the
wastewater main to facilitate observation, sampling and measure of the waste
being discharged. Such manhole shall be constructed in accordance with the plans
and specifications approved by the Borough. The manhole shall be installed and
maintained in a safe condition at the expense of the Owner and to be so located
as to be accessible at all times to authorized employees of the Borough without
the consent of the Owner. Samples for the determination of all characteristics
and concentrations of the waste shall be collected in such a manner as to be
representative of the actual quality of the waste, and "Standards Methods of
Analysis" shall be used.

               (e)  Any authorized employee of the Borough bearing proper
credentials and identification shall be permitted to enter upon any private
property discharging industrial waste into the wastewater main at any time for
the purpose of observation, measuring, sampling, repair and maintenance of any
portion of the wastewater main which is an obligation of the Borough.

                                       7
<PAGE>

               (f)  No person shall maliciously, willfully, or negligently
break, uncover, deface or tamper with any structure, appurtenance or equipment
which is part of the Borough's Wastewater System. Any person violating the
provision shall be subject to a fine of not less than ten ($10.00) dollars nor
more than one thousand ($1,000.00) dollars plus all costs incurred in
restoration, repair and/or regulatory agency fines placed against the Borough.

               (g)  The Borough reserves the right to cancel any agreement
between the industry and the Borough upon the industry's violation of the
conditions of this Ordinance or the Agreement. Agreements for industrial
water(?) will be written for a one-year period. If the Borough elects not to
cancel the agreement on or before its anniversary, the agreement will
automatically renew itself for another period of one (1) year.

     SECTION III. DISCHARGES OF PROHIBITED WASTES
                  -------------------------------

          Except as otherwise provided in this Ordinance no person shall
discharge nor cause to be discharged any of the following described substances,
materials or wastes into the sanitary sewers.

     1. Any cooling water, either polluted or unpolluted from industrial or
  commercial processes.

     2. Any ashes, cinders, sand, mud, straw, shavings, metal, glass, rags,
  feathers, fur, plastics, wood, paunch manure, butchers offal, hair or any
  other solids or viscous substance capable of causing obstruction to the flow
  in the wastewater ________________ (blank from top of page cut off when
  xeroxed) the Downingtown Regional Wastewater System.

     3. Any inert insoluble solids such as: asphalt, clay, slag, and mil scale,
  or sludges and slurries.

     4. Any waters or waste containing radioactive isotopes.

     5. Any vapor or steam.

                                       8
<PAGE>

     6. Any liquid having a temperature higher than one hundred forty (140)
  degrees Fahrenheit.

     7. Any fluid waste containing in excess of one hundred (100) parts per
  million of fat, oil, wax, grease, either vegetable or mineral, or containing
  substances which may solidify between thirty-two (320 and one hundred (100)
  degrees F.

     8. Gasoline, naptha, fuel oil or other volatile, explosive or flammable
  substance which by reason of its nature or quality may cause fire or explosion
  or be in any way injurious to persons, to the sanitary sewers or to the
  wastewater treatment facilities.

     9. Any unshredded garbage. The installation and operation of any garbage
  grinder equipped with a motor of three quarter (3/4) horsepower or greater
  shall be subject to review and approval by the Borough.

     10. Any fluid having a pH lower than five and five-tenths (5.5) and higher
  than eight and five-tenths (8.5).

     11. Any waste water containing any substances which are not compatible to
  treatment or reduction by the biochemical waste water treatment processes
  employed or are amenable to the treatment only to such a degree that the
  effluent of the treatment works cannot meet the requirements of agencies
  having jurisdiction over the discharge to the receiving stream.

     SECTION IV. QUALITATIVE LIMITS
                 ------------------

          The following limits shall be applied to all industrial waste
discharges to the wastewater system of the Borough:

                                       9
<PAGE>

      ITEM                                                   PARTS PER MILLION
      ----                                                   -----------------

1.  Arsenic                                                        0.05

2.  Barium                                                          2.0

3.  Beryllium                                                       1.0

4.  Biochemical Oxygen Demand (Total)                            1000.0

5.  Bromides                                                      250.0

6.  Cadmium                                                         0.1

7.  Chemical Oxygen Demand                                       2000.0

8.  Chlorides                                                     500.0

9.  Chlorine Demand (15 minutes)                                   50.0

10. Chromium (hexavalent)                                           1.0

11. Chromium(trivalent)                                             1.0

12. Cobalt                                                          0.5

13. Copper                                                          1.0

14. Cyanides (as CN)                                                0.5

15. Fluorides                                                      10.0

16. Hydrogen Sulfides                                               0.1

17. Iron                                                            5.0

18. Lead                                                            0.1

19. Manganese                                                       1.0

20. Mercury                                                        0.05

21. Nickel                                                          2.0

22. Ammonia Nitrogen (as N)                                        30.0

                                      10
<PAGE>

23. Nitrate Nitrogen (as N)                                            10.0

24. Phenols                                                            0.05

25. Phosphates (as PO4)                                                50.0

26. Selenium                                                           0.05

27. Sulfates                                                          500.0

28. Suspended Solids                                                 1000.0

29. Tin                                                                 2.0

30. Total Dissolved Solids                                           1000.0

31. Zinc                                                                1.0

          Limits subject to further reduction as required of the Borough by
Regulatory Agencies or as technical revelations may dictate.

          The industrial waste discharged into the sanitary sewers shall be
sampled and analyzed by and at the expense of the discharger and results of
laboratory analyses shall be submitted to the Borough within fifteen (15) days.
Frequency of sampling and analysis shall be quarterly (4 times per year) as a
minimum. Discharges having a significant contribution to the system, or which
are variable in composition, will require more frequent monitoring, possibly
monthly, weekly or daily. The requirement shall be incorporated into the
discharge Agreement.

          The laboratory analyses shall be made on a representative composite
wastewater sample, and all analytical procedures shall be consistent with the
latest revised edition of Standard Methods. The choices of analytical laboratory
shall be subject to approval by the Borough.

     SECTION V. SOURCES OF INDUSTRIAL WASTES
                ----------------------------

          The following industries are generally significant sources of
industrial waste and re included herein for guidance. This list is by no means
complete as it is not practical to itemize all industrial activities:

                                      11
<PAGE>

     Paper and Allied Products

     Dairy Products

     Textiles

     Seafoods

     Pharmaceuticals

     Leather Tanning and Finishing

     Sugar

     Petroleum Refining

     Meat Products

     Grain Milling

     Fruit and Vegetables

     Beverages

     Plastic and Synthetic Materials

     Blast Furnaces, Steel Works, and Rolling and Finishing

     Organic Chemicals

     Metal Finishing and Electroplating

     Inorganic Fertilizers

     Electric and Steam Generation

     Aluminum

     Flat Glass, Cement, Lime, Concrete Products, Gypsum, and Asbestos

     Inorganic Chemicals

     Industrial Gas Products

     Food Processing or Products

                                      12
<PAGE>

     SECTION VI. MEASURING VOLUMES FOR THE PURPOSES
                 ----------------------------------

                 OF RENTAL RATES AND SURCHARGES
                 ------------------------------

          A.   Methods of Measuring Volumes:
               ----------------------------

               1.   Whenever a person purchases all water used from the Borough
and discharges the same volume as Domestic and/or Industrial Waste into the
Wastewater System, the volume of water used, as determined from meter readings
of the Borough, shall be used in computing the wastewater rentals.

               2.   In cases where persons have sources of water supply in
addition to or other than the Borough and discharge Domestic Wastewater and/or
Industrial Wastewater into the Wastewater System, those persons shall permit the
Borough to install a meter on such additional or other source of supply. The
total amount of water consumed, as shown by these meter readings, will be used
in computing the wastewater rentals.

         [page cut off at top]

     any part of the water so used is not discharged into the wastewater system,
the quantity of water used to determine the wastewater rentals shall be computed
by one of the following methods:

          Method No. 1 - By placing a meter or measuring device on the
          ------------
     wastewater connection. The readings from the meter or measuring device
     shall be used in computing the wastewater rentals.

          Method No. 2 - By placing a meter or measuring device on the effluent
          ------------
     not discharging into the Wastewater System. The reading from this meter or
     measuring device will then be deducted from the total water meter readings,
     and the remainder will be used in computing the wastewater rentals.

                                      13
<PAGE>

          Method 3 - When, in the opinion of the superintendent of the
          --------
     Wastewater Department, it is not practical to install measuring devices to
     determine continuously the quantity of water discharged or not discharged
     into the Wastewater System, the Superintendent of the Wastewater Department
     will determine, in such manner and by such method as he may prescribe, the
     percentage of total water used which is discharged into the Wastewater
     System and the quantity of water used to compute the wastewater rentals
     shall be the percentage so determined. Any dispute as to the percentage of
     such discharge determined by the Superintendent of the Wastewater
     Department shall be submitted to the Borough Council, whose decision on the
     matter shall be final for the current calendar year.

          B.   Measuring Devices
               ------------

               All meters or measuring devices required to be used under the
provisions of this Ordinance (except those provided by the Borough for a normal
water service) shall be furnished and installed by the Borough at the expense of
the property owner. All such meters or measuring devices shall be under the
control of the Borough and may be tested, inspected or repaired by the Borough
employees whenever the Superintendent of the Wastewater Department shall deem
necessary. The Owner of the property upon which such measuring device is
installed shall be responsible for its maintenance and safekeeping, and all
repairs thereto shall be made by the Borough, at the property owner's expense,
whether such repairs are made necessary by ordinary wear and tear or other
causes. Bills for such installation and repairs shall be due and payable at the
same time and collected in the same manner as are the bills for Wastewater
services: such bills from and after their due date, shall institute a lien upon
the property upon which such measuring device is installed.

          C.   Meter Readings
               --------------

               The Borough shall be responsible for the reading of all meters or
measuring devices, and they shall be made available to Borough employees for
meter reading at any reasonable time.

          SECTION VII.   MISCELLANEOUS PROVISIONS
                         ------------------------

                                      14
<PAGE>

          Changes in classification, additional classification and modification
of the definition of industrial waste customer, time and methods of payments,
penalties, delinquent wastewater rentals, liens, and enforcement shall be
consistent and in accordance with the Basic Rate Ordinance of the Borough, as it
may from time to time be amended.

          In the event that an industry illegally discharges its waste into the
wastewater system which causes damage to the system or the wastewater treatment
facilities or to any employee thereof, or the discharge of any substance that
damages the receiving stream, the Industry shall be liable for the damage
thereof; this shall include all costs incurred for restoration, replacement,
fines, etc. The limit of the damage shall be determined by the Borough and the
Industry shall be billed therefor. Legal action may be taken to enforce
collection and/or the Borough may resort to the termination of their connection
to the wastewater system, and/or shall institute a lien upon the industrial
property making said illegal discharges.

     SECTION VIII.  SURCHARGE FORMULA
                    -----------------

          Industrial waste of unusual strength or character accepted by the
Borough for treatment shall be subject to a surcharge to be paid by the industry
concerned. The basic rate for the purpose of surcharge calculation shall be the
rate per thousand gallons as set forth in the Rate Ordinance for wastewater.

          The magnitude of the surcharge is based upon the degree to which the
waste exceeds the strength of normal sanitary sewage. These normal values are:

               (a)  A 5-day, 20(degree)C. BOD of 240 ppm.

               (b)  A suspended solids content of 300 ppm.

               (c)  A fats, oils, and grease concentration of 100.

               (d)  A chlorine demand of 20 ppm.

                                      15
<PAGE>

<TABLE>
<S>                   <C>
     Surcharge Factor - 1 - (0.45) A-240 + (0.41) B-300 - (0.10) C-100 - (0.04) D-20

                                   -----          -----          -----          ----

                                    240            300            100            20
</TABLE>

     Where Q = Water usage in gallons per quarter

           A = BODs in ppm

           B = Suspended solids in ppm

           C = Fats, oils and grease in ppm

           D = Chlorine demand in ppm

     The surcharge factor shall not be less than one (1) nor shall any term in
the factor be negative.

               (e)  Waste containing substances or materials beyond those
contained in the surcharge formula and which are acceptable for treatment by the
Borough, but with extra care and costs, the Borough may accept such waste after
a study of the waste has been made and a special surcharge cost term has been
established.

               (f)  In order to ascertain the strength of every industrial
waste, the Borough shall cause appropriate analysis to be made of each and every
industrial waste entering the sanitary sewer system at least four times each
year, the average of which shall be used to establish the surcharge.

                                      16
<PAGE>

     SECTION IX. VALIDITY
                 --------

          The provisions of this Ordinance are several and if any provision or
part thereof shall be held illegal, invalid or unconstitutional, it shall not
affect or impair any remaining provisions or parts of this ordinance. It is
hereby declared to be the legislative intent that this ordinance would have been
adopted if such invalid or unconstitutional provisions had not been included
therein.

               All ordinances or parts of ordinances inconsistent hereto are
hereby repealed.

               Adopted this ___ day of ___________, 1974.

                                                            /s/
                                                         -----------------------

                                                            President of Council

     Attest:    /s/
             -------------------

                   Secretary

                    Approved this ___ day of ___________, 1974.

                                                               /s/
                                                         -----------------------

                                                            Mayor

                                  APPENDIX C
                                  ----------

                             SPECIFIC REQUIREMENTS
                             ---------------------

                                      17
<PAGE>

          1.   The volume of discharge permitted hereunder and referred to in
Section 1 is 200 qpd.

          2.   The site referred to in Sections 1 and 8(b) of this Industrial
Waste Discharge Agreement is the Metzeler Motorcycle Tire North America
Corporation facility located at Suite 106, 400 Eagleview Boulevard, Exton, PA
19341.

     3.   The Resolution of the Authority referred to in Section 4(a) of this
Industrial Waste Discharge Agreement was adopted on February 19, 1990.

          4.   The Ordinance of the Municipality referred to in Section 4(b) of
this Industrial Waste Discharge Agreement was enacted on May 29, 1990.

        **5.   The sampling manhole referred to in Section 8(a) of this
Industrial Waste Discharge Agreement has been installed in the sewer line from
400 Eagleview Boulevard prior to the point where the line connects to the
Municipality's sanitary sewer system.

          6.   In addition to the substances and characteristics listed in
Section 8(c)(1), the Industrial Discharger shall also have the quarterly
wastewater sample analyzed, at its own expense, for the following:

               Color

               Silver

               Toluene

               Trichlorethane

               Trichloroethene
<PAGE>

          7.   The telephone number of the Municipality referred to in Section
18(b) is (215) 363-9450.
<PAGE>

                      3-DIMENSIONAL PHARMACEUTICALS, INC.

                              PHASE II EXPANSION

                                BASIS OF DESIGN

                            BCE PROJECT NO. 307118

                        BALA CONSULTING ENGINEERS, INC.

                         231 Clarksville Road, Suite I

                            Lawrenceville, NJ 08648

                           Revised: October 31, 1997
<PAGE>

                               TABLE OF CONTENTS

                                                                   Pages
                                                                   -----

     EXECUTIVE SUMMARY                                               1

     ARCHITECTURAL                                                 2-7

     HEATING, VENTILATING AND AIR CONDITIONING                    8-22

                                      -i-
<PAGE>

     EXECUTIVE SUMMARY
--------------------------------------------------------------------------------

     3-Dimensional Pharmaceuticals, Inc. (3-DP) is contracting with The Hankin
Group to construct an addition to their headquarters facility which contains
their administrative and laboratory functions. The first phase of this work was
completed in 1995. The second phase addition is expected to begin construction
around September of this year, for an occupancy the first quarter next year. The
fit-out of this phase is to allow a complete operation including programmed
expansion through the year 2002. This will require an additional 15,000 square
feet of building area added to the existing 15,000 square feet.

     The tone of the first phase has been successful, and the same design is to
continue. The new facility expresses an approach of the 21St century, by being a
facility which expresses their highly technical nature. This Basis of Design
will focus on the expansion of the interior environment Electrical
considerations are not a part of this report.

     This building continues to be a non-smoking facility. A smoking area will
be designated on the grounds.
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         OFFICE FACILITIES

         It continues to be the 3-DP philosophy to take a team approach in
research. They state all the staff are in this venture together. Because of this
philosophy the appearance of offices is to reflect their uniformity. Each person
will have a standard office format in which they can perform their functions.
All offices, and work stations will have computer terminals connected to the
in-house network systems. During the programming phase of this work, flexibility
is to be considered, however, the privacy of researchers is also to be
respected.

         Executive Offices 31 through 37 will be demolished and moved to the new
addition. There will be 10 new Executive Offices including relocated offices for
the CEO, CFO and the CSO. An additional 9 offices are needed for PhD's at 8'xlO'
each.

         All new administrative and laboratory offices will have the standard
Eagle view carpet. New executive offices will receive upgraded carpet similar to
that found in existing executive offices. Walls will be low luster painted
gypsum wall board, and the ceilings will be acoustic ceiling panels on a
suspended exposed painted metal grid.

         Administration:
         --------------

                  Population:       9

                  Area:    910 square feet

                  Offices are to be provided for the CFO at 120 square feet and
         an adjoining 230 square foot office. There are to be seven (7)
         additional administrative offices of 80 square feet each.

         Research Offices:
         ----------------

                  Population:       7

                  Area:    600 square feet

                  Offices are to be 120 square feet for the senior chemist and
         six (6) PhD offices at 80 square feet each.

         Administrators Offices:
         ----------------------

                  Population:       2

                  Area:    220 square feet

                  The CFO administrator is to have a 120 square foot open
         cubical and the senior scientist is to have an open cubical of 100
         square feet

         Open Office Area:
         ----------------

                                      -2-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

                  Population:       40

                  Area:    1,940 square feet

                  Open office is required to serve the laboratories in the
         addition. This Open Office Area is split between the Chemistry Lab (28
         people) and the Biology Lab (12 people).

         Facilities Manager's Office:
         ---------------------------

                  Population:       I

                  Area:    200 square feet

                  The facilities manager requires a private office. Finishes are
         to be similar to the adjacent corridor space. This office will be near
         the Mechanical Room.

         LABORATORY FACILITIES

         Chemistry Laboratory:

         The wet chemistry laboratory will be an open laboratory of 2,700 square
feet. The wet laboratory requires 5-foot entries from a service corridor, and
3-foot entries from the office area. The service corridor to the laboratories is
to be 8 feet in width. The service exit corridor is to be 9 feet in width. Each
lab will have vinyl composition tile flooring, epoxy painted gypsum board walls,
and NRC 60 minimum vinyl faced acoustic ceiling panels, in a suspended exposed
painted metal gild. Standard metal benches will have epoxy resin bench tops at
36" nominal height Services to the chemistry laboratories will include hot and
cold water to three (3) laboratory sinks, and cold water and oil-free instrument
grade compressed air to each of the twelve (12) chemical fume hoods. A vented
solvent storage cabinet will be located under six (6) hoods and a vented acid
cabinet under the six (6) adjoining fume hoods. Each hood will have two (2) cup
sinks with cold water and compressed air as standard. Laboratory vacuum and
inert gas services to fume hoods can be provided as an Owner-approved option.
Each hood will also have two (2), 120V, 20A duplex service outlets.

         Optional vacuum will be Centralized in a building system or independent
near laboratory fume hoods. If requested by Owner, inert gas piping can be
provided from the manifold in the Service Corridor to the wall side benches or
located independently within the laboratories. The three (3) epoxy resin sinks
will each have an eye wash. The laboratory will also have access to safety
showers in the Corridor.

         There will be twelve (12) 8-foot fume hoods in the chemistry
laboratory. The laboratory is to have space for robotics to be added.

                                      -3-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Biology Laboratory

         This new 900 square foot laboratory requires three (3) sinks with hot
and cold water, an 8'-O" fume hood with two (2) cup sinks, cold water and
compressed air. Electrically, the fume hood requires two (2) 120V 20 AMP duplex
service outlets. The fume hood will have a vented solvent storage cabinet below.

         Solvents will be based on common Biology Lab usage. Radioisotopes may
also be used in trace amounts.

         NMR Laboratory

         A 230 square foot NMR laboratory will be located away from movable
metal objects and car traffic. It will be located on an outside wall with an
exterior warning barrier for the magnetic field. This laboratory will contain a
sensitive imaging device.

         Environmental Cold Room Laboratory

         A second environmental cold room is needed to supplement the existing
cold room. Approximately 100 square feet is needed. A 10-foot bench is also
required.

         BUILDING SUPPORT SPACES
         -----------------------

         Existing Building Modifications:

         Break Room:
         ----------

                  Population:       I

                  Area:    150 square feet

                  Provide an office for the CSO at the existing break room area.
         The balance of the break room will be used as is and providing an exit
         to the building.

         Library:
         -------

                  Population:       2

                  Area:    200 square feet

                  Provide two (2) offices for Laboratory 18 and relocate the
library.

         Existing Main Conference Room:
         -----------------------------

                  Expand the conference room 160 square feet.

                                      -4-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Coffee Areas:
         ------------

                  Population:       0

                  Area:    Existing

                  Relocate the coffee area next to the expanded conference room.
         The area will remain approximately 60 square feet at the former office
         area.

         Laboratory Storage:
         ------------------

                  Population: 0

                  Area:    Existing

                  A new laboratory storage room will take approximately 125
         square feet of former office area.

         Archive Mobile Storage:
         ----------------------

                  Population:       0

                  Area:    Existing

                  310 square feet of former office area will be used for a
         mobile storage filing system. This system is track mounted and lockable
         when not in use.

         Administrator to the CEO:
         ------------------------

                  Population:       1

                  Area:    Existing

                  Will be relocated to permit corridor passage to the addition.
         It will remain at approximately 120 square feet

         Business Development Office:
         ---------------------------

                  Population:       1

                  Area:    Existing

                  The Business Development Office will be located at the current
         CEO office. The CEO will move to the adjoining office. No physical plan
         changes are required.

                                      -5-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Storage:
         -------

                  Population:       0

                  Area:    Existing

                  Building storage is to have access to the main service
         corridor. The space will be approximately 100 square feet.

         Addition:
         --------

         Meeting Room:
         ------------

                  Population:       0

                  Area:    900 square feet.

                  This space is needed to seat up to 100 people for
         presentation. The space is also to contain 100 linear feet of shelving
         for library reference. Off of the meeting room will be a kitchenette to
         serve the space as a break room. 50 square feet is required to contain
         casework with a sink and a refrigerator/freezer.

         Computational Room:
         ------------------

                  Population:       0

                  Area:    150 square feet

                  Data transmission lines, servers, and telephone lines will be
         housed in this space. This server room is to be networked with the
         present computational room.

         Chemical Storage Room:
         ---------------------

                  Population:       0

                  Area:    70 square feet

                  The chemical storage room is to have 3-60 gallon vented
         solvent storage cabinets. Floor and shelf space is needed for other
         chemicals.

         Mechanical Room:
         ---------------

                  Population:       0

                  Area:    450 square feet

                  A Mechanical Room will contain boiler equipment, hot water
         heater and motor control centers for roof top equipment

         Toilet Rooms:
         ------------

                                      -6-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         The male and female toilet rooms are to have four (4) stalls each. They
will have Ceramic tile floors and painted wails with ceramic tile behind the
water closets.

         The existing loading dock and janitor's closet will serve this
addition.

                                      -7-

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         GENERAL

         Systems will be designed In accordance with the latest applicable
Codes, Standards, and Authorities having jurisdiction and In accordance with
current engineering practices. Items denoted with an asterisk (*) represent
specific Owner requirements.

         DESIGN CRITERIA

         Ambient Weather Criteria: Outdoor ambient conditions used for the
         ------------------------
         design of the HVAC systems will be based on tabulated data for West
         Chester, Pennsylvania from the 1993 ASHRAE Handbook -Fundamentals.

                  Administrative Office Areas:

                  Winter:
                  ------

                  Dry bulb:         13(degree)F (97.5% frequency of occurrence)

                  Humidity:         0 grains per pound of dry air

                  Wind:             15 mph

                  Summer:
                  ------

                  Dry bulb:         89(degree)F (2.5% frequency of occurrence)

                  Wet bulb:         74(degree)F (coincident with design dry
                                    bulb)

                  Mean daily range: 20(degree)F

                  Wind:             7.5 mph

                  Laboratory Areas:

                  Winter:
                  ------

                  Dry bulb:         9(degree)F (99% frequency of occurrence)

                  Humidity:         0 grains per pound of dry air

                  Wind:             15mph

                  Summer:
                  ------

                  Dry bulb:         92(degree)F (1% frequency of occurrence)

                  Wet bulb:         75(degree)F (coincident with design dry
                                    bulb)

                  Mean daily range: 20(degree)F

                  Wet bulb for

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

                  evaporative cooling:      77(degree)F (1% frequency of
                                            occurrence)

                  Dry bulb:         85(degree)F (assumed coincident with design
                                    wet bulb)

                  Wind:    7.5 mph

         Space Temperature and Humidity: These criteria indicate indoor design
         ------------------------------
conditions to be maintained within the building when outdoor conditions are
within the limits described above.

         Offices, Office Support, Conference Rooms:

         Summer:  75(degree)F db/50% RH (+3(degree)F db,+/-10% RH)

         Winter.  70(degree)F db/30% RH (+10% RH)

         Laboratories, Lab Support Areas:

         Summer:  72(degree)F db/50% RH (+3(degree)F db,+7.5% RH)

         Winter:  70(degree)F db135% RH (+7.5% RH)

         Mechanical and Electrical Equipment Rooms:

         Summer   105(degree)F db maximum (ventilated to maintain temperatures
10(degree)F above ambient)

         Winter            60(degree)F db minimum

         Internal Load Criteria

         People:

                                    Sensible Heat Gain          Latent Heat Gain
                    Area            BTU/H                       BTU/H
                    ----            -----                       -----

                    Offices         250                         200
                    Laboratories    250                         250

         Lighting:

                                    Heat Gain
                    Area            Watts/Sq. Ft.
                    ----            -------------

                    Offices         2.0
                    Laboratories    2.5
                    Corridors       1.0

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Equipment:

                                    Heat Gain
                    Area            Watts/Sq. Ft.
                    ----            -------------

                    Offices             3.5
                    Laboratories        10.0
                    Corridors           0.0

         Where available, specific heat gain data and use schedules for actual
equipment will be used.

         Ventilation Criteria

         In general, laboratory areas shall be supplied with 100% outdoor air
and shall be exhausted. Supply air rates shall be based on sensible cooling
load, minimum dilution ventilation requirements, and/or exhaust air
requirements, whichever is greatest

         Outdoor air supply rates for other areas shall be based on minimum
dilution ventilation requirements for occupant comfort, occupant density,
pressurization criteria, and/or exhaust air requirements. Outdoor air shall be
provided at a minimum rate of 20 cubic feet per minute (CFM) per person or 0.2
CFM per square foot, whichever is greater.

         Air Motion Criteria

         The Room Data Sheets at the end of this section list the recommended
minimum room air motion for human comfort in occupied air conditioned spaces, or
for dilution or removal of odors. The tables list these quantities in air
changes per hour (ACPH) based on total airflow through each type of space. In
variable air volume conditioned areas, air motion and ventilation rates may fall
below these rates under part load conditions.

         Pressurization Criteria

         To control the migration of odors and contaminant, all systems shall be
designed to attain desirable pressure levels within the rooms relative to all
adjacent areas. Refer to the Room Data Sheets for individual room pressure
requirements. In general, the following guidelines will apply:

         .   Laboratories will be under negative pressure relative to adjacent
areas.

         .   The White Laboratory will be under positive pressure relative to
adjacent areas.

         .   Exterior zones will generally be under positive pressure relative
to the outdoors.

         If the laboratory air system design permits a reduction in airflow
during "unoccupied" hours, the relative directions of airflow between spaces
will remain consistent with "occupied" operation.

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Filtration Criteria

         Air handling units serving laboratory and lab support areas shall
supply air through 30% ASHRAE efficient prefilters and, as a minimum, 85% ASHRAE
efficient afterfilters. Exhaust air subject to contamination by potentially
hazardous gases or particulate materials shall be filtered through high
efficiency particulate air (HEPA) filters, activated carbon filters or fume
scrubbers prior to discharge to the atmosphere. (Note: To date, Owner has not
identified any requirements for special exhaust air filtration or scrubbing).

         Air handling units serving administrative office areas shall supply air
through 30% ASHRAE efficient prefilters.

         Units serving mechanical and electrical equipment rooms shall supply
air through 30% ASHRAE efficient filters.

         Acoustical Criteria

         The following noise criteria will be used in the mechanical design of
the spaces identified. These NC ratings do not take into account any noise
generated by operating machinery or activities planned within the space. Where
applicable, air silencers will be used.

                 Space                                       Design NC Rating
                 -----                                       ----------------

                 Laboratories                                NC-55
                 General Offices                             NC-40
                 Conference Rooms                            NC-35

         Environmental Control Zone Criteria

         In general, individual thermostat control shall be provided for each
laboratory. During occupied hours, minimum air change rates shall be maintained.
Room temperature control shall be accomplished by modulating a terminal reheat
coil control valve via a wall-mounted thermostat Exhaust airflow shall exceed
supply airflow to assure negative pressure within the laboratories relative to
adjacent spaces.

         Moisture addition required for relative humidity control shall be
provided at the central station air handling units and shall satisfy the
requirements for the majority of space served. No individual room humidity
control shall be provided. During unoccupied hours, supply and exhaust airflows
may be reduced provided that negative room pressure is maintained within the
laboratories.

         Building Operating Schedule

                  Offices           10 hrs./day      5 days/week

                  Laboratories      10 hrs./day      5 days/week

<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Supply and exhaust air quantities may be reduced in non-critical areas
during unoccupied periods.

         Space pressurization criteria must be maintained and space conditions
must remain between 65-85(degree)F.

         Fume and Exhaust Hood Criteria

         In general, fume hood design criteria shall be based on achieving 0.10
ppm control level as tested per ASHRAE Standard 110-1985, Method of Testing
                                                          -----------------
Performance of Laboratory Fume Hoods. Fume hood face velocity shall be based on
------------------------------------
the guidelines established by the American Conference of Governmental Industrial
Hygienists (ACGIH) in the 20th edition of Industrial Ventilation which
                                          ----------------------
recommends an average face velocity of 100 feet per minute (FPM) for all fume
hood applications, provided that hoods are located in low traffic areas away
from doors and trafficways, and that no equipment in the hood is closer than six
inches to the face of the hood.

         Bench hoods will feature a vertical or combination sash configuration.
Supply and exhaust systems shall be designed to achieve an average face velocity
of 100 FPM with the sash half open.

         All constant volume fume hoods shall come equipped with self-contained
bypass make-up air controls. Each fume hood shall be equipped with a visual
and/or audible alarm device to detect low face velocity. Biological safety
cabinets shall be Class II, Type B3 in accordance with the National Sanitation
Foundation (NSF) Standard 49. Biological safety cabinets shall be designed for
an average face velocity of 100 FPM, or per manufacturer's recommendations.
Flammable storage cabinets (if required) in laboratories shall be vented to the
outdoors through a direct connection to the exhaust system or through fume hoods
located above the cabinets.

         Air Distribution Criteria

         All ductwork construction shall be based on SMACNA duct pressure
classification. Exposed supply air ductwork in laboratories shall be constructed
of stainless steel. All other supply ductwork shall be galvanized steel. -

         General room exhaust ductwork shall be constructed of galvanized steel
with the following exceptions:

         . Fume hood exhaust 304L stainless steel.

         . Flammable room exhaust - 304L stainless steel for corrosive solvents
(if applicable).

         . Moisture laden exhaust - 316L stainless steel (if applicable).

         Fume hood exhaust fans shall be AMCA Type B spark resistant
construction. Fume hood exhaust discharge shall be at the highest elevation of
the building. Outdoor air intakes and exhaust discharges shall be located to
minimize cross-contamination potential in this and other buildings. The
discharge shall be directed vertically upward at a minimum velocity of 3000 FPM
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

during occupied hours. The discharge nozzle shall be high enough to exit
effluents into the dilution wake zone as determined in a wind wake analysis.

         Future Expansion Criteria

         Laboratory HVAC equipment sizes listed in Appendix A have no allowance
for future expansion. In order to make provisions to add four (4) fume hoods to
Laboratory 63 and expand the new biology laboratory to include five (5)
additional fume hoods, the. new laboratory HVAC system capacity will have to be
increased. The anticipated increase in air flow quantity as a result of the
above mentioned fume hood additions will be approximately 10,000 cfm. The
following system components will require an increase in size: air handling unit,
exhaust fans, chiller, steam boiler and hot water generating equipment, pumps,
and all of their related appurtenances (i.e. piping, ductwork, electrical
services, etc.). Appendix B represents equipment sizes which allow for the
future fume hood additions.

         SYSTEMS DESCRIPTION

         Heating Systems

         A new packaged, gas-fired, steel, Scotch-type horizontal fire-tube
boiler, located within the new Mechanical Equipment Room, will generate low
pressure (15 psig) steam for air handling unit preheat coils and humidification.

         Low pressure condensate from preheat coils and humidifiers will be
returned to the boiler feed unit located in the Mechanical Equipment Room.

         Laboratory supply air terminals will use hot water coils to reheat
conditioned supply air to maintain minimum space temperature. Two options were
considered for hot water generation. In option 1, two (2) gas-fired, finned
copper water-tube boilers, each sized for 50% of the peak demand, will generate
hot water for reheat coils. Each boiler will come equipped with a two-stage gas
valve, resulting in a four-stage system.

         In option 2, two (2) shell and tube heat exchangers, each sized for 50%
of the peak demand, will use low pressure (15 psig) steam to generate hot water
for reheat systems. Each heat exchanger will incorporate a parallel control
valve arrangement to provide more accurate control at part-load conditions and
assure that steam is available during valve maintenance or failure. This design
will require an increase in the steam boiler output of approximately 40%. This
design will also allow the interconnection of the new and existing steam boilers
which will provide added reliability should one of the boilers fail.

         In either option two (2) constant speed hot water pumps (one active;
one standby) will circulate constant temperature hot water to laboratory supply
air reheat coils. Two-way control valves will modulate hot water flow to
maintain space temperature. Pressure relief valves controlled by a differential
pressure sensor located at the most hydraulically remote terminals will bypass
water during reduced load periods.
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         Heat Exchanger Design (Option 2):

         Advantages:
         ----------

         .        The. heat exchangers will require less maintenance than the
hot water boilers.

         Disadvantages:
         -------------

 .        Higher operating costs due to the fact that the large steam boiler will
         have to be operational during the spring and summer seasons to provide
         hot water for reheat

 .        Because the boiler will have to be capable to modulate down to low
         loads (possibly 10%) the equipment costs, hence installation costs,
         will be higher.

         Recommendations:
         ---------------

 .        It is recommended that the boiler method for generating hot water be
         installed in the new addition because of the economic gains associated
         with the lower operating and installation costs.

         Cooling Systems

         Laboratory air handling unit cooling coils will use a 30% propylene
glycol/water solution. The propylene glycol solution affords a high degree of
reliability and maximum freeze protection for 100% outdoor air systems.

         Constant speed centrifugal pumps located in the Mechanical Equipment
Room will circulate (42(degree) F) chilled water from a pad-mounted air-cooled
chiller located adjacent to the building to rooftop air handling units.

         The system will include one (1) nominal 130-ton air-cooled water
chiller sized for 100% of the peak demand. The new water chiller will be an R-22
packaged electric motor driven reciprocating vapor compression chiller, with
solenoid-actuated control valves for capacity control. The new chiller Will
include hot gas bypass for low load stability and factory designed
microprocessor based controls tied to the building automation control system for
performance monitoring.

         The new water chiller will have constant flow evaporator flow rate. The
evaporator flow rate will be 2 gpm/ton of rated cooling capacity.

         The chiller will be started and stopped locally or remotely, through
the Facility Management System (FMS), but not without operator confirmation. The
plant automation controls will start the chilled water pump associated with each
chiller, and modulate the chilled water flow control valves during chiller
operation.

         Two chilled water operating sequences are possible. In option 1, the
base design, the new chiller will serve as a stand-alone system for the new
expansion. This system is comprised of one
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

(I) packaged air-cooled chiller and two (2) constant speed primary chilled water
circulating pumps (one active; one standby).

         In option 2, the new and the existing chillers will operate in
parallel. This configuration will match the number of chillers (compressors)
operating to the laboratory cooling load requirements. For example, during
periods of reduced cooling load which occur during mild outdoor air temperatures
or during a reduction in the laboratory fume hood exhaust and supply air flow,
only one chiller will be required to operate. Upon an increase in chilled water
demand, both chillers will operate. In addition, piping the chillers in parallel
will afford added reliability by allowing selected laboratories to remain in
operation should one of the chillers fail. This design includes one (1) packaged
air-cooled chiller, one (1) constant speed primary chilled water circulating
pump, and two (2) constant speed chilled water booster pumps.

         Parallel Chiller Design (Option 1):

         Advantages:
         ----------

 .        Improves chilled water efficiency during off peak cooling load
         conditions resulting in lower energy costs.

 .        Provides partial backup of chilled water generation capability In the
         event of a failure of any one chiller.

         Disadvantages:
         -------------

 .        Higher installation costs, as compared to the base chiller design. This
         is due to the additional chilled water piping, an extra primary chilled
         water pump and some added automatic temperature control work.

 .        May have a impact on lab operations due to the fact that the existing
         chilled water system will need to be shut down in order to complete
         the necessary piping tie-ins and control
         work. This will depend on what time of the year the tie-ins are done
         (i.e. spring / summer or fall / winter).

         Recommendations:
         ---------------

 .        Because of the factors of added reliability and higher operating
         efficiencies, the installation of the new chiller in parallel with the
         existing chiller is recommended.

         Air Handling Systems

         Office and Office Support Areas:

         All administrative office and office support systems will be
single-zoned, constant volume. Air handling system will be a single-package,
rooftop-mounted, combination air-to-air direct-expansion (DX) cooling system and
gas-fired heating system, complete with automatic controls.
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         In the unoccupied mode, the FMS will deenergize the air conditioning
unit

         When the outdoor air temperature is lower than the return air
temperature the economizer will control the air handling unit to use up to 100%
outdoor air to minimize the load. Coupled with each unit will be a centrifugal
return or relief air fan.

         Laboratory Areas:

         The laboratory air handling system will be 100% outdoor air,
variable-air-volume terminal reheat The air handling unit will provide constant
550 F temperature air to air terminals. A pressure independent
variable-air-volume terminal will deliver a varying airflow to the laboratory
areas. A room thermostat will modulate a two-way terminal reheat coil control
valve to maintain room temperature set point Exhaust airflow will exceed supply
airflow to assure negative pressure within the space relative to adjacent
corridors to prevent particulate, fume and odor migration from laboratories and
pilot plant areas to adjacent spaces. In the unoccupied mode, supply and exhaust
airflows may be reduced by indexing the supply and exhaust terminal boxes to a
lower setting. Settings will assure that the system maintains negative room
pressure within the space during unoccupied periods.

         Each laboratory will be provided with a dedicated variable-air-volume
supply air terminal with a hot water reheat coil. Each fume hood will be
provided with a dedicated variable-air-volume exhaust air terminal.

         Moisture addition (steam injection) required for relative humidity
control will be provided at the air handling unit and will satisfy the
requirements for the majority of spaces served. No individual room humidity
control will be provided.

         A variable-air-volume, draw-through air handling unit will service the
laboratory space and will include the following components:

         1.       Outdoor air dampers

         2.       Prefilters - 30% efficient

         3.       Final Filters - 85% efficient

         4.       Access section

         5.       Steam integral face and bypass (IFB) preheat coil

         6.       Access section

         7.       Glycol/chilled water cooling coil

         8.       Centrifugal supply fan with variable inlet vanes

         9.       Sound attenuator (located in supply ductwork)
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         10.      Airflow measuring station (located in supply ductwork)

         11.      Humidifier (located in supply ductwork)

         Coupled with the unit will be a centrifugal exhaust fan(s) with
variable inlet vanes.

         Night setback will be used to reduce the airflow to approximately 50%
for energy savings, however, pressure differentials will be maintained 24 hours
a day.

         Mechanical/Electrical Equipment Room Heating and Ventilating System:

         Heating and ventilating units and exhaust fans will provide ventilation
in mechanical/electrical equipment rooms.

         Control System

         General:

         Each office air conditioning unit shall include a stand alone automatic
temperature control system factory installed by the air conditioning unit
manufacturer. The laboratory control system shall be an extension of the
existing Facility Management System (EMS) and the Phoenix Controls laboratory
airflow control system defined as follows:

         Scope:

         The requirements of the laboratory control system will include the
design of a complete stand alone, automated temperature control system made up
of distributed digital controllers (DiDC) networked together to provide
automated control and monitoring of various mechanical and electrical equipment.
The EMS controllers will be electronic, with the majority of control devices
(dampers and valves) being pneumatically actuated. Each DiDC will include all
hardware, software, signal conditioning and termination devices to provide full
monitoring and control. All controllers will be furnished with emergency power
from dedicated emergency power panels.

         Networked controllers will be connected by a communication data
highway. Each DiDC will be capable of peer-to-peer communication for sharing of
point status and value information.

         Communication from one DiDC to another will not depend on a central
host computer. The optimum system architecture will be configured during the
design development.

         Where required, electronic-to-pneumatic (EIP) interface panels shall be
provided adjacent to each DiDC. This panel will contain all l/P, PIT
transducers, solenoid valves, pressure gauges, as well as interfacing relays.

         Installation requirements of this project with respect to the FMS will
require a complete turnkey approach with selected contractor.

         System Requirements:
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         The application of electronic distributed digital control and pneumatic
control loops for the main HVAC systems and associated areas served are as
follows:

         Laboratory air handling unit (AHU) and associated exhaust fan(s) will
         be controlled by a dedicated DiDC. Typical parameters to be controlled
         and monitored include temperature, humidity, airflow/pressurization,
         start-stop, safety shutdown (low temperature, high static and fire
         alarm interface).

         General Zone Control: Laboratories, offices, and support areas will be
         controlled by traditional pneumatic controls with an alternate to
         evaluate electronic DDC control.

         The FMS will control and/or monitor the following equipment

         .        Air handling unit and exhaust fans

         .        Water chiller(s)

         .        Steam to water heat exchangers

         .        Pumps

         .        Airflow/pressurization control

         .        Miscellaneous: to be defined

         AHU duct airflow/pressure control shall be performed and integrated
with the FMS. All components for this control (airflow stations, differential
pressure transmitters and probes) will be electronic devices.

         Air Distribution Systems:

         Preheat, cooling and primary humidification control shall be provided
for the laboratory air handling system. Supply or exhaust system duct pressure
or airflow shall be controlled by the FMS via variable inlet vanes.

         Exhaust fans shall have isolation dampers with end switches to be
hardwired to fan starter in order to prevent fan from operating when damper is
closed.

         Laboratory air handling unit and associated exhaust fans will be
interlocked via software within DIDC. The FMS will perform automated system
startup. Hardwire control interlocks are necessary for all safety devices
(freeze-thermostat, smoke detection, high static pressure, and damper end
switches).

         Note: The EMS shall provide sequential startup of systems for demand
control upon return of utility power after a power failure. The FMS will also
provide prioritized startup of systems designated to operate on emergency power.

         Control Devices:
<PAGE>

         ARCHITECTURAL
--------------------------------------------------------------------------------

         All temperature sensing for the HVAC systems will be accomplished using
either electronic RTD sensors with transmitters (critical areas) or thermistors
(non-critical areas).

         Duct-mounted electronic relative humidity sensors will be used to
control AHU discharge humidification. A pneumatic high limit safety will be
incorporated to prevent supersaturation of the air.

         Steam control valves at heat exchangers will be industrial quality.
Cooling coil, reheat and preheat valves will be commercial grade. Reheat control
valves applied to the laboratories, and office areas will be commercial grade.

         Flange type tow leakage dampers will be specified for all applications.

         A centralized compressed air system will be provided in the Mechanical
Equipment Room along with a central refrigerated drier system.

         Temperature Control Zones:

         The following spaces will receive individual thermostatic control:
         Laboratories, main conference room, mechanical equipment rooms, and any
         other spaces with equipment load equivalent of 5 watts per square foot
         or greater which may vary independently with time and usage.

         Offices shall be grouped wherever possible for optimizing quantity of
         individual thermostatic controlled rooms. Perimeter office and support
         areas will be grouped by orientation exposure under one thermostatic
         control zone for an area no greater than 750 sq. ft. Interior office
         and support areas will be grouped under one thermostatic control zone
         for an area not greater than 1,500 sq. ft. -

         Temperature/Air Quantity Setback: This will be provided for various
laboratory, conference and office areas identified in the design development
process.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]